Advertisement

Literaturverzeichnis

  • Heinz Ludwig
Chapter
  • 14 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. 1.
    Abdou, N.I., Abdou, N.L.: Anti-immunoglobulins in multiple myeloma. Clin. Exp. Immunol. 11: 57–65, 1972PubMedGoogle Scholar
  2. 2.
    Abdou, N. I., Abdou, N. L.: The monoclonal nature of lymphocytes in multiple myeloma. Effects on therapy. Ann. Intern. Med. 83: 42–45, 1975PubMedGoogle Scholar
  3. 3.
    Abramson, N., von Kapff, C., Ginsburg, A.D.: The phagocytic plasma cells. N. Engl. J. Med. 283: 248–250, 1970PubMedCrossRefGoogle Scholar
  4. 4.
    Abt, A. B., Deppisch, L. M.: Multiple myeloma involving the extrahepatic biliary system. Mt. Sinai J. Med. (N. Y.) 36: 48–54, 1969Google Scholar
  5. 5.
    Acute Leukemia Group B: Correlation of abnormal immunoglobulin with clinical features of myeloma. Arch. Intern. Med. 135: 46–52, 1975CrossRefGoogle Scholar
  6. 6.
    Acute Leukemia Group B and the Eastern Cooperative Oncology Group: Ineffectiveness of fluoride therapy in multiple myeloma. N. Eng. J. Med. 286: 1283–1288, 1972CrossRefGoogle Scholar
  7. 7.
    Adams, W.S., Ailing, E.L., Lawrence, J.S.: Multiple myeloma: Its clinical and laboratory diagnosis with emphasis on electrophoretic abnormalitis. Amer. J. Med. 6: 141–161, 1949PubMedCrossRefGoogle Scholar
  8. 8.
    Adams, W.S., Skoog, W.A.: The management of multiple myeloma. J. Chronic. Dis. 6: 446–456, 1957PubMedCrossRefGoogle Scholar
  9. 9.
    Adelstein, A.M.: Occupational mortality: Cancer. Ann. Occup. Hyg. 15: 53–57, 1972PubMedCrossRefGoogle Scholar
  10. 10.
    Alberts, D.S., Chen, H.S.G., Benz, D., Mason, N.L.: Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Brit. J. Cancer 43: 330–334, 1981PubMedCrossRefGoogle Scholar
  11. 11.
    Alberts, D.S., Durie, B.G.M., Salmon, S.E.: Doxorubicin/B. C. N. U. chemotherapy for multiple myeloma in relapse. Lancet 1: 926–928, 1976Google Scholar
  12. 12.
    Alberts, D. S., Durie, B. G. M., Salmon, S. E.: Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Treat. Rep. 61: 381–388, 1977Google Scholar
  13. 13.
    Alberts, D.S., Salmon, S. E.: Adriamycin (NSC-123127) in the treatment of alkylator- resistant multiple myeloma: A pilot study. Cancer Chemother. Rep. 59: 345–350, 1975Google Scholar
  14. 14.
    Alexanian, R: Plasma cell neoplasms. Cancer J. Clin. 26: 38–49,1976CrossRefGoogle Scholar
  15. 15.
    Alexanian, R: Blood volume in monoclonal gammopathy. Blood 49: 301–307, 1977PubMedGoogle Scholar
  16. 16.
    Alexanian, R.: Localized and indolent myeloma. Blood 56: 521–525, 1980PubMedGoogle Scholar
  17. 17.
    Alexanian, R.: Treatment of multiple myeloma. Acta Haematol. 63: 237–240, 1980PubMedCrossRefGoogle Scholar
  18. 18.
    Alexanian, R., Balcerzak, S., Bonnet, J.D., Gehan, E. A., Haut, A., Hewlett, J.S., Monto, R.W.: Prognostic factors in multiple myeloma. Cancer 36: 1192–1201, 1975PubMedCrossRefGoogle Scholar
  19. 19.
    Alexanian, R, Bergsagel, D.E., Migliore, P. J., Vaughn, W.K., Howe, C.D.: Melphalan therapy for plasma cell myeloma. Blood 31: 1–10, 1968PubMedGoogle Scholar
  20. 20.
    Alexanian, R, Bonnet, J., Gehan, E., Haut, A., Hewlett, J., Lane, M., Monto, R, Wilson, H.: Combination chemotherapy for multiple myeloma. Cancer 30: 382–389, 1972PubMedCrossRefGoogle Scholar
  21. 21.
    Alexanian, R, Haut, A., Khan, A.U., Lane, M., McKelvey, E.M., Migliore, P. J., Stuckey, W. J., W.lson, H. E.: Treatment for multiple myeloma — combination chemotherapy with different melphalan dose regimens. J. Amer. Med. Ass. 208: 1680–1685, 1969CrossRefGoogle Scholar
  22. 22.
    Alexanian, R., Migliore, P.J.: Normal immunoglobulins in multiple myeloma: Effect of melphalan chemotherapy. J. Lab. Clin. Med. 75: 225–233, 1970PubMedGoogle Scholar
  23. 23.
    Alexanian, R., Nadell, J., Alfrey, C.: Oxymetholone treatment for the anemia of bone marrow failure. Blood 40: 353–365, 1972PubMedGoogle Scholar
  24. 24.
    Alexanian, R., Salmon, S. E., Bonnet, J., Gehan, E., Haut, A., Weick, J.: Combination therapy for multiple myeloma. Cancer 40: 2765–2771, 1977PubMedCrossRefGoogle Scholar
  25. 25.
    Alexanian, R., Salmon, S., Gutterman, J., Dixon, D., Bonnet, J., Haut, A.: Chemoim– munotherapy for multiple myeloma. Cancer 47: 1923–1929, 1981PubMedCrossRefGoogle Scholar
  26. 26.
    Allan, T.M.: ABO blood groups and myelomatosis. (Letter), Brit. Med. J. 2: 178, 1970CrossRefGoogle Scholar
  27. 27.
    Alper, C.A., Johnson, A.M.: Immunofixation electrophoresis: A technique for the study of protein polymorphism. Vox Sang. 17: 445–452, 1969PubMedCrossRefGoogle Scholar
  28. 28.
    Alwall, N.: Urethan and stilbamidine in multiple myeloma: Report on two cases. Lancet 2: 388–389, 1947PubMedCrossRefGoogle Scholar
  29. 29.
    Alwall, N.: Urethane in multiple myeloma. Acta Med. Scand. 144: 114–118, 1952PubMedCrossRefGoogle Scholar
  30. 30.
    Amiel, J. L.: Study of the leukocyte phenotypes in Hodgkin’s disease. In: Histocompatibility Testing 1967. Hrsg.: Curtoni, E.S., Mattiuz, P., Tosi, R.M., Munksgaard, Copenhagen, SS. 79–81, 1967Google Scholar
  31. 31.
    Andaloro, V. A., Babott, D.: Testicular involvement in plasma cell leukemia. Urology 3: 636–638, 1974PubMedCrossRefGoogle Scholar
  32. 32.
    Anday, G.J., Fishkin, B., Gabor, E.P.: Cytogenetic studies in multiple myeloma. J. Natl. Cancer Inst. 52: 1069–1075, 1974PubMedGoogle Scholar
  33. 33.
    Anderson, J., Osgood, E.E.: Acute plasmacytic leukemia responsive to cyclophosphamide. J. Amer. Med. Ass. 193: 844–847, 1965CrossRefGoogle Scholar
  34. 34.
    Apitz, K.: Die neuen Anschauungen von Plasmocytom des Knochenmarks, dem sogenannten multiplen Myelom. Klin. Wschr. 2: 1025–1029, 1940CrossRefGoogle Scholar
  35. 35.
    Apitz, K.: Die Paraproteinosen (über die Störung des Eiweiβstoffwechsels beim Plasmacytoma). Virchow’s Arch, pathol. Anat. 306: 631–699, 1940CrossRefGoogle Scholar
  36. 36.
    Arend, W.P., Adamson, J.W.: Non–secretory myeloma. Immunofluorescent demonstration of paraprotein within bone marrow plasma cells. Cancer 33: 721–728, 1974PubMedCrossRefGoogle Scholar
  37. 37.
    Arnold, H., Bourseaux, F., Brock, N.: Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B518-ASTA) in experimental tumours of the rat. Nature (London) 181: 931, 1958CrossRefGoogle Scholar
  38. 38.
    Audhuy, B., Lang, J.M., Bergerat, J. P., Weill–Bousson, M., Oberling, F.: Les plasma- cytomes extra-squelettiques. Sem. Hôp. Paris 55: 229–233, 1979PubMedGoogle Scholar
  39. 39.
    Audran, R., Fine, J.M., Moullec, J., Matte, C.: Les facteurs de groupes sériques Gma, Gmb chez 79 sujets atteints de myélome multiple. Rev. Franc. Etudes Clin. Biol. 6: 807–811, 1961Google Scholar
  40. 40.
    Axelson, O., Dahlgreen, E., Jansson, C.D.: Arsenic exposure and mortality: a case referent study from a Swedish copper smelter. Brit. J. Ind. Med. 35: 8–15, 1978Google Scholar
  41. 41.
    Axelsson, U.: An eleven-year follow up on 64 subjects with M-components. Acta Med. Scand. 201: 173–175, 1977Google Scholar
  42. 42.
    Axelsson, U., Hällen, J.: Review of fifty-four subjects with monoclonal gammopathy. Brit J. Haematol. 15: 417–420, 1968CrossRefGoogle Scholar
  43. 43.
    Azam, L., Delamore, I. W.: Combination therapy for myelomatosis. Brit. Med. J. 4: 560–563, 1974PubMedCrossRefGoogle Scholar
  44. 44.
    Azar, H. A.: The myeloma cell. In: Multiple Myeloma and Related Disorders. Hrsg.: Azar, H. A., Potter, M., Harper & Row, New York-Evanston-San Francisco-London, SS. 86–152, 1973Google Scholar
  45. 45.
    Azar, H. A., Potter, M.: Multiple myeloma and related disorders. Harper & Row, New York, 1973Google Scholar
  46. 46.
    Azar, H. A., Zaino, E. C., Pham, T. D., Yannopoulos, K.:,Non-secretory‘plasma cell myeloma: Observations on seven cases with electron microscopic studies. Amer. J. Clin. Pathol. 58: 618–629, 1972Google Scholar
  47. 47.
    Badrinas, F., Rodriguez-Roisin, R., Rives, A., Picado, C.: Multiple myeloma with pleural involvement. Amer. Rev. Respir. Dis. 110: 82–87, 1974Google Scholar
  48. 48.
    Baenkler, H. W.: Monoclonal gammopathy of IgA and IgE type in a case of chronic lymphatic leukaemia. Acta Haematol. 56: 189–192, 1976PubMedCrossRefGoogle Scholar
  49. 49.
    Baitz, T., Kyle, R. A.: Solitary myeloma in chronic osteomyelitis. Arch. Intern. Med. 113: 872–876, 1964PubMedCrossRefGoogle Scholar
  50. 50.
    Baltzer, G., Jacob, H., Esselborn, H., Gassel, W.D.: Über den Einfluβ jodhältiger Kontrastmittel auf die Nierenfunktion bei Patienten mit multiplem Myelom. Eine re- trospektive Studie. Fortschr. Röntgenstr. 129: 208–211, 1978CrossRefGoogle Scholar
  51. 51.
    Barandun, S., Morell, A., Skvaril, F., Keller, H.: Immunoperturbation in paraproteinemia. Birth Defects 11: 95–98, 1975Google Scholar
  52. 52.
    Bark, C.J., Feinberg, S.: Solitary plasmocytoma and obstructive jaundice. J. Amer. Med. Ass. 201: 491, 1967CrossRefGoogle Scholar
  53. 53.
    Baroni, C.D., Tommasco, C.M., Ricci, C, Guarino, S., Mandelli, F.: Solitary secretory plasmocytoma of the lung in a 14–year old boy. Cancer 40: 2329–2332, 1977PubMedCrossRefGoogle Scholar
  54. 54.
    Bartl, R., Burckhardt, R., Fateh-Moghadam, A., Gierster, P., Bauer-Gell, R.: The bone marrow histobiopsy as a staging procedure of the routine in monoclonal paraprotein disorders. 5th Meeting; Europ. & Afric. Div. Int. Soc. Haematol., Hamburg 1979Google Scholar
  55. 55.
    Bartl, R., Gierster, P., Sandel, P., Fateh–Moghadam, A.: Significance of bone marrow biopsy in the diagnosis of multiple myeloma. 4th Meeting Intern. Soc. Haematol., Istambul, 1977Google Scholar
  56. 56.
    Bast, E.J.E.G., Van Camp, B., Boom, S.E., Jaspers, F.C.A., Ballieux, R.E.: Differentiation between benign and malignant monoclonal gammopathy by the presence of J chain. Clin. Exp. Immunol. 44: 375–382, 1981PubMedGoogle Scholar
  57. 57.
    Bataille, R., Durie, B.G., Sany, J., Salmon, S.E.: Myeloma bone marrow acid phosphatase staining. A correlative study of 38 patients. Blood 55: 802–805, 1980PubMedGoogle Scholar
  58. 58.
    Bataille, R., Morlock, G., Rosenberg, F., Sany, J., Serre, H.: Appréciation de la masse tumorale et de sa régression sous traitement dans le myéloma multiple des os. Rev. Rhumatol. 45: 1–5, 1978Google Scholar
  59. 59.
    Bataille, R., Sany, J.: Solitary myeloma. Clinical and prognostic features of a review of 114 cases. Cancer 48: 845–851, 1981PubMedCrossRefGoogle Scholar
  60. 60.
    Bauer, K., Deutsch, E.: Antikörper-ähnliche Aktivität von monoklonalem IgM-Para- protein gegen Röntgenkontrastmittel, die 3-Amino-2,4,6-Trijodbenzoesäuregruppen enthalten. Verh. dtsch. Ges. inn. Med. 81: 1224–1226, 1975PubMedGoogle Scholar
  61. 61.
    Baumal, R., Birshtein, B.K., Coffino, P., Scharff, M.D.: Mutations in immunoglobu– lin-producing mouse myeloma cells. Science 182: 164–166, 1973PubMedCrossRefGoogle Scholar
  62. 62.
    Bayrd, E. D.: The bone marrow on sternal aspiration in multiple myeloma. Blood 3: 987–1018, 1948PubMedGoogle Scholar
  63. 63.
    Begemann, H.: Klinische Hamatologie. Thieme, Stuttgart, SS. 642–657, 1970Google Scholar
  64. 64.
    Bell, E.T.: Renal lesions associated with multiple myeloma. Amer. J. Pathol. 9: 393–419, 1933Google Scholar
  65. 65.
    Belpomme, D., Simon, F., Pouillart, P., Amor, B., Feuilhade de Chauvin, F., Belpom– me, A., Menkes, C., Delrieu, A., Depierre, R., le Mevel, B., Serrou, B., Fries, D., Del- barre, F., Mathe, G.: Prognostic factors and treatment of multiple myeloma: Interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone. In: Recent Results in Cancer Research. Lymphoid Neoplasias. II.Clinical and Therapeutic Aspects. Hrsg.: Mathé, G., Seligman, M., Tubiana, M., Springer Verlag, Berlin-Heidelberg-New York, SS. 28–40, 1978Google Scholar
  66. 66.
    Bence Jones, H.: On a new substance occurring in the urine of a patient with mollities ossium. Philos. Trans. R. Soc. (London) 55–62, 1948Google Scholar
  67. 67.
    Benjamin, I., Taylor, H., Spindler, J.: Orbital and conjunctival involvement in multiple myeloma: Report of a case. Amer. J. Clin. Pathol. 63: 811–817, 1975Google Scholar
  68. 68.
    Bennet, J. M., Silber, R., Ezdini, E., Levitt, M., Oken, M., Bakemeier, R. F., Bailar, J.C., Carbone, P. P.: Phase II study of adriamycin and bleomycin in patients with multiple myeloma. Cancer Treat. Rep. 62: 1367–1369, 1978Google Scholar
  69. 69.
    Bennich, H., Johansson, S.G.O.: Structure and function of human immunoglobulin E. Adv. Immunol. 13: 1–55, 1971PubMedCrossRefGoogle Scholar
  70. 70.
    Benning, C.D.: Plasmocytom im Mastoid. H.N.O. (Berlin) 19: 245–246, 1971Google Scholar
  71. 71.
    Benson, W.J., Scarffe, J.H., Todd, I.D.H., Palmer, M., Crowther, D.: Spinal cord compression in myeloma. Brit. Med. J. 1: 1541–1544, 1979PubMedCrossRefGoogle Scholar
  72. 72.
    Berg, J. W.: The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma. J. Natl. Cancer Inst. 38: 741–752, 1967PubMedGoogle Scholar
  73. 73.
    Bergel, F., Stock, J. A.: Cytotoxic alpha amino acids and peptides. Brit. Emp. Cancer Campaign Annual Report 31: 6–7, 1953Google Scholar
  74. 74.
    Bergsagel, D.E.: Phase II trials of mitomycin C, AB-100, NSC-1026,1-sarcolysin, and meta-sarcolysin in the treatment of multiple myeloma. Cancer Chemother. Rep. 16: 261–266, 1962PubMedGoogle Scholar
  75. 75.
    Bergsagel, D.E.: An assessment of massive dose chemotherapy of malignant disease. Can. Med. Ass. J. 104: 31–36, 1971PubMedGoogle Scholar
  76. 76.
    Bergsagel, D.E.: Plasma cell myeloma. An interpretive review. Cancer 30: 1588–1594, 1972PubMedCrossRefGoogle Scholar
  77. 77.
    Bergsagel, D.E.: Annotation: The treatment of plasma cell myeloma. Brit. J. Haematol. 33: 443–449, 1976CrossRefGoogle Scholar
  78. 78.
    Bergsagel, D.E., Bailey, A. J., Langley, G.R., McDonald, R.N., White, D.F., Miller, A. B.: The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N. Engl. J. Med. 301: 743–748, 1979PubMedCrossRefGoogle Scholar
  79. 79.
    Bergsagel, D.E., Cowan, D.H., Hasselback, R.: Plasma cell myeloma: Response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. Can. Med. Ass. J. 107: 851–855, 1972PubMedGoogle Scholar
  80. 80.
    Bergsagel, D. E., Migliore, P. J., Griffith, K. M.: Myeloma proteins and the clinical response to melphalan therapy. Science 148: 376–377, 1965CrossRefGoogle Scholar
  81. 81.
    Bergsagel, DE., Sprague, C.C., Austin, C., Griffith, K.M.: Evaluation of new chemo- therapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother. Rep. 21: 87–99, 1962PubMedGoogle Scholar
  82. 82.
    Bergsagel, D. E., Pruzanski, W.: Treatment of plasma cell myeloma with cytotoxic agents. Arch. Intern. Med. 135: 172–176, 1975PubMedCrossRefGoogle Scholar
  83. 83.
    Bernard, D.B., Lynch, S.R., Bothwell, T.H., Bezwoda, W.R., Stevens, K., Shulman, G.: Multiple myeloma. II. The value of melphalan. S. Afr. Med. J. 48: 1026–1028, 1974PubMedGoogle Scholar
  84. 84.
    Berneaud-Kötz, G.: Augenbeteiligung bei Dys- und Paraproteinämien (Fundus para- proteinaemicus). Beih. klin. Mbl. Augenheilk. 32: 1–50, 1959Google Scholar
  85. 85.
    Bertrams, J., Kuwert, U., Böhme, U., Reis, H.E., Gallmeier, W.M., Wetter, O., Schmidt, C.G.: HL-A antigens in Hodgkin’s disease and multiple myeloma. Tissue Antigens 2: 41–46, 1972PubMedCrossRefGoogle Scholar
  86. 86.
    Besinger, U.A., Toyka, K.V., Anzil, A. P., Fateh-Moghadam, A., Neumeier, D., Rauscher, R., Heininger, K.: Myeloma neuropathy: Passive transfer from man to mouse. Science 213: 1027–1030, 1981PubMedCrossRefGoogle Scholar
  87. 87.
    Bessis, M.: Living Blood Cells and Their Ultrastructure. Springer Verlag, Berlin- Heidelberg-New York, 1973Google Scholar
  88. 88.
    Bezares, R., Bomchil, G., Saslavsky, J., Pavlovsky, S., Curutchet, M., Quirogamicheo, E., Maccha, A., Musso, A., Suarez, A., Pizzolato, M.: Assessment of a nitrosourea combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma. Sangre 24: 241–251, 1979PubMedGoogle Scholar
  89. 89.
    Bhoopalam, N., Chen, Y., Yakulis, V., Heller, P.: Surface immunoglobulins of lymphocytes in plasmacytoma. V. The effect of RNA-rich extract from mouse plasmacytoma MOPC-104 E on the immune response. Clin. Exp. Immunol. 24: 357–367, 1976PubMedGoogle Scholar
  90. 90.
    Bhoopalam, N., Yakulis, V., Costea, N., Heller, P.: Surface immunoglobulins of circulating lymphocytes in mouse plasmacytoma. II. The influence of plasmacytoma RNA on surface immunoglobulins of lymphocytes. Blood 36: 465–471, 1972Google Scholar
  91. 91.
    Biberfeld, P., Mellstedt, H., Pettersson, D.: Ultrastructural and immunocytochemical characterization of circulating mononuclear cells in patients with myelomatosis. Acta Pathol. Microbiol. Scand. 85: 611–624, 1977Google Scholar
  92. 92.
    Bierbach, H., Zeile, G., Wellek, S., Fischer, J.: Akute Leukamie bei multiplem Myelom. Klin. Wschr. 57: 769–777, 1979PubMedCrossRefGoogle Scholar
  93. 93.
    Bihrer, R., Flury, R., Morell, A.: Biklonale Paraproteinemic. Schweiz. med. Wschr. 104: 39–45, 1974PubMedGoogle Scholar
  94. 94.
    Billiau, A., Bloemmen, J., Bogaerts, M., Claeys, H., van Damme, J., de Ley, J., de Somer, P., Drochmans, A., Heremans, H., Kriel, A., Schetz, J., Tricot, G., Vermylen, C., Verwilghen, R., Waer, M.: Interferon therapy in multiple myeloma: Failure of human fibroblast interferon administration to affect the course of light chain disease. Eur. J. Cancer Clin. Oncol. 17: 875–882, 1981PubMedCrossRefGoogle Scholar
  95. 95.
    Bjørneboe, M., Jensen, K.B.: Plasma volume, colloid-osmotic pressure and gamma globulin in multiple myeloma. Acta Med. Scand. 186: 475–478, 1969Google Scholar
  96. 96.
    Blade, J., Montserrat, E., Bruguera, M., Aranalde, J., Granena, A., Cervantes, F., Rozman, C.: Multiple myeloma in primary biliary cirrhosis. Scand. J. Haematol. 26: 14–18, 1981PubMedCrossRefGoogle Scholar
  97. 97.
    Blattner, W. A.: Epidemiology of multiple myeloma and related plasma cell disorders: An analytic review. In: Progress in Myeloma. Hrsg.: Potter, M., Elsevier/North- Holland, New York-Oxford-Amsterdam, SS. 1–65, 1980Google Scholar
  98. 98.
    Blattner, W. A., Garber, J., Mann, D. L.: Macroglobulinemia and autoimmune disease in a family. (Abstract), Proc. Amer. Soc. Clin. Oncol. 20: 413, 1979Google Scholar
  99. 99.
    Bloch, K.J., Maki, D.G.: Hyperviscosity syndromes associated with immunoglobulin abnormalities. Semin. Hematol. 10: 113–124, 1973PubMedGoogle Scholar
  100. 100.
    Blokhin, N., Larionov, L., Perevodichikova, N., Chebotareva, L., Merkulova, O.S.: Clinical experiences with sarcolysin in neoplastic diseases. Ann. N. Y. Acad. Sci. 68: 1128–1132, 1958PubMedCrossRefGoogle Scholar
  101. 101.
    Blom, J., Hansen, O.P., Mansa, B.: The ultrastructure of bone marrow plasma cells obtained from patients with multiple myeloma during the clinical course of the dis¬ease. Acta Pathol. Microbiol. Scand. 88: 25–39, 1980Google Scholar
  102. 102.
    Blot, W.J.: Cancer mortality in U.S. counties with petroleum industries. Science 198: 51–53, 1977PubMedCrossRefGoogle Scholar
  103. 103.
    Bohrod, M.G., Bottcher, E. J.: Multiple myeloma, hemolytic anemia, and protein phagocytosis. Arch. Pathol. 76: 700–707, 1963PubMedGoogle Scholar
  104. 104.
    Bonvoisin, B., Bouvier, M., Creyssel, R., Lejeune, E., Coeur, P., Daumont, A.: Le myelome a IgE: Revue generale a l’occasion d’une observation personelle. Lyon Medical 241: 647–652, 1979Google Scholar
  105. 105.
    Bosshard, C., Speiser, P., Mayr, A.C.: Plasmozytom der Orbita. Klin. Monatsbl. Augenheilk. 176: 666–671, 1980CrossRefGoogle Scholar
  106. 106.
    Bouvet, J.P., Buffe, D., Oriol, R., Liacopoulos, P.: Two myeloma globulins IgG1-kappa and IgG1-lambda, from a single patient (Im). Immunology 27: 1095–1101, 1974PubMedGoogle Scholar
  107. 107.
    Bouvet, J.P., Feingold, J., Oriol, R., Liacopoulos, P.: Statistical study on double paraproteinemias: Evidence for a common cellular origin of both myeloma globulins. Bio– medicine 22: 517–523, 1975Google Scholar
  108. 108.
    Bouvier, M., Creyssel, R., Lejeune, E., Coeur, P., Daumont, A.: Aspect clinique du myelome IgE. A propos d’une observation personelle et d’une revue de la littèrature. Rev. Rhumatol. 45: 185–192, 1978Google Scholar
  109. 109.
    Bradshaw, T.R.: The recogniton of myelopathic albumin in the urine. Brit. Med. J. 2: 1442–1444, 1906PubMedCrossRefGoogle Scholar
  110. 110.
    Bramwell, V., Calvert, R.T., Edwards, G., Scarffe, H., Crowther, D.: The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother. Pharmacol. 3: 253–259, 1979PubMedCrossRefGoogle Scholar
  111. 111.
    Brautbar, N., Luboshitzky, R.: Combined Calcitonin and oral phosphate treatment for hypercalcemia in multiple myeloma. Arch. Intern. Med. 137: 914–916, 1977PubMedCrossRefGoogle Scholar
  112. 112.
    Breathnach, S.M., Wells, G.C.: Amyloid vascular disease: Cord-like thickening of mucocutaneous arteries, intermittent claudication and angina in a case with underlying myelomatosis. Brit. J. Dermatol. 102: 591–595, 1980CrossRefGoogle Scholar
  113. 113.
    Brinton, L.A., Stone, B.J., Blot, W.J.: Nasal cancer in U.S. furniture industry counties. Lancet 2: 628, 1976PubMedCrossRefGoogle Scholar
  114. 114.
    Broder, S., Humphrey, R., Durm, M., Blackman, M., Meade, B., Goldman, C., Strober, W., Waldmann, T. A.: Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma: Role of suppressor cells. N. Engl. J. Med. 293: 887–892, 1975PubMedCrossRefGoogle Scholar
  115. 115.
    Broder, S., Waldmann, T. A.: Characteristics of multiple myeloma as an immunodeficiency disease. In: Progress in Myeloma. Hrsg.: Potter, M., Elsevier/North-Holland, New York-Oxford-Amsterdam, 1980Google Scholar
  116. 116.
    Brook, J., Bateman, J.R., Gocka, E.F., Nakamura, E., Steinfeld, J.L.: Long-term low dose melphalan treatment of multiple myeloma. Arch. Intern. Med. 131: 545–548, 1973PubMedCrossRefGoogle Scholar
  117. 117.
    Brouet, J.C., Clauvel, J. P., Danon, F., Klein, M., Seligman, M.: Biologic and clinical significance of cryoglobulins: A report of 86 cases. Amer. J. Med. 57: 775–788, 1974PubMedCrossRefGoogle Scholar
  118. 118.
    Brox, L., Mowles, D., Pollock, B., Belch, A.: The DNA content of human plasma cells. Cancer 47: 2433–2436, 1981PubMedCrossRefGoogle Scholar
  119. 119.
    Brüdigam, B., Moeller, J.: Über ein atypisches Plasmocytom mit einer schweren Über- empfindlichkeitsreaktion auf Perabrodil. Klin. Wschr. 35: 280–284, 1957PubMedCrossRefGoogle Scholar
  120. 120.
    Buckley, C.E.III., Dorsey, F.C.: Serum immunoglobulin levels throughout the life-span of healthy man. Ann. Intern. Med. 75: 673–682, 1971PubMedGoogle Scholar
  121. 121.
    Bunn, P., Schecter, G., Ihde, D., Cohen, M., Binder, R., Minna, J.: Cyclic alternating combination chemotherapy for multiple myeloma. Proc. Amer. Soc. Oncol. 20: 410, 1979Google Scholar
  122. 122.
    Buonnanno, G., Tortarolo, M., Valente, A., Castaldo, C., Russolillo, S., Gonnella, F.: Drug resistant multiple myeloma. A trial with the M–2 cyclic alkylating agent poly- chemotherapy. Haematologica 63: 45–55, 1978Google Scholar
  123. 123.
    Burkhardt, R.: Die Myelotomie. Eine neue Methode zur routinemäβig kombinierten cytologisch-histologischen Knochenmarksbiopsie. Blut 2: 267–276, 1956PubMedCrossRefGoogle Scholar
  124. 124.
    Burkhardt, R.: Myelogene Osteopathien. In: Klinische Osteologie B. Hrsg.: Kuhlencordt, F., Bartelheimer, H., Springer Verlag, Berlin-Heidelberg-New York, SS.1057–1188, 1980Google Scholar
  125. 125.
    Burstein, M., Fine, J.M.: Sur le taux des β-lipoprotéines dans les myélomes et la macroglobulinémie de Waldenström. Rev. Hematol. 14: 380–383, 1959PubMedGoogle Scholar
  126. 126.
    Butterworth, C.E., Frommeyer, W.B., Rieser, W.H.: Erythrophagocytosis in a case of plasma cell leukemia. Blood 8: 519–523, 1953PubMedGoogle Scholar
  127. 127.
    Byars, N., Kidson, C.: Programmed synthesis and export of immunoglobulin by synchronized myeloma cells. Nature 226: 648–650, 1970PubMedCrossRefGoogle Scholar
  128. 128.
    Caggiano, V., Cuttner, J., Solomon, A.: Myeloma proteins, Bence-Jones proteins and normal immunoglobulins in multiple myeloma. Blood 30: 265–287, 1967PubMedGoogle Scholar
  129. 129.
    Cairns, J.: Mutation selection and the natural history of cancer. Nature 255: 197–200, 1975PubMedCrossRefGoogle Scholar
  130. 130.
    Calvin, M., Padgett, C. A., Fenselau, C.: A biologically active metabolite of cyclophosphamide. Cancer Res. 33: 915–918, 1973Google Scholar
  131. 131.
    Campell, A. E., de Vine, J., Azam, L., Hamid, J., Delamore, I. W., McFarlane, H.: Lymphocyte transformation in patients with paraproteinaemia. Brit. J. Haematol. 29: 179–188, 1975CrossRefGoogle Scholar
  132. 132.
    Canlas, M.S., Dillon, M.L., Loughrin, J. J.: Primary cutaneous plasmacytoma. Report of a case and review of the literature. Arch. Dermatol. 115: 722–724, 1979PubMedCrossRefGoogle Scholar
  133. 133.
    Carbone, P.P., Frei, E.III., Owens, A.H.Jr., Olson, K.B., Miller, S.P.: 6-Thioguanine (NSC-752) therapy in patients with multiple myeloma. Cancer Chemother. Rep. 36: 59–62, 1964PubMedGoogle Scholar
  134. 134.
    Carson, C.P., Ackerman, L.V., Maltby, J.D.: Plasma cell myeloma. A clinical pathologic and roentgenologic review of ninety cases. Amer. J. Clin. Pathol. 25: 849–888, 1955Google Scholar
  135. 135.
    Carter, A., Tatarsky, I.: The physiopathological significance of benign monoclonal gammopathy: A study of 64 cases. Brit. J. Haematol. 46: 565–574, 1980CrossRefGoogle Scholar
  136. 136.
    Case, D.C.: Therapy of myeloma. (Letter), Blood 55: 1070, 1980PubMedGoogle Scholar
  137. 137.
    Case, D.C., Lee, B.J., Clarkson, B.D.: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, BCNU: M-2 protocol. Amer. J. Med. 63: 897–903, 1977PubMedCrossRefGoogle Scholar
  138. 138.
    Cassuto, J. P., Hammon, J.C., Pastorelli, E., du Jardin, P., Masseyeff, R.: Plasma cell acid phosphatase, a discriminative test for benign and malignant monoclonal gammo- pathies. Biomedicine 27: 197–199, 1977PubMedGoogle Scholar
  139. 139.
    Cassuto, J. P., Piereschi, J., Maiolini, R., Dujardin, P., Ribeil, R., Masseyeff, R.: Marqueurs HLA dans les myélomes et les dysglobulinémies monoclonales benignes. Nouv. Press Med. 10: 252–253, 1981Google Scholar
  140. 140.
    Castaldi, P. A., Penny, R.: A macroglobulin with antibody activity against coagulation factor VIII. Blood 35: 370–376, 1970PubMedGoogle Scholar
  141. 141.
    Castellano, M., Cattaneo, C.: Repeated remissions in a case of beta-plasmocytoma; variations in the blood protein picture during p-bis(2-chloroethyl)-amino-phenylalanine therapy. Minerva Med. 50: 2365–2369, 1959PubMedGoogle Scholar
  142. 142.
    Catovsky, D., Ikoku, N.B., Pitney, W.R., Galton, D.A.G.: Thrombembolie complications in multiple myeloma. Brit. Med. J. 3: 438–439, 1970PubMedCrossRefGoogle Scholar
  143. 143.
    Cavagnaro, F., Lein, J.M., Pavlovsky, S., Becherini, J.O., Pileggi, J.E., Micheo, E.Q., Jait, C., Musso, A., Suarez, A., Pizzolato, M.: Comparison of two combination chemotherapy regimens for multiple myeloma: Methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. Cancer Treat. Rep. 64: 73–79, 1980PubMedGoogle Scholar
  144. 144.
    Cavo, M., Gobbi, M., Tura, S.: Peptichemio in multiple myeloma. Haematologica 66: 208–215, 1981PubMedGoogle Scholar
  145. 145.
    Cejka, J., Kithier, K.: IgD myeloma protein with „unreactive“light chain determinants. Clin. Chem. 25: 1495–1498, 1979PubMedGoogle Scholar
  146. 146.
    Chang, T.: Transmissibility of human myelomatosis. Lancet 1: 94, 1972PubMedCrossRefGoogle Scholar
  147. 147.
    Chapman, I., Jimenez, F.A.: Aleutian–mink disease in man. N. Engl. J. Med. 269: 1171–1174, 1963PubMedCrossRefGoogle Scholar
  148. 148.
    Charks, N.D., Durant, J., Barry, W.E.: Bone pain in multiple myeloma. Arch. Intern. Med. 120: 53–58, 1971Google Scholar
  149. 149.
    Chen, C.Y., Chuang, C. Y., Lin, H.T., Chiang, F.T.: Immunological diagnosis of IgD paraprotein. J. Immunol. Meth. 13: 207–213, 1976CrossRefGoogle Scholar
  150. 150.
    Cheson, B.D., Plass, R.R., Rothstein, G.: Defective opsonization in multiple myeloma. Blood 55: 602–606, 1980PubMedGoogle Scholar
  151. 151.
    Chomette, G., Laumonier, R., Tayot, J.: Anatomie pathologique des lesions osseuses des hemopathies malignes. Sang. 31: 183–205, 1960Google Scholar
  152. 152.
    Chone, B.: Kombinierte Strahlen- und Chemotherapie beim Plasmozytom: Röntgen- diagnostische und eiweiβchemische Verlaufsperspektiven. In: Kombinierte Strahlen– und Chemotherapie. Hrsg.: Wannenmacher, M., Gauwerky, F., Streffer, C., Urban & Schwarzenberg, München-Wien-Baltimore, SS. 205–212, 1979Google Scholar
  153. 153.
    Christopherson, W.M., Miller, A. J.: A re-evaluation of solitary plasma-cell myeloma of bone. Cancer 3: 240–252, 1950CrossRefGoogle Scholar
  154. 154.
    Chronic Leukemia-Myeloma Task Force of the National Cancer Institute: Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother. Rep. 1: 17–39, 1968Google Scholar
  155. 155.
    Citrin, D.L., Ressent, R.G., Greig, W.R.: A comparison of the sensitivity and accuracy of the 99mTc-phosphate bone scan and skeletal radiography in the diagnosis of bone metastases. Clin. Radiol. 28: 107–117, 1977PubMedCrossRefGoogle Scholar
  156. 156.
    Clamp, J.R.: Some aspects of the first recorded case of multiple myeloma. Lancet 2: 1354–1356, 1967PubMedCrossRefGoogle Scholar
  157. 157.
    Clarke, E.: Cranial and intracranial myelomas. Brain 77: 61–81, 1954PubMedCrossRefGoogle Scholar
  158. 158.
    Clarke, E.: Spinal cord involvement in multiple myeloma. Brain 79: 332–348, 1956PubMedCrossRefGoogle Scholar
  159. 159.
    Clauvel, J. P., Dannon, F., Seligman, M.: Immunoglobulines monoclonales decelées en l’absence de myelome ou de macroglobulinemie de Waldenström. Nouv. Rev. Fr. Hematol. 11: 677–688, 1971PubMedGoogle Scholar
  160. 160.
    Cleary, B., Binder, R. A., Kales, A.N., Veltry, B. J.: Simultaneous presentation of acute myelomonocytic leukemia and multiple myeloma. Cancer 41: 1381–1386, 1978PubMedCrossRefGoogle Scholar
  161. 161.
    Cline, M.J., Haskell, C.M.: Multiple myeloma and macroglobulinemia. In: Cancer Chemotherapy. W.B.Saunders, Philadelphia, SS. 331–352, 1980Google Scholar
  162. 162.
    Clubb, J.S., Posen, S., Neale, F.C.: Disappearance of a serum paraprotein after parathyroidectomy. Arch. Intern. Med. 114: 616–620, 1964PubMedCrossRefGoogle Scholar
  163. 163.
    Clyne, D.H., Pollak, V.E.: Renal handling and pathophysiology of Bence Jones proteins. Contr. Nephrol. 24: 78–87, 1981Google Scholar
  164. 164.
    Coffino, P., Scharff, M.D.: Rate of somatic mutation in immunoglobulin production by mouse myeloma cells. Proc. Nat. Acad. Sci. 68: 219–223, 1971PubMedCrossRefGoogle Scholar
  165. 165.
    Cohen, D.M., Svien, H. J., Dahlin, D.C.: Long-term survival of patients with myeloma of the vertebral column. J. Amer. Med. Ass. 187: 914–917, 1964CrossRefGoogle Scholar
  166. 166.
    Cohen, H.: Hexamethylmelamine: A new agent effective in the treatment of refractory multiple myeloma. Blood Suppl. I, 50: 339, 1977Google Scholar
  167. 167.
    Cohen, H.J., Rundles, R. W.: Managing the complications of plasma cell myeloma. Arch. Intern. Med. 135: 177–184, 1975PubMedCrossRefGoogle Scholar
  168. 168.
    Cohen, H.J., Silberman, H.R., Larsen, W.E., Johnson, L., Bartolucci, A. A., Durant, J.R.: Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. Blood 54: 824–836, 1979PubMedGoogle Scholar
  169. 169.
    Cohen, P., Gardner, F.H.: Induction of subacute skeletal fluorosis in a case of multiple myeloma. N. Engl. J. Med. 271: 1129–1133, 1964PubMedCrossRefGoogle Scholar
  170. 170.
    Coleman, M., Vigliano, E.M., Weksler, M.E., Nachmann, R.L.: Inhibition of fibrin monomer polymerization by lambda myeloma globulin. Blood 39: 210–233, 1972PubMedGoogle Scholar
  171. 171.
    Cone, L., Uhr, J.W.: Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. J. Clin. Invest. 43: 2241–2248, 1964PubMedCrossRefGoogle Scholar
  172. 172.
    Conklin, R., Alexanian, R.: Clinical classification of plasma cell myeloma. Arch. Intern. Med. 135: 139–143, 1975PubMedCrossRefGoogle Scholar
  173. 173.
    Cornelius, C. E.: Animal models: A neglected medical resource. N. Engl. J. Med. 281: 934–944, 1969PubMedCrossRefGoogle Scholar
  174. 174.
    Cornell, C.J., Mclntyre, O.R., Kochwa, S., Weksler, B.B., Pajak, T.F.: Response to therapy in IgG myeloma patients excreting lambda or kappa light chains. CALGB experience. Blood 54: 23–29, 1979PubMedGoogle Scholar
  175. 175.
    Cornwell, G.G.III., Michaelsen, T.E., Sanders, W.H.: Comparative studies of a monoclonal IgG-lambda and two IgE-kappa components from an individual patient: Evidence for shared idiotypic determinants between the two IgE proteins but not with the IgG protein. Immunology 39: 511–517, 1980PubMedGoogle Scholar
  176. 176.
    Cornwell, G.G.III., Pajak, T.F., Mclntyre, O.R.: Hypersensitivity reactions to i.v. melphalan during treatment of multiple myeloma: Cancer und Leukemia Group B experience. Cancer Treat. Rep. 63: 399–403, 1979PubMedGoogle Scholar
  177. 177.
    Corwin, J., Lindberg, R.D.: Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma. Cancer 43: 1007–1013, 1979PubMedCrossRefGoogle Scholar
  178. 178.
    Costa, G., Carbone, P.P., Gold, G.L., Owens, A.H.Jr., Miller, S.P., Krint, M.J., Baro V.H.Jr.: Clinical trials of vinblastine in multiple myeloma. Cancer Chemother. Rep. 27: 87–89, 1963PubMedGoogle Scholar
  179. 179.
    Costa, G., Engle, R.L.Jr., Schilling, A., Carbone, P., Kochwa, S., Nachman, R.L., Glidewell, O.: Melphalan and prednisone: An effective combination for the treatment of multiple myeloma. Amer. J. Med. 54: 589–599, 1973CrossRefGoogle Scholar
  180. 180.
    Costea, N., Yakulis, V.J., Libnoch, J. A., Pilze, C.G., Heller, P.: Two myeloma globulins (IgG and IgA) in one subject and one cell line. Amer. J. Med. 42: 630–635, 1967PubMedCrossRefGoogle Scholar
  181. 181.
    Cox, D.R.: Regression models and life tables (with discussion). J. Roy. Statis. Soc. B. 34: 187–220, 1972Google Scholar
  182. 182.
    Cream, J.J.: Cryoglobulins in vasculitis. Clin. Exp. Immunol. 10: 117–126, 1972PubMedGoogle Scholar
  183. 183.
    Cutler, S.J., Young, J.L.: The third national cancer survey: incidence data. Natl. Cancer Inst. Monogr. 41, 1975Google Scholar
  184. 184.
    Cuzick, J.: Radiation–induced myelomatosis. N. Engl. J. Med. 304: 204–210, 1981PubMedCrossRefGoogle Scholar
  185. 185.
    Czitober, H.: Klinische Pathologie und Differentialdiagnose häufiger Osteopathien. Dtsch. med. Wschr. 22: 285–290, 1971Google Scholar
  186. 186.
    Dahlin, D.C.: Bone Tumours. Ch.C.Thomas, Springfield, Illinois, SS. 159–172, 1978Google Scholar
  187. 187.
    Dahlström, U., Järpe, S., Lindström, F. D.: Paraplegia in myelomatosis — A study of 20 cases. Acta Med. Scand. 205: 173–178, 1979Google Scholar
  188. 188.
    Dalrymple, J.: On the microscopical character of mollities ossium. Dublin Q. J. Med. Sci. 2: 85–95, 1846Google Scholar
  189. 189.
    Dalton, A., Potter, M., Merwin, R.M.: Some ultrastructural characteristics of a series of primary and transplanted plasma–cell tumors of the mouse. J. Natl. Cancer Inst. 26: 1221–1267, 1961PubMedGoogle Scholar
  190. 190.
    Damiani, G., Cosulich, E., Bargellesi, A.: Synthesis and secretion of IgG in synchronized mouse myeloma cells. Exp. Cell Res. 118: 295–303, 1979PubMedCrossRefGoogle Scholar
  191. 191.
    Dammaco, F., Clausen, J.: Antibody deficiency in paraproteinemia. Acta Med. Scand. 179: 755–768, 1966CrossRefGoogle Scholar
  192. 192.
    Dammacco, F., Miglietta, A., Tribalto, M., Mandelli, F., Bonomo, L.: The expanding spectrum of clinical and laboratory features of IgE myeloma. La Ricerca Clin. Lab. 10: 583–590, 1980CrossRefGoogle Scholar
  193. 193.
    Darbari, B.S., Bansal, N.C., Phadke, S.N., Arora, M.M.: Bilateral orbit plasmacytoma. Indian J. Ophthalmol. 20: 28–30, 1972PubMedGoogle Scholar
  194. 194.
    Davidson, S.: Solitary myeloma with peripheral polyneuropathy-recovery after treatment. Calif. Med. 116: 68–71, 1972PubMedGoogle Scholar
  195. 195.
    Davies, P.: Phase II studies of hydroxyurea (NSC–32065) in adults: Multiple myeloma and lymphoma. Cancer Chemother. Rep. 40: 51–52, 1964Google Scholar
  196. 196.
    Davies-Jones, G.A.B., Esiri, M.M.: Neuropathy due to amyloid in myelomatosis. Brit. Med. J. 2: 444, 1971PubMedCrossRefGoogle Scholar
  197. 197.
    Dawson, A. A., Ogston, D.: Factors influencing the prognosis in myelomatosis. Postgrad. Med. J. 47: 635–638, 1971PubMedCrossRefGoogle Scholar
  198. 198.
    Decoufle, P., Stanislawczyk, K., Houten, L.: A retrospective survey of cancer in relation to occupation. DHEW Publication No. (NIOSH) 77–178, Washington DC, US Government Printing Office, 1977Google Scholar
  199. 199.
    Deodhare, S.G., Pujari, B.D., Apte, P.G.: Plasmacytomas of gastrointestinal tract. J. Postgrad. Med. 21: 145–150, 1975PubMedGoogle Scholar
  200. 200.
    De Fronzo, R. A., Cooke, C. R., Wright, J. R., Humphrey, R. L.: Renal function in patients with multiple myeloma. Medicine 57: 151–166, 1978Google Scholar
  201. 201.
    De Fronzo, R.A., Humphrey, R.L., Wright, J.R., Cooke, C.R.: Acute renal failure in multiple myeloma. Medicine 54: 209–223, 1975CrossRefGoogle Scholar
  202. 202.
    Delauche, M. C., Clauvel, J. P., Seligmann, M.: Peripheral neuropathy and plasma cell neoplasias: A report of 10 cases. Brit. J. Haematol. 48: 383–392, 1981CrossRefGoogle Scholar
  203. 203.
    Dellagi, K., Brouet, J.C., Danon, F.: Cross-idiotypic antigens among monoclonal immunoglobulin-M from patients with Waldenström’s macroglobulinemia and polyneuropathy. J. Clin. Invest. 64: 1530–1534, 1979PubMedCrossRefGoogle Scholar
  204. 204.
    Derechin, M. M., Goldberg, L. S., Herron, L.: Extraosseous plasmacytomas causing extrahepatic cholestasis and cardiac tamponade: a unique case of multiple myeloma. Scand. J. Haematol. 7: 318–321, 1970PubMedCrossRefGoogle Scholar
  205. 205.
    Derot, M., Wajcner, G., Petrover, M.: L’insuffisance renale aigue de la maladie de Kahler. Presse Med. 77: 43–46, 1969PubMedGoogle Scholar
  206. 206.
    De Vita, V.T.Jr., Serpick, A. A., Carbone, P.P.: Combination chemotherapy in the treatment of Hodgkin’s disease. Ann. Intern. Med. 73: 881–895, 1970Google Scholar
  207. 207.
    Dexter, R.X., Mullinax, F., Estep, H.L., Williams, R.C.: Monoclonal IgG gammopathy and hyperparathyroidism. Ann. Intern. Med. 77: 759–764, 1972PubMedGoogle Scholar
  208. 208.
    Dillman, C. E., Silverstein, M. N.: Alkaline phosphatase in multiple myeloma. Amer. J. Med. Sci. 249: 445–447, 1965PubMedCrossRefGoogle Scholar
  209. 209.
    Dillman, R. O., Royston, I., Meserve, B. L., Griffiths, J. C.: Alterations of peripheral blood B-lymphocyte populations in plasma cell disorders. Cancer 48: 2211–2217, 1981PubMedCrossRefGoogle Scholar
  210. 210.
    D’lncalci, M., Bolis, G., Facchinetti, T., Mangioni, C., Morasca, L., Morazzoni, P., Salmona, M.: Decreased half life of cyclophosphamide in patients under continual treatment. Eur. J. Cancer 15: 7–10, 1979CrossRefGoogle Scholar
  211. 211.
    Djaldetti, M., Joshua, H.: Acute plasma cell leukemia. A case report. Isr. Med. J. 20: 109–113, 1961PubMedGoogle Scholar
  212. 212.
    Dolin, S., Dewar, J.P.: Extramedullary plasmacytoma. Amer. J. Pathol. 32: 83–103, 1956Google Scholar
  213. 213.
    Dolphin, G.W.: A comparison of the observed and expected cancers of the haematopoietic and lymphatic systems among workers at Windscale. Natl. Radiol. Prot. Board, NRPB-R54, Harwell, 1976Google Scholar
  214. 214.
    Dörken, H., Vollmer, I.: Die Epidemiologic des multiplen Myeloms — Untersuchungen an 149 Fällen. Arch. Geschwulstforsch. 31: 18–38, 1968PubMedGoogle Scholar
  215. 215.
    Dorrington, K.J., Painter, R.H.: Biological activities of the constant region of immune-globulin G. In: Progress in Immunology III. Hrsg.: Mandel, T.E., Cheers, Ch., Hosking, C.S., McKenzie, I.F.C., Nossal, G.J.V., North-Holland Publishing Comp., Amsterdam SS. 298–305, 1977Google Scholar
  216. 216.
    Doss, L.L.: Simultaneous extramedullary plasmacytomas of the vagina and vulva. A case report and review of the literature. Cancer 41: 2468–2474, 1978PubMedCrossRefGoogle Scholar
  217. 217.
    Douglas, D.C., Russell, R.G., Preston, C.J., Prenton, MA., Duckworth, T., Kanis, J. A., Preston, F. E., Woodhead, J. S.: Effect of dichloromethylene diphosphonate in Paget’s disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1: 1043–1047, 1980PubMedCrossRefGoogle Scholar
  218. 218.
    Douglas, S. D., Kamin, R. M., Fudenberg, H. H.: Human lymphocyte response to phy-tomitogens,in vitro‘: normal, agammaglobulinemic and paraproteinemic individuals. J. Immunol. 103: 1185–1195, 1969PubMedGoogle Scholar
  219. 219.
    Drewinko, B., Alexanian, R.: The changing growth kinetics of multiple myeloma. Blood Suppl. I, 50: 145, 1977Google Scholar
  220. 220.
    Drewinko, B., Alexanian, R., Boyer, H., Barlogie, B., Rubinow, S. I.: The growth fraction of human myeloma cells. Blood 57: 333–338, 1981PubMedGoogle Scholar
  221. 221.
    Drewinko, B., Brown, B. W, Humphrey, R., Alexanian, R.: Effect of chemotherapy on the labelling index of myeloma cells. Cancer 34: 526–531, 1974PubMedCrossRefGoogle Scholar
  222. 222.
    Drewinko, B., Trujillo, J. M., Tessmer, C. F.: Functional sequences modulated by morphological transitions in human lymphoid cells grown in vitro. Science 171: 185–186, 1971PubMedCrossRefGoogle Scholar
  223. 223.
    Driedger, H., Pruzanski, W.: Plasma cell neoplasia with peripheral polyneuropathy. Medicine 59: 301–310, 1980PubMedCrossRefGoogle Scholar
  224. 224.
    Durie, B.G.M., Cole, P.W., Chen, H.S.G., Himmelstein, K.J., Salmon, S.E.: Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma. Brit. J. Haematol. 47: 7–19, 1981CrossRefGoogle Scholar
  225. 225.
    Durie, B.G., Russel, D.H., Salmon, S.E.: Reappraisal of plateau phase in myeloma. Lancet 2: 65–67, 1980PubMedCrossRefGoogle Scholar
  226. 226.
    Durie, B. G. M., Salmon, S. E.: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36: 842–854, 1975PubMedCrossRefGoogle Scholar
  227. 227.
    Durie, B. G. M., Salmon, S.: The kappa (k)/lambda (λ) survival difference in multiple myeloma (MM): Evidence for a biologic basis. Proc. Amer. Soc. Clin. Oncol. 21: C- 642, 1980Google Scholar
  228. 228.
    Durie, B.G.M., Salmon, S.E., Moon, T.E.: Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55: 364–372, 1980PubMedGoogle Scholar
  229. 229.
    Durie, B. G. M., Salmon, S. E., Mundy, G. R.: Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Brit. J. Haematol. 47: 21–30, 1981CrossRefGoogle Scholar
  230. 230.
    Ende, M.: Multiple myeloma: a cluster in Virginia? Va. Med. 106: 114–116, 1979Google Scholar
  231. 231.
    Endo, T., Okumura, H., Kikuchi, K., Munakata, J., Otake, M., Nomura, T., Asakawa, H.: Immunoglobulin E (IgE) multiple myeloma. A case report and review of the literature. Amer. J. Med. 70: 1127–1132, 1981PubMedCrossRefGoogle Scholar
  232. 232.
    Engle, R.L., Wallis, L.A.: Immunoglobulinopathies. Ch.C.Thomas, Springfield, Illinois, 1969Google Scholar
  233. 233.
    Eriksen, N.: Serum macroglobulin levels in relation to age, sex and disease. J. Lab. Clin. Med. 51: 521–529, 1958PubMedGoogle Scholar
  234. 234.
    Ewing, M.R., Foote, F.W.Jr.: Plasma-cell tumors of the mouth and upper air passages. Cancer 5: 499–513, 1952PubMedCrossRefGoogle Scholar
  235. 235.
    Faber, M.: Twenty–eight years of continuous follow–up of patients injected with Thorotrast for cerebral angiography. Environ. Res. 18: 37–43,1979Google Scholar
  236. 236.
    Factor, S. M., Winn, R. M., Biempica, L.: The histiocytic origin of the multinucleated giant cells in myeloma kidney. Hum. Pathol. 9: 114–120, 1978PubMedCrossRefGoogle Scholar
  237. 237.
    Fadem, R. S.: Differentation of plasmocytic response from myelomatous disease on the basis of bone-marrow findings. Cancer 5: 128–137, 1952PubMedCrossRefGoogle Scholar
  238. 238.
    Fagiolo, E., Tosato, G.: IgM plasmacytoma: Report of a case and review of the literature. Haematologia 12: 221–229, 1978PubMedGoogle Scholar
  239. 239.
    Fagreus, A.: Antibody production in relation to the development of plasma cells. Acta Med. Scand., Suppl. 204,130: 3–122, 1948Google Scholar
  240. 240.
    Fahey, J. L., Scoggins, R., Utz, J. P., Szwed, C. F.: Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia. Amer. J. Med. 35: 698–707, 1963PubMedCrossRefGoogle Scholar
  241. 241.
    Farhangi, M., Osserman, E.F.: The treatment of multiple myeloma. Semin. Hematol. 10: 149–161, 1973PubMedGoogle Scholar
  242. 242.
    Farhangi, M., Osserman, E. F.: Myeloma with xanthoderma due to an IgG lambda monoclonal antiflavin antibody. N. Engl. J. Med. 294: 177–183, 1976PubMedCrossRefGoogle Scholar
  243. 243.
    Farhangi, M., Osserman, E.F.: Biology, clinical patterns, and treatment of multiple myeloma and related plasma–cell dyscrasias. In: The Immunopathology of Lympho- reticular Neoplasms. Hrsg.: Twomey, M.B., Good, R.A., Plenum Press, London, SS. 641–718, 1978CrossRefGoogle Scholar
  244. 244.
    Fateh-Moghadam, A.: Paraproteinämische Hämoblastosen. Handbuch der inneren Medizin. Band II/5, Hrsg.: Begemann, H., Springer-Verlag, Berlin-Heidelberg-New York, SS. 245–452, 1974Google Scholar
  245. 245.
    Fateh-Moghadam, A., Lamerz, R., Knedel, M., Bauer, B.: Quantitative immunologische Bestimmung von Serumproteinen bei Paraproteinämien. Dtsch. med. Wschr. 98: 309–318, 1973PubMedGoogle Scholar
  246. 246.
    Fayemi, A. O., Wisniewski, M.: Pulmonary calcification in a patient with multiple myeloma. Chest 64: 765–769, 1973PubMedCrossRefGoogle Scholar
  247. 247.
    Feinleib, M., MacMahon, B.: Duration of survival in multiple myeloma. J. Natl. Cancer Inst. 24: 1259–1269, 1960PubMedGoogle Scholar
  248. 248.
    Festen, J.J. M., Marrink, J., Sijpesteijn, J.A.K., van Loghem, E., Nijenhuis, L. E., Mandema, E.: A study on the association between myelomatosis and immunoglobulin allotypes, HLA, and blood groups. Immunogenetics, 3: 201–203, 1976CrossRefGoogle Scholar
  249. 249.
    Fialkow, P.J., Denmann, A.M., Jacobson, R.J., Lowenthal, M.N.: Chronic myelocytic leukemia: Origin of some lymphocytes from leukemic stem cells. J. Clin. Invest. 62: 815–823, 1978PubMedCrossRefGoogle Scholar
  250. 250.
    Fine, J. D., Luke, R. G., Rees, E. D.: Multiple myeloma and renal involvement. Lancet 2: 1205–1206, 1973PubMedCrossRefGoogle Scholar
  251. 251.
    Fine, J.M., Lambin, P., Müller, J.Y.: The evolution of asymptomatic monoclonal gammopathies. Acta Med. Scand. 205: 339–341, 1979PubMedCrossRefGoogle Scholar
  252. 252.
    Firkin, F., Lee, N., Ramsay, R., Robertson, I.: Visual loss caused by corneal crystals in multiple myeloma. Med. J. Aust. 2: 677–678, 1979PubMedGoogle Scholar
  253. 253.
    Fisher, E.R., Perez-Stable, E, Zawadzki, Z.A.: Ultrastructural renal changes in multiple myeloma with comments relative to the mechanism of proteinuria. Lab. Invest. 13: 1561–1574, 1964PubMedGoogle Scholar
  254. 254.
    Fisher, E. R., Zawadzki, Z.: Ultrastructural features of plasma cells in patients with paraproteinemias. Amer. J. Clin. Pathol. 54: 779–789, 1970Google Scholar
  255. 255.
    Fishkin, B.G., Glassy, F.J., Hattersley, P.G., Hirose, F.M., Spiegelberg, H.L.: IgD multiple myeloma: A report of 5 cases. Amer. J. Clin. Pathol. 53: 209–214, 1970Google Scholar
  256. 256.
    Fitchen, J.H., Lee, S.: Phagocytic myeloma cells. Amer. J. Clin. Pathol. 71: 722–723, 1979Google Scholar
  257. 257.
    Fleegler, D., Fogarty, C., Owens, G., Cohen, E., Cassileth, P. A.: Pathologic flail chest complicating multiple myeloma. Arch. Intern. Med. 140: 414–415, 1980PubMedCrossRefGoogle Scholar
  258. 258.
    Foa, P.: Sulla produzione cellulare nell’ inflammazione ed in altri processi analoghi specialmente in cio che si referisce alle plasmacellulare. Folia Haematol. (Leipzig) 1: 166–167, 1904Google Scholar
  259. 259.
    Fogelman, J.: Skeletal uptake of diphosphonate: A review. Eur. J. Nucl. Med. 5: 473–476, 1980PubMedGoogle Scholar
  260. 260.
    Forster, G.V., Doyle, F.H.: Effects of thyrocalcitonin on bone. Lancet 2: 1428–1431, 1966CrossRefGoogle Scholar
  261. 261.
    Foye, L.V.Jr., Chapman, C.G., Willet, F.M., Adams, W.S.: Cyclophosphamide: A preliminary study of a new alkylating agent. Cancer Chemother. Rep. 6: 39–40, 1960PubMedGoogle Scholar
  262. 262.
    Frangione, B., Milstein, C., Pink, J. R. L.: Structural studies of immunoglobulin G. Nature 221: 145–148, 1969PubMedCrossRefGoogle Scholar
  263. 263.
    Franklin, E.C., Zucker-Franklin, D.: Current concepts of amyloid. Adv. Immunol. 15: 249–304, 1972PubMedCrossRefGoogle Scholar
  264. 264.
    Fülle, H. H., Pribilla, W.: Diagnose und Therapie der Plasmazellenleukamie. Dtsch. med. Wschr. 98: 874–881, 1973PubMedCrossRefGoogle Scholar
  265. 265.
    Furie, B., Green, E., Furie, B.C.: Syndrome of acquired factor X deficiency and systemic amyloidosis. In vivo studies of the metabolic fate of factor X. N. Engl. J. Med. 297: 81–85, 1977PubMedCrossRefGoogle Scholar
  266. 266.
    Gach, J., Simar, L., Salmon, J.: Multiple myeloma without M–type proteinemia. Amer. J. Med. 50: 835–844, 1971PubMedCrossRefGoogle Scholar
  267. 267.
    Garret, T.J., McCans, J.L., Parker, J.O.: Fatal involvement of the heart with multiple myeloma. Can. Med. Ass. J. 107: 979–980, 1972Google Scholar
  268. 268.
    Gasparotto, G., Samanzato, G., Tosato, F., Cazzaro, G., Amadori, G.: Etude de l’immunologic cellulaire dans les gammapaties monoclonales malignes et benignes. Schweiz. med. Wschr. 106: 1823–1825, 1976PubMedGoogle Scholar
  269. 269.
    George, E.R., Cohen, H.J.: The kinetics of immunoglobulin synthesis by Pokeweed mitogen stimulated peripheral blood lymphocytes in multiple myeloma. Amer. J. Haematol. 6: 361–371, 1979CrossRefGoogle Scholar
  270. 270.
    George, R.P., Poth, J.L., Gordon, D., Schrier, S.L.: Multiple myeloma–intermittent combination chemotherapy compared to continuous therapy. Cancer 29: 1665–1670, 1972PubMedCrossRefGoogle Scholar
  271. 271.
    Geschickter, Ch.F., Copeland, M.M.: Multiple myeloma. Arch. Surg. 16: 807–863, 1928CrossRefGoogle Scholar
  272. 272.
    Getaz, P., Handler, L., Jacobs, P., Tunley, I.: Osteosclerotic myeloma with peripheral neuropathy. S. Afr. Med. J. 48: 1246–1250, 1974PubMedGoogle Scholar
  273. 273.
    Ghanta, V.K., Jones, M.T., Woodard, D.A., Durant, J.R., Hiramoto, R.N.: Cis- dichlorodiammineplatinum (II) chemotherapy in experimental murine myeloma MO PC 104 E. Cancer Res. 37: 771–774, 1977PubMedGoogle Scholar
  274. 274.
    Ghosh, M.L., Sayeed, A.: Unusual cases of myelomatosis. Scand. J. Haematol. 12: 147–154, 1974PubMedCrossRefGoogle Scholar
  275. 275.
    Gilbert, E.S., Marks, S.: An analysis of mortality of workers in a nuclear facility. Ra– diat. Res. 79: 122–148, 1979PubMedCrossRefGoogle Scholar
  276. 276.
    Ginsberg, D. M.: Circulating plasma cells in multiple myeloma. A method for detection and review of the problem. Ann. Intern. Med. 57: 843–846, 1962PubMedGoogle Scholar
  277. 277.
    Glaser, G.H.: Neurologic complications of internal diseases. In: Clinical Neurology. Hrsg.: Baker, A.B., Hoeber Harper, New York, 1962Google Scholar
  278. 278.
    Glaus, A.: Über multiples Myelozytom mit eigenartigen, zum Teil kristallähnlichen Zelleinlagerungen, kombiniert mit Elastolyse und ausgedehnter Amyloidose und Ver– kalkung. Virchow’s Arch, pathol. Anat. 223: 301–339, 1917CrossRefGoogle Scholar
  279. 279.
    Gleich, G. J., Averbeck, A. K., Swedlund, H. A.: Measurement of IgE in normal and allergic serum by radioimmunoassay. J. Lab. Clin. Med. 77: 690–698, 1971PubMedGoogle Scholar
  280. 280.
    Glenchur, H., Zinneman, H. H., Hall, W. H.: A review of fifty-one cases of multiple myeloma: emphasis on pneumonia and other infections as complications. Arch. Intern. Med. 103: 173–183, 1959CrossRefGoogle Scholar
  281. 281.
    Glenner, G.G., Page, D.L.: Amyloid, amyloidosis, and amyloidogenesis. Int. Rev. Exp. Pathol. 15: 1–92, 1976PubMedGoogle Scholar
  282. 282.
    Glenner, G. G., Terry, W. D.: Characterization of amyloid. Ann. Rev. Med. 25: 131–135, 1974PubMedCrossRefGoogle Scholar
  283. 283.
    Glenner, G.G., Terry, W., Harada, M., Iserky, C., Page, D.: Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science 172: 1150–1151, 1971PubMedCrossRefGoogle Scholar
  284. 284.
    Glueck, H.I., Hong, R.: A circulating anticoagulant in gamma1-A multiple myeloma: Its modification by penicillin. J. Clin. Invest. 44: 1866–1881, 1965PubMedCrossRefGoogle Scholar
  285. 285.
    Gluzinski, A., Reichenstein, M.: Myeloma und Leucaemia lymphatica plasmocellularis. Wien. klin. Wschr. 19: 336–339, 1906Google Scholar
  286. 286.
    Godal, H. C., Borchgrevnik, C. F.: The effect of plasmapheresis on the hemostatic function in patients with macroglobulinemia Waldenstrom and multiple myeloma. Scand. J. Clin. Lab. Invest. 17: Suppl. 84, 133–137, 1965Google Scholar
  287. 287.
    Goeggel-Lamping, C., Kahn, S.B.: Gastrointestinal polyposis in multiple myeloma. J. Amer. Med. Ass. 239: 1786–1787, 1978CrossRefGoogle Scholar
  288. 288.
    Goldman, R., Adams, W.S., Luchsinger, E.B.: Renal function in multiple myeloma. J. Lab. Clin. Med. 40: 519–522, 1952PubMedGoogle Scholar
  289. 289.
    Goldstein, W. B., Poker, N.: Multiple myeloma involving the gastrointestinal tract. Gastroenterology 51: 87–93, 1966PubMedGoogle Scholar
  290. 290.
    Gompertz, B.: On the nature of the function expressive of the law of human mortality, and on the new mode of determining the value of life contingencies. Philos. Trans. R. Soc. Lond. (Biol.) 115: 513–585, 1825CrossRefGoogle Scholar
  291. 291.
    Gonzalez, F., Trujillo, M., Alexanian, R.: Acute leukemia in multiple myeloma. Ann. Intern. Med. 86: 440–443, 1973Google Scholar
  292. 292.
    Good, R.A., Kelly, W.D., Rotstein, J., Varco, R.L.: Immunological deficiency diseases. Progr. Allergy 6: 187–319, 1962Google Scholar
  293. 293.
    Goodman, J.R., Hall, S.G.: Plasma cells containing iron. An electron micrographic study. Blood 28: 83–93, 1966PubMedGoogle Scholar
  294. 294.
    Goodman, T.F.Jr., Abele, D.C., West, C.S.Jr.: Electron microscopy in the diagnosis of amyloidosis. Arch. Dermatol. 106: 393–397, 1972PubMedCrossRefGoogle Scholar
  295. 295.
    Gootnick, L.T.: Solitary myeloma: Review of sixty-one cases. Radiology 45: 385–391, 1945Google Scholar
  296. 296.
    Gordon, H., Bandmann, M., Sandbank, U.: Multiple myeloma associated with progressive multifocal leukoencephalopathy and Pneumocystis carinii pneumonia. Isr. J. Med. Sci. 7: 581–588, 1971PubMedGoogle Scholar
  297. 297.
    Gordon-Smith, E.C., Harrison, R.J., Hobbs, J.R.: Multiple myeloma presenting as cryoglobulinemia. Proc. Roy. Soc. Med. 61: 1112–1115, 1968PubMedGoogle Scholar
  298. 298.
    Grabar, P., Williams, C. A.: Methode permettande l’étude conjuguée des proprietés electrophorétiques et immunochimiques d’un mélange de protéines: application au sérum sanguin. Biochim. Biophys. Acta 10: 193–194, 1953PubMedCrossRefGoogle Scholar
  299. 299.
    Graham, R.C., Bernier, G. M.: The bone marrow in multiple myeloma: Correlation of plasma cell ultrastructure and clinical state. Medicine 54: 225–243, 1975PubMedCrossRefGoogle Scholar
  300. 300.
    Greene, M.H., Hoover, R.N., Eck, R.L., Fraumeni, J.F.Jr.: Cancer mortality among printing plant workers. Environ. Res. 20: 66–73, 1979PubMedCrossRefGoogle Scholar
  301. 301.
    Grey, H.M., Kohler, P.F.: Cryoimmunoglobulins. Semin. Hematol. 10: 87–112, 1973PubMedGoogle Scholar
  302. 302.
    Grey, H.M., Kunkel, H.G.: H chain subgroups of myeloma proteins and normal 7 S- gamma-globulin. J. Exp. Med. 120: 253–266, 1964PubMedCrossRefGoogle Scholar
  303. 303.
    Gross, R., Lambers, K.: Erste Erfahrungen in der Behandlung maligner Tumoren mit einem neuen N-lost-phosphamid-ester. Dtsch. med. Wschr. 83: 458–462, 1958PubMedCrossRefGoogle Scholar
  304. 304.
    Gunz, F. W., Gunz, J. P., Leigh, J.: Contacts among patients with haematological malignancies. Cancer 41: 2379–2387, 1978PubMedCrossRefGoogle Scholar
  305. 305.
    Gutterman, J. U., Blumenschein, G. R., Alexanian, R., Yap, H. Y., Buzdar, A. U., Cabanillas, F., Hortobagyi, G.N., Hersh, E.M., Rasmussen, S.L., Harmon, M., Kramer, M., Pestka, S.: Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann. Intern. Med. 93: 399–406, 1980PubMedGoogle Scholar
  306. 306.
    Guzzo, C. E., Pachas, W. N., Prinals, R. S., Krant, M. D.: Urinary hydroxyproline excretion in patients with cancer. Cancer 24: 382–387, 1969PubMedCrossRefGoogle Scholar
  307. 307.
    Haeney, M.R., Ross, I.N., Thompson, R.A., Asquith, P.: IgG myeloma presenting as ulcerative colitis. J. Clin. Pathol. 30: 862–867, 1977PubMedCrossRefGoogle Scholar
  308. 308.
    Hamaker, W. R., Lindell, M. E., Gomez, A. C.: Plasmacytoma arising in a pacemaker pocket. Ann. Thorac. Surg. 21: 354–356, 1976PubMedCrossRefGoogle Scholar
  309. 309.
    Hamburger, A., Salmon, S.: Primary bioassay of human myeloma stem cells. J. Clin. Invest. 60: 846–854, 1977PubMedCrossRefGoogle Scholar
  310. 310.
    Hansen, O.P.: Bone marrow studies in myelomatosis. Scand. J. Haematol. 21: 265–272, 1978PubMedCrossRefGoogle Scholar
  311. 311.
    Hansen, O.P., Jessen, B., Videback, A.: Prognosis of myelomatosis on treatment with prednisone and cytostatics. Scand. J. Haematol. 10: 282–290, 1973PubMedCrossRefGoogle Scholar
  312. 312.
    Harboe, M., Følling, I., Haugen, O. A., Bauer, K.: Sudden death caused by interaction between a macroglobulin and a divalent drug. Lancet 2: 285–288, 1976PubMedCrossRefGoogle Scholar
  313. 313.
    Harley, J.B., Pajak, T.F., Mclntyre, O.R., Kochwa, S., Cooper, M.R., Coleman, ML, Cuttner, J.: Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: A study of the CALGB. Blood 54: 13–22, 1979PubMedGoogle Scholar
  314. 314.
    Harley, J.B., Ramanan, S.V., Kim, I., Thiagarajan, P.Y., Chen, J.H., Gomez, R., Koppel, D., Hyde, F., Gustke, S., Krall, J.: The cyclic use of multiple alkylating agents in multiple myeloma. W. Va. Med. J. 68: 1–3, 1972Google Scholar
  315. 315.
    Harris, J.E., Alexanian, R., Hersh, E.M., Migliore, P.: Immune function in multiple myeloma: Impaired responsiveness to keyhole limpet hemocyanin. Can. Med. Ass. J. 104: 389–392, 1971PubMedGoogle Scholar
  316. 316.
    Hart, J.S., Lawrence, M.C., Ritzmann, S.E., Levin, W.C.: II. Hyper- and hypopro- teinemias. 1. Hyperproteinemia. Correlations of elevated total serum protein values and their responsible globulin fractions with various polyclonal and monoclonal gammopathies. A study of 173 sera. Texas Rep. Biol. Med. 23: 445–457, 1965Google Scholar
  317. 317.
    Harwood, A.R., Knowling, M. A., Bergsagel, D.E.: Radiotherapy of extramedullary plasmacytoma of the head and neck. Clin. Radiol. 32: 31–36, 1981PubMedCrossRefGoogle Scholar
  318. 318.
    Hayes, D.W., Bennett, W. A., Heck, F.J.: Extramedullary lesions in multiple myeloma. Review of literature and pathologic studies. Arch. Pathol. 53: 262–272, 1952Google Scholar
  319. 319.
    Hayes, J.S., Jankey, N., Cuthbert, A.L.: Massive proteinuria in light chain disease. Arch. Intern. Med. 138: 785–786, 1978PubMedCrossRefGoogle Scholar
  320. 320.
    Hedinger, E.: Zur Frage des Plasmocytoms. Frankfurt Z. Pathol. 7: 343–350, 1911Google Scholar
  321. 321.
    Heilmann, D.: Plasmocytom auf dem Boden einer chronischen Osteomyelitis bei gleichzeitiger Osteitis deformans. Munch. Med. Wschr. 99: 1586–1588, 1957PubMedGoogle Scholar
  322. 322.
    Heilmann, E., Schuckall, A., Intorp, H.: Ein Plasmozytom mit wechselnder Parapro– teinämie. Folia Haematol. (Leipzig) 105: 750–753, 1978Google Scholar
  323. 323.
    Heilmeyer, L., Begemann, H.: Blut und Blutkrankheiten. Handbuch der inneren Medizin. Band II, Springer Verlag, Berlin-Göttingen-Heidelberg, S. 735–751, 1951Google Scholar
  324. 324.
    Hendersen, J.W.: Orbital Tumors. W.B.Saunders, Philadelphia, 1973Google Scholar
  325. 325.
    Heremans, J.F., Laurell, A.H., Martensson, L., Heremans, M.T., Laurell, C.B., Sjoquist, J., Waldenström, J.: Studies in „abnormal“serum M-components in myeloma, macroglobulinemia and related disease. Acta Med. Scand. 170: Suppl. 367, 1–126, 1961Google Scholar
  326. 326.
    Herskovic, T., Bartholomew, L.G., Green, P. A.: Amyloidosis and the malabsorption syndrome. Arch. Intern. Med. 114: 629–633, 1964PubMedCrossRefGoogle Scholar
  327. 327.
    Heyburn, P. J., Child, J. A., Peacock, M.: Relative importance of renal failure and in¬creased bone resorption in the hypercalcaemia of myelomatosis. J. Clin. Pathol. 34: 54–57, 1981PubMedCrossRefGoogle Scholar
  328. 328.
    Hill, G. S., Morel-Maroger, L., Mery, J. P., Mignon, F.: Correlations between relative electrophoretic motilities of light chains and renal lesions in multiple myeloma. (Abstract), Proc. Amer. Soc. Nephrol. 78, 1978Google Scholar
  329. 329.
    Hippe, E., Paaske Hansen, O., Drivsholm, J.: Decreased serum cobalamin in multiple myeloma without sign of vitamin B12 deficiency: a preliminary report. Scand. J. Gastroenterol. 9: Suppl. 29, 85–87, 1974Google Scholar
  330. 330.
    Hobbs, J.R.: Paraproteins, benign or malignant? Brit. Med. J. 2: 699–704, 1967CrossRefGoogle Scholar
  331. 331.
    Hobbs, J.R.: Immunochemical classes of myelomatosis. Including data from a therapeutic trial conducted by a medical research council working party. Brit. J. Haematol. 16: 599–606, 1969CrossRefGoogle Scholar
  332. 332.
    Hobbs, J. R.: Growth rates and responses to treatment in human myelomatosis. Brit. J. Haematol. 16: 607–617, 1969CrossRefGoogle Scholar
  333. 333.
    Hoffbrand, A.V., Hobbs, J.R., Kremenchuzky, S., Mollin, D.L.: Incidence and pathogenesis of megaloblastic erythropoiesis in multiple myeloma. J. Clin. Pathol. 20: 699–705, 1967PubMedCrossRefGoogle Scholar
  334. 334.
    Hofmann, V., Salmon, S. E., Durie, B. G. M.: Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine. Blood 58: 471–476, 1981PubMedGoogle Scholar
  335. 335.
    Holland, J.F., Hosley, H., Scharlan, C., Carbone, P.P., Frei, E.III., Brindley, C.O., Hall, T.C., Shnider, B.I., Gold, G.L., Lasagna, L., Owens, A.H.Jr., Miller, S.: A controlled trial of Urethane treatment in multiple myeloma. Blood 27: 328–342, 1966PubMedGoogle Scholar
  336. 336.
    Hollander, V. P., Takakura, K., Yamada, H.: Endocrine factors in the pathogenesis of plasma cell tumors. Recent Prog. Horm. Res. 24: 81–137, 1968PubMedGoogle Scholar
  337. 337.
    Holm, G., Mellstedt, H., Pettersen, D., Biberfeld, P.: Idiotypic immunglobulin structures on blood lymphocytes in human plasma cell myeloma. Immunol. Rev. 34: 139–164, 1977PubMedCrossRefGoogle Scholar
  338. 338.
    Holman, R. L., Hill, C.: Complete anuria due to blockage of renal tubules by protein casts in a case of multiple myeloma. Arch. Pathol. 27: 748–752, 1939Google Scholar
  339. 339.
    Hoogstraten, B.: Steroid therapy of multiple myeloma and macroglobulinaemia. Med. Clin. North Amer. 57: 1321–1330, 1973Google Scholar
  340. 340.
    Hoogstraten, B., Sheche, P.R., Cuttner, J., Cooper, T., Kyle, R.A., Oberfild, R.A., Townsend, S. R., Harley, J. B., Hayes, D. M., Costa, G., Holland, J. F.: Melphalan in multiple myeloma. Blood 30: 74–83, 1967PubMedGoogle Scholar
  341. 341.
    Hoover, R.G., Hickman, S., Gebel, H.M., Rebbe, N., Lynch, R.G.: Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma. J. Clin. Invest. 67: 308–311, 1981PubMedCrossRefGoogle Scholar
  342. 342.
    Hopper, J. E., Haren, J. M., Kmiecik, T. E.: Evidence for shared idiotypy expressed by the IgM, IgG, and IgA serum proteins of a patient with a complex multiple paraprotein disorder. J. Immunol. 122: 2000–2006, 1979PubMedGoogle Scholar
  343. 343.
    Horton, J.E., Koopman, A. J., Farrer, J. J., Fuller-Bonar, J., Mergenhagen, S.E.: Partial purification of a bone resorbing factor elaborated from human allogeneic cultures. Cell. Immunol. 43: 1–10, 1979PubMedCrossRefGoogle Scholar
  344. 344.
    Horton, J.E., Raisz, L.G., Simons, H.A., Oppenheim, J. J., Mergenhagen, S.E.: Bone resorbing activity in supernatant fluid from human cultured peripheral blood leukocytes. Science 177: 793–795, 1972PubMedCrossRefGoogle Scholar
  345. 345.
    Hosley, H.G., Taft, E.G., Olson, K.B., Gates, S., Beeby, R.: Hydroxyproline excretion in malignant disease. Arch. Intern. Med. 118: 565–571, 1966PubMedCrossRefGoogle Scholar
  346. 346.
    Houwen, B., Ockhuizen, T., Marrink, J., Nieweg, H. O.: Yindesine therapy in melphalan-resistant multiple myeloma. Eur. J. Cancer 17: 227–232, 1981PubMedCrossRefGoogle Scholar
  347. 347.
    Howell, M.: Acquired factor X deficiency associated with systemic amyloidosis: Report of a case. Blood 21: 739–744, 1963PubMedGoogle Scholar
  348. 348.
    Hozumi, N., Tonegawa, S.: Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc. Nat. Acad. Sci. US 73: 3628–3632, 1976CrossRefGoogle Scholar
  349. 349.
    Huber, H., Douglas, S. D., Nusbacher, J., Kochwa, S., Rosenflld, R. E.: IgG subclass speciflty of human monocyte receptor site. Nature 229: 419–420, 1971PubMedCrossRefGoogle Scholar
  350. 350.
    Hübner, K. F., Andrews, G. A., Hayes, R. L., Poggenburg, J. K., Solomon, A.: The use of rare-earth radionuclides and other bone-seekers in the evaluation of bone lesions in patients with multiple myeloma or solitary plasmocytoma. Radiology 125: 171–176, 1977PubMedGoogle Scholar
  351. 351.
    Hughes, J.C., Votaw, M.L.: Pleural effusion in multiple myeloma. Cancer 44: 1150–1154, 1979PubMedCrossRefGoogle Scholar
  352. 352.
    Huhn, D.R., Burkhardt, R., Eulitz, M., Fateh-Moghadam, A.: Klinische und elektro- nenmikroskopische Untersuchungen bei Plasmocytorn mit ossärer und extraossärer Ausbreitung. Klin. Wschr. 46: 1132–1139, 1968PubMedCrossRefGoogle Scholar
  353. 353.
    Ichimaru, T., Otake, M., Ichimaru, M.: Dose–response relationship of neutrons and gamma-rays to leukemia incidence among atomic bomb survivors in Hiroshima and Nagasaki by type of leukemia 1950–1971. Radiat. Res. 77: 377–394, 1979CrossRefGoogle Scholar
  354. 354.
    Illiger, H. J., Schmidt, R.E., Hartlapp, J.H.: Melphalanresorptionsstörung als Ursache des primären und sekundären Therapieversagens beim multiplen Myelom. Verhdl. dtsch. Ges. inn. Med. 87: 1117–1121, 1981Google Scholar
  355. 355.
    Imbert, J.C., Bennani, M., Kadiri, A., Kabbage, M.: Les myélomes multiples a vitesse de sedimentation normale. Concours Med. 101: 6765–6775, 1979Google Scholar
  356. 356.
    Indiveri, F., Barabino, A., Santolini, M.E.: Non-secretory multiple myeloma. Report of a case. Acta Haematol. 51: 302–309, 1974PubMedCrossRefGoogle Scholar
  357. 357.
    Indiveri, F., Puppo, F., Bandacio, E., Franceschini, R., Barabino, A., Corsini, G.: In- ibizione della migrazione granulocitaria indotta da sieri di pazienti affetti da mieloma multiplo e morbo di Waldenström. Folia Allergol. Immunol. Clin. 25: 425–430, 1978Google Scholar
  358. 358.
    Ingram, M.: Inhibition of leukocyte phagocytic activity by hypergammaglobulinemic multiple myeloma plasma. Proc. Soc. Exp. Biol. Med. 105: 404–407, 1960PubMedGoogle Scholar
  359. 359.
    Isaacson, P.: Immunochemical demonstration of J chain: A marker of B cell malignancy. J. Clin. Pathol. 32: 802–807, 1979PubMedCrossRefGoogle Scholar
  360. 360.
    Isbister, J. P., Biggs, J. C., Penny, R.: Experience with large volume plasmapheresis in malignant paraproteinaemia and immune disorders. Aust. N.Z. J. Med. 8: 154–164, 1978PubMedCrossRefGoogle Scholar
  361. 361.
    Ishizaka, K., Ishizaka, T., Hornbrook, M.M.: Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity with gammaE-globulin antibody. J. Immunol. 97: 840–853, 1966PubMedGoogle Scholar
  362. 362.
    Isobe, T., Ikeda, Y., Ohta, H.: Comparison of sizes and shapes of tumor cells in plasma cell leukemia and plasma cell myeloma. Blood 53: 1028–1030, 1979PubMedGoogle Scholar
  363. 363.
    Isobe, T., Osserman, E.F.: Pathologic conditions associated with plasma cell dyscrasias: A study of 806 cases. Ann. N. Y. Acad. Sci. 190: 507–518, 1971PubMedCrossRefGoogle Scholar
  364. 364.
    Ito, K., Hino, N., Fukuiya, A.: Three cases of IgD myeloma and clinical review of 85 cases reported in Japan. Therapeutics (Tokio) 32: 1019–1024, 1978Google Scholar
  365. 365.
    Iwamoto, H., Nakagawa, S., Matsui, N., Yoshiyama, N., Shinoda, T., Shibamoto, T., Takeuchi, J.: An experience of plasma exchange by membrane separator for IgA myeloma. In: Plasma Exchange: Plasmapheresis-Plasma Separation. Hrsg.: Sieberth, H.G, F. K. Schattauer Verlag, Stuttgart-New York, SS. 377–380, 1980Google Scholar
  366. 366.
    Iwashita, H., Argyrakis, A., Lowitzsch, K., Spaar, F. W.: Polyneuropathy in Waldenström’s macroglobulinemia. J. Neurol. Sci. 21: 341–354, 1974PubMedCrossRefGoogle Scholar
  367. 367.
    Jacobson, H.G., Poppel, M.H., Shapiro, J.H., Grossberger, S.: The vertebral pedicle sign: A roentgen finding to differentiate metastatic carcinoma from multiple myeloma. Amer. J. Roentgenol. 80: 817–821, 1958PubMedGoogle Scholar
  368. 368.
    Jacobson, R.J., Shulman, G.: Plsma cell myeloma and Waldenström’s macroglobulinemia in black and white South Africans. In: Progress in Myeloma. Hrsg.: Potter, M., Elsevier/North Holland, New York-Oxford-Amsterdam, 1980Google Scholar
  369. 369.
    Jaffe, J. P., Bosch, A., Raich, P. C.: Sequential hemibody radiotherapy in advanced multiple myeloma. Cancer 43: 124–128, 1979PubMedCrossRefGoogle Scholar
  370. 370.
    Jaffe, J. P., Moscher, D. F.: Calcium binding by a myeloma protein. Amer. J. Med. 67: 343–346, 1979PubMedCrossRefGoogle Scholar
  371. 371.
    Jaffe, M.D.: Myelomatosis (Multiple myeloma). In: Tumors and Tumorous Conditions of the Bones and Joints. Lea & Febinger, Philadelphia, 1958Google Scholar
  372. 372.
    James, W. III., Harland, W. R.: Plasma cell disease and xanthomatosis. Trans. Amer. Clin. Chem. Ass. 79: 115–123, 1968Google Scholar
  373. 373.
    Jancelewicz, Z., Takatsuki, K., Sugai, S., Pruzanski, W.: IgD multiple myeloma: Review of 133 cases. Arch. Intern. Med. 135: 87–93, 1975PubMedCrossRefGoogle Scholar
  374. 374.
    Jansen, J., Blok, P.: Primary plasmacytoma of lymph nodes. A case report. Acta Haematol. 61: 100–105, 1979PubMedCrossRefGoogle Scholar
  375. 375.
    Jansen, J., Huijgens, P. C., van der Velde, E. A.: The prognosis of multiple myeloma. Neth. J. Med. 23, 246–251, 1980PubMedGoogle Scholar
  376. 376.
    Jean, G., Lambertenghi-Deliliers, G., Ranzi, T., Polli, E.: Ultrastructural aspects of bone marrow and peripheral blood cells in a case of plasma cell leukemia. Acta Haematol. 45: 36–49, 1971PubMedCrossRefGoogle Scholar
  377. 377.
    Jeannet, M., Magnin, C: HL-A antigens in haematological malignant diseases. Eur. J. Clin. Invest. 2: 39–42, 1976CrossRefGoogle Scholar
  378. 378.
    Jefferis, R., Mathews, J.B.: Structural studies of human IgD paraproteins. Immunol. Rev. 37: 25–49, 1977PubMedCrossRefGoogle Scholar
  379. 379.
    Jenette, J. C., Wilkman, A. S., Benson, J. D.: IgD myeloma with intracytoplasmic crystalline inclusions. Amer. J. Clin. Pathol. 75: 231–235, 1981Google Scholar
  380. 380.
    Jesserer, H.: Knochenkrankheiten. Urban & Schwarzenberg, München, 1971Google Scholar
  381. 381.
    Johansen, P., Jensen, M. K.: Enzymecytochemistry and immunohistochemistry in monoclonal gammopathy and reactive plasmacytosis. Acta Pathol. Microbiol. Scand. Sect. A. 88: 377–382, 1980Google Scholar
  382. 382.
    Johansson, B.: Interferon therapy for myeloma. Int. Soc. Hematol. & Int. Soc. Blood Transf., Montreal, Canada, Aug. 16–22, 1980Google Scholar
  383. 383.
    Johansson, S.G.O., Bennich, H.: Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 13: 381–394, 1967PubMedGoogle Scholar
  384. 384.
    Johnson, W.J., Kyle, RA., Dahlberg, P. J.: Dialysis in the treatment of multiple myeloma. Mayo Clin. Proc. 55: 65–72, 1980PubMedGoogle Scholar
  385. 385.
    Jones, S. E., Tucker, WG., Haut, A., Tranum, B. L., Vaughn, C., Chase, E. M., Durie, B. G. M.: Phase II trial of piperazinedione in Hodgkin’s disease, non-Hodgkin’s lym¬phoma and multiple myeloma: A Southwest Oncology Group Study. Cancer Treat. Rep. 61: 1617–1621, 1977PubMedGoogle Scholar
  386. 386.
    Jones, S.V., McFairlane, H.: T and B cells in myelomatosis. Brit. J. Haematol. 31: 545–552, 1975CrossRefGoogle Scholar
  387. 387.
    Jordan, E., Burnstein, S. J., Calabro, J. J., Henderson, E.S.: Multiple myeloma complicating the course of seronegative lupus erythematosus. Arthritis Rheum. 21: 260–263, 1978PubMedCrossRefGoogle Scholar
  388. 388.
    Josse, R. G., Murray, T. M., Mundy, G. R., Jez, D., Heersche, J. N. M.: Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast–activating factor. J. Clin. Invest. 67: 1472–1481, 1981PubMedCrossRefGoogle Scholar
  389. 389.
    Joyner, M.V., Cassuto, J. P. Dujardin, R, Schneider, M., Ziegler, G., Euller, L., Masseyeff, R.: Non-excretory multiple myeloma. Brit. J. Haematol. 43: 559–566, 1979CrossRefGoogle Scholar
  390. 390.
    Julien, J., Vital, C., Vallet, J. M., Lagueny, A., Deminiere, C., Darriet, D.: Polyneuropathy in Waldenström’s macroglobulinemia: deposition of M component on myelin sheats. Arch. Neurol. 35: 423–425, 1978PubMedCrossRefGoogle Scholar
  391. 391.
    Jung, A., Ouwenaller, C.von, Chantraine, A., Courvoisier, B.: Parenteral diphosphonates for treating malignant hypercalcemia. Cancer 48: 1922–1925, 1981PubMedCrossRefGoogle Scholar
  392. 392.
    Kahler, O.: Zur Symptomatologie des multiplen Myeloms: Beobachtung von Albu- mosurie. Prag. med. Wschr. 14: 45–49, 1889Google Scholar
  393. 393.
    Kahn, R.A., Hughes, S., Lavender, P., Leon, M., Spyron, N.: Autoradiography of technetium-labelled diphosphonate in rat. J. Bone Joint Surg. 61B: 221–224, 1979Google Scholar
  394. 394.
    Kapadia, S.B.: Multiple myeloma: A clinico-pathologic study of 62 consecutively autopsied cases. Medicine 59: 380–392, 1980PubMedCrossRefGoogle Scholar
  395. 395.
    Kaplan, H.S.: Hodgkin’s Disease. Harvard University Press, Cambridge-London, 1980Google Scholar
  396. 396.
    Karcioglu, G. L., Hardison, J. E.: Iron-containing plasma cells. Arch. Intern. Med. 138: 97–100, 1978PubMedCrossRefGoogle Scholar
  397. 397.
    Kardinal, C.G.: Multiple myeloma in a husband and wife. J. Amer. Med. Ass. 239: 22–23, 1979CrossRefGoogle Scholar
  398. 398.
    Karle, H., Hansen, N.E., Plesner, T.: Neutrophil defect in multiple myeloma: Studies on intraneutrophilic lysozyme in multiple myeloma and malignant lymphoma. Scand. J. Haematol. 17: 62–70, 1976PubMedCrossRefGoogle Scholar
  399. 399.
    Karp, J.E., Burke, P. J., Humphrey, R.L.: Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma. Blood 49: 925–934, 1977PubMedGoogle Scholar
  400. 400.
    Karp, J.E., Humphrey, R. L., Burke, P. J.: Timed sequential chemotherapy of Cytoxan- refractory multiple myeloma with Cytoxan and adriamycin based on induced tumor proliferation. Blood 57: 468–75, 1981PubMedGoogle Scholar
  401. 401.
    Kasturi, J., Saraya, A.K.: Platelet functions in dysproteinaemia. Acta Haematol. 59: 104–113, 1978PubMedCrossRefGoogle Scholar
  402. 402.
    Katzmann, J. A.: Myeloma induced immunosuppression: A multistep mechanism. J. Immunol. 121: 1405–1409, 1978PubMedGoogle Scholar
  403. 403.
    Katzmann, J., Giacomoni, D., Yakulis, V., Heller, P.: Characterization of 2 plasmacytoma fractions and their RNA capable of changing lymphocyte surface immunoglobulins (cell conversion). Cell. Immunol. 18: 98–109, 1975PubMedCrossRefGoogle Scholar
  404. 404.
    Kaye, R.L., Martin, W.J., Campbell, D.C., Lipscomb, P.R.: Long survival in disseminated myeloma with onset as solitary lesion: Two cases. Ann. Intern. Med. 54: 535–544, 1961PubMedGoogle Scholar
  405. 405.
    Kelly, J. J., Kyle, R. A., Miles, J.M., O’Brien, P.C., Dyck, P. J.: The spectrum of peripheral neuropathy in myeloma. Neurology 31: 24–31, 1981PubMedGoogle Scholar
  406. 406.
    Kennard, J., Cooper, N. S., Zolla–Pazner, S.: Suppression of in vitro antibody response by a soluble factor from spleen cells of plasmacytoma-bearing mice. Fed. Proc. 37: 2170, 1978Google Scholar
  407. 407.
    Kennard, J., Zolla-Pazner, S.: Origin and function of suppressor macrophages in myeloma. J. Immunol. 124: 268–273, 1980PubMedGoogle Scholar
  408. 408.
    Kenny, J. J., Maloney, W.C.: Long term survival in multiple myeloma: Report of three cases. Ann. Intern. Med. 45: 950–957, 1956PubMedGoogle Scholar
  409. 409.
    Kiang, D.T., Loken, M.K., Kennedy, B.J.: Mechanism of the hypocalcaemic effect of mithramycin. J. Clin. Endocr. Metab. 48: 341–344, 1979PubMedCrossRefGoogle Scholar
  410. 410.
    Kilburn, K.H., Schmidt, A.M.: Intrathoracic plasmacytoma: Report of a case and review of the literature. Arch. Intern. Med. 106: 862–869, 1960CrossRefGoogle Scholar
  411. 411.
    Killmann, S. A., Cronkite, E.P., Fliedner, T.M., Bond, V.P.: Cell proliferation in multiple myeloma studied with tritiated thymidine in vivo. Lab. Invest. 11: 845–853, 1963Google Scholar
  412. 412.
    Kim, I., Harley, J.B., Weksler, B.: Multiple myeloma without initial paraproteins. Amer. J. Med. Sci. 264: 267–275, 1972PubMedCrossRefGoogle Scholar
  413. 413.
    Kim, S.I., Lee, C.K.: Leukemia among Koreans — a statistical and hematological study of 601 cases of leukemia and allied conditions. GANN Mon. Cancer Res. 18: 229, 1976Google Scholar
  414. 414.
    Kindler, U.: Über das extraossale Plasmocytom. Dtsch. med. Wschr. 90: 1043–1049, 1965PubMedCrossRefGoogle Scholar
  415. 415.
    Kintzer, J.S., Rosenow, E.C., Kyle, R.A.: Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch. Intern. Med. 138: 727–730, 1978PubMedCrossRefGoogle Scholar
  416. 416.
    Klein, F., Lafeber, G.J.M., Jongepier-Geerdes, Y. E.J.M., Cats, A., Kauffmann, R. H., Michiels, J. J.: Presence of immune complex-like material in sera of patients with paraproteinaemia. J. Clin. Pathol. 34: 1036–1039, 1981PubMedCrossRefGoogle Scholar
  417. 417.
    Klintworth, G.K., Bredehenft, S.J., Reed, J.W.: Analysis of corneal crystalline deposits in multiple myeloma. Amer. J. Ophthalmol. 86: 303–313, 1978Google Scholar
  418. 418.
    Klos, J. R., Bortz, J. W.: Multiple myeloma: An overview for the clinician. J. Amer. Orthop. Ass. 79: 113–119, 1979Google Scholar
  419. 419.
    Knapp, W., Baumgarten, G.: Monocyte mediated suppression of human B lymphocyte differentiation in vitro. J. Immunol. 121: 1177–1183, 1978PubMedGoogle Scholar
  420. 420.
    Knapp, W., Shuit, H. R. E., Bolhuis, R. L. H., Hijmans, W.: Surface immunoglobulins in chronic lymphatic leukemia, macroglobulinemia and myelomatosis. Clin. Exp. Immunol. 16: 541–552, 1974Google Scholar
  421. 421.
    Knolle, J., Meyer zum Büschenfelde, K.H.: IgD-Plasmozytom. Übersicht über 102 Fälle der Literatur. Immun. Infekt. 3: 125–134, 1975PubMedGoogle Scholar
  422. 422.
    Kobayashi, H., Potter, M., Dunn, T. B.: Bone lesions produced by transplanted plasma-cell tumors in BALB/c mice. J. Natl. Cancer Inst. 28: 649–677, 1962PubMedGoogle Scholar
  423. 423.
    Kobernick, S.D., Whiteside, J.H.: Renal glomeruli in multiple myeloma. Lab. Invest. 6: 478–485, 1957PubMedGoogle Scholar
  424. 424.
    Kolb, J. P., Arrian, S., Zolla-Pazner, S.: Suppression of the humoral immune response by plasmacytomas: Mediation by adherent mononuclear cells. J. Immunol. 118: 702–709, 1977PubMedGoogle Scholar
  425. 425.
    Kopp, W. L., MacKinney, A. A. Jr., Wasson, G.: Blood volume and hematocrit value in macroglobulinemia and myeloma. Arch. Intern. Med. 123: 394–396, 1969PubMedCrossRefGoogle Scholar
  426. 426.
    Koppenfels, R.v.: Klinische Erfahrungen mit dem Plasmozytom unter besonderer Berücksichtigung der Röntgendiagnostik und der Strahlentherapie. Arch. klin. exp. Radio. 142: 276–285, 1971Google Scholar
  427. 427.
    Kopsa, H., Schmidt, P., Zazgornik, J., Balcke, P., Deutsch, E.: Erfolgreiche Dialysebehandlung eines akuten Nierenversagens bei Myelom. Med. Klin. 73: 668–670, 1978PubMedGoogle Scholar
  428. 428.
    Korst, D.R., Frenkel, E.P., Nixon, J.C.: Multiple myeloma: Studies of mouse plasma cell tumor and human myeloma. Responsiveness to cyclophosphamide (Cytoxan). Ann. Intern. Med. 60: 217–230, 1964PubMedGoogle Scholar
  429. 429.
    Koshland, M.E.: Structure and function of the J-chain. Adv. Immunol. 20: 41–69, 1975PubMedCrossRefGoogle Scholar
  430. 430.
    Koszewski, B.: The occurrence of megaloblastic erythropoiesis in patients with hemochromatosis. Blood 7: 1182–1195, 1952PubMedGoogle Scholar
  431. 431.
    Kövary, P.M., Kohn, J., Intorp, H.W., Zimmermann, R.E.: Beitrag zum Phänomen von Doppellinien für IgG in der Immunelektrophorese. Immunität Infektion 8: 117–120, 1980Google Scholar
  432. 432.
    Kövary, P.M., Macher, E.: Hautkrankheiten und monoklonale Gammopathien. Z. Hautkr. 54: 1002–1007, 1979PubMedGoogle Scholar
  433. 433.
    Krainin, P., D’Angio, C. J., Smelin, A.: Multiple myeloma with new bone formation. Arch. Intern. Med. 84: 976–982, 1949CrossRefGoogle Scholar
  434. 434.
    Krakauer, R.S., Strober, W., Waldmann, T.A.: Hypogammaglobulinemia in experimental myeloma: The role of suppressor factors from mononuclear phagocytes. J. Immunol. 118: 1385–1390, 1977PubMedGoogle Scholar
  435. 435.
    Kraut, E.H., Sagone, A.L.Jr.: Alternative pathway of complement in multiple myeloma. Amer. J. Hematol. 11: 335–345, 1981CrossRefGoogle Scholar
  436. 436.
    Kreibich, C.: Plasmomyelom der Haut. Folia Haematol. (Basel) 18: 94–99, 1914Google Scholar
  437. 437.
    Kronwall, G., William, R.C.: Differences in antiprotein A activity among IgG subgroups. J. Immunol. 103: 828–833, 1969Google Scholar
  438. 438.
    Krook, G., Waldenstrom, J.G.: Relapsing annular erythema and myeloma successfully treated with cyclophosphamide. Acta Med. Scand. 203: 289–292, 1978CrossRefGoogle Scholar
  439. 439.
    Krueger, R. G., Fair, D. S., Kyle, R. A.: Monoclonal IgM, IgA, and IgG in the serum of a single individual: immunofluorescence identification of cells producing the immunoglobulins. Eur. J. Immunol. 9: 602–606, 1979PubMedCrossRefGoogle Scholar
  440. 440.
    Krueger, R. G., Hilton, P. M., Boehlecke, J. M., Kyle, R. A., Fair, D. S.: The cellular origin of multiple monoclonal immunoglobulins reflects the postulated pathways of iso- type differentiation of antibody-forming cells. Cell Immunol. 54: 402–413, 198Google Scholar
  441. 441.
    Kruse, K., Stein, H., Hitzig, W.H., Joller, P., Lasson, U.: Lymph node plasmacytoma in a child: Clinical and immunological findings with special reference to S-Ig and complement receptor subtypes. Eur. J. Pediatr. 129: 239–257, 1978PubMedCrossRefGoogle Scholar
  442. 442.
    Kubagawa, H., Vogler, L. B., Capra, J. D., Conrad, M. E., Lawton, A. R., Cooper, M. D.: Studies on the clonal origin of multiple myeloma. Use of individually specific (Idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B–cell differentiation. J. Exp. Med. 150: 792–807, 1979PubMedCrossRefGoogle Scholar
  443. 443.
    Kubagawa, H., Vogler, L.B., Lawton, A.R., Cooper, M.D.: The extent of clonal involvement in multiple myeloma. In: Progress in Myeloma. Hrsg.: Potter, M., Elsevier/ North Holland, New York-Oxford-Amsterdam, SS. 195–208, 1980Google Scholar
  444. 444.
    Kuehl, W. M.: Synthesis of immunoglobulin in myeloma cells. Curr. Top. Microbiol. Immunol. 76: 1–47, 1977PubMedCrossRefGoogle Scholar
  445. 445.
    Kunkel, H.G., Prendergast, R. A.: Subgroups of gammaA immune globulins. Proc. Soc. Exp. Biol. Med. 122: 910–913, 1966PubMedGoogle Scholar
  446. 446.
    Kwan, S. P., Scharff, M. D.: Regulation of synthesis, assembly, and secretion of immunoglobulins. In: Biological Basis of Immunodeficiency. Hrsg.: Gelfand, E. W., Dosch, H.M., Raven Press, New York, SS. 177–188, 1980Google Scholar
  447. 447.
    Kyle, R. A.: Multiple myeloma: Review of 869 cases. Mayo Clin. Proc. 50: 29–40, 1975Google Scholar
  448. 448.
    Kyle, R. A.: Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Amer. J. Med. 64: 814–826, 1978PubMedCrossRefGoogle Scholar
  449. 449.
    Kyle, R. A.: „Smouldering“ multiple myeloma. N. Engl. J. Med. 302: 1347–1349, 1980PubMedCrossRefGoogle Scholar
  450. 450.
    Kyle, R. A.: Primary amyloidosis and amyloidosis with myeloma. Int. J. Dermatol. 20: 20–25, 1981PubMedCrossRefGoogle Scholar
  451. 451.
    Kyle, R.A.: Monoclonal gammopathies of undetermined significance. 6th Meeting; Europ. & Afric. Div. Int. Soc. Haematol, Athen, 1981Google Scholar
  452. 452.
    Kyle, R. A., Bayrd, E. D.: The monoclonal gammopathies: Multiple Myeloma and Related Plasma-Cell Disorders. Ch.C.Thomas, Springfield, Illinois, 1976Google Scholar
  453. 453.
    Kyle, R. A., Elveback, L.R.: Management and prognosis of multiple myeloma. Mayo Clin. Proc. 51: 751–760, 1976Google Scholar
  454. 454.
    Kyle, R.A., Gailani, S., Seligman, B.R., Blom, J., Mclntyre, O.R., Pajak, T.F., Holland, J.F.: Multiple myeloma resistant to melphalan: Treatment with cyclophospha¬mide, prednisone, and BCNU. Cancer Treat. Rep. 63: 1265–1269, 1979PubMedGoogle Scholar
  455. 455.
    Kyle, R.A., Greipp, P.R.: Smoldering multiple myeloma. N. Engl. J. Med. 302: 1347–1349, 1980PubMedCrossRefGoogle Scholar
  456. 456.
    Kyle, R. A., Heath, C. W.Jr., Carbone, P.: Multiple myeloma in spouses. Arch. Intern. Med. 127: 944–946, 1971PubMedCrossRefGoogle Scholar
  457. 457.
    Kyle, R. A., Herbert, L., Evatt, B.L., Heath, C. W. Jr.: Multiple myeloma — a community cluster. J. Amer. Med. Ass. 213: 1339–1341, 1970CrossRefGoogle Scholar
  458. 458.
    Kyle, R.A., Jowsey, J.: Effect of sodium fluoride, calcium carbonate, and vitamin D on the skeleton in multiple myeloma. Cancer 45: 1669–1674, 1980PubMedCrossRefGoogle Scholar
  459. 459.
    Kyle, R. A., Jowsey, J., Kelly, P. J., Taves, D.R.: Multiple-myeloma bone disease: The comparative effect of sodium fluoride and calcium carbonate or placebo. N. Engl. J. Med. 293: 1334–1338, 1975PubMedCrossRefGoogle Scholar
  460. 460.
    Kyle, R.A., Maldonado, J.E., Bayrd, E.D.: Plasma cell leukemia. Report on 17 cases. Arch. Intern. Med. 133: 813–818, 1974PubMedCrossRefGoogle Scholar
  461. 461.
    Kyle, R.A., Pierre, R.V., Bayrd, E.D.: Multiple myeloma and acute leukemia associated with alkylating agents. Arch. Intern. Med. 135: 185–192, 1975PubMedCrossRefGoogle Scholar
  462. 462.
    Kyle, R. A., Robinson, R. A., Katzmann, J. A.: The clinical aspects of biclonal gammopathies. Review of 57 cases. Amer. J. Med. 71: 999–1008, 1981PubMedCrossRefGoogle Scholar
  463. 463.
    Kyle, R. A., Spencer, R. J., Dahlin, D.C.: Value of rectal biopsy in the diagnosis of primary systemic amyloidosis. Amer. J. Med. Sci. 251: 501–506, 1966PubMedCrossRefGoogle Scholar
  464. 464.
    Lackner, H.: Hemostatic abnormalities associated with dysproteinemias. Semin. Hematol. 10: 125–133, 1973PubMedGoogle Scholar
  465. 465.
    Ladefoged, A. J., Nielsen, B., Pederson, K.: Akut nyreinsuffieiens ved myelomatose. Ugeskr. Laeg. 132: 641–646, 1970PubMedGoogle Scholar
  466. 466.
    Lajtha, L.G., Schofield, R.: Regulation of stem cell renewal and differentiation: Possible significance in ageing. In: Advances in Gerontological Research. Hrsg.: Strehler, B.L., Academic Press, New York, SS. 131–146, 1971Google Scholar
  467. 467.
    Lake-Lewin, D., Myers, J., Lee, B.J., Yung, C. W.: Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy. Cancer Treat. Rep. 63: 1403–1404, 1979PubMedGoogle Scholar
  468. 468.
    Larionov, L. F., Shkodinskaja, E. N., Troosheikina, V. I., Khokhlov, A. S., Vasina, O. S., Novikoa, M.A.: Studies on the antitumor activity of p-di-(2-chloroethyl)amino- phenylalanine (sarcolysin). Lancet 2: 169–171, 1955CrossRefGoogle Scholar
  469. 469.
    Laskov, R., Baumal, R., Polliak, A.: Surface morphology of cultured myeloma cells: Bleb formation in cell variants with defects in immunoglobulin production and secretion. J. Reticuloendothel. Soc. 23: 361–372, 1978PubMedGoogle Scholar
  470. 470.
    Latov, N., Sherman, W. H., Nemni, R., Galassi, G., Shyong, J. S., Penn, A. S., Chess, L., Olarte, M. R., Rowland, L. P., Osserman, E. F.: Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral–nerve myelin. N. Engl. J. Med. 303: 618–621, 1980PubMedCrossRefGoogle Scholar
  471. 471.
    Lazarus, H.M., Lederman, M., Lubin, A., Herzig, R.H., Schiffmann, G., Jones, P., Wine, A., Rodman, H.M.: Pneumococcal vaccination: The response of patients with multiple myeloma. Amer. J. Med. 69: 419–423, 1980PubMedCrossRefGoogle Scholar
  472. 472.
    Lazor, M.Z., Rosenberg, L., Carbone, P.: Studies of calcium metabolism in multiple myeloma with 48Ca and metabolic balance techniques. J. Clin. Invest. 42: 1238–1247, 1963PubMedCrossRefGoogle Scholar
  473. 473.
    Lea, T., Forre, T., Michaelsen, T.E., Natvig, J.B.: Shared idiotypes on human peripheral blood B and T lymphocytes. J. Immunol. 12: 2413–2417, 1979Google Scholar
  474. 474.
    Leder, P., Max, E. E., Seidman, J. G.: The organization of immunoglobulin genes and the origin of their diversity. In: Immunology 80. Progress in Immunology IV. Hrsg.: Fougereau, M., Dausset, J., Academic Press, London-New York, SS. 34–50, 1980Google Scholar
  475. 475.
    Lee, B. J., Korngold, L., Weiner, M. J.: Melphalan and antigenic type of Bence Jones proteins in myeloma. Science 149: 564–565, 1965CrossRefGoogle Scholar
  476. 476.
    Lee, B. J., Sahakian, G., Clarkson, B. D., Krakoff, I. H.: Combination chemotherapy of multiple myeloma with alkeran, Cytoxan, vincristine, prednisone, and BCNU. Cancer 33: 533–538, 1974PubMedCrossRefGoogle Scholar
  477. 477.
    Leech, S.H., Polesky, H.F., Shapiro, F.L.: Chronic hemodialysis in myelomatosis. Ann. Intern. Med. 77: 239–242, 1972PubMedGoogle Scholar
  478. 478.
    Lenhard, R.E.Jr., Oken, M.M., Humphrey, R.L., Barnes, J.M., Glick, J.H., Bennett, J.M.: High dose cyclophosphamide: An effective treatment for refractory multiple myeloma. (Abstract C-798), Proc. Amer. Assoc. Cancer Res. 22: 537, 1981Google Scholar
  479. 479.
    Lennert, K., Mohri, N., Stein, H., Kaiserling, E., Müller-Hermelink, H.K.: Malignant lymphomas other than Hodgkin’s disease. Springer Verlag, Berlin-Heidelberg-New York, 1978Google Scholar
  480. 480.
    Leonard, R.C.F., Owen, J.P., Proctor, S.J., Hamilton, P. J.: Multiple myeloma: Radiology or bone scanning? Clin. Radiol. 32: 291–295, 1981Google Scholar
  481. 481.
    Lergier, J.E., Jimenez, E., Maldonado, N., Veray, F.: Normal pregnancy in multiple myeloma treated with cyclophosphamide. Cancer 34: 1018–1022, 1974PubMedCrossRefGoogle Scholar
  482. 482.
    Levi, D. F., Williams, R. C, Linstrom, F. D.: Immunofluorescent studies of the myeloma kidney with special reference to light chain disease. Amer. J. Med. 44: 922–933, 1968PubMedCrossRefGoogle Scholar
  483. 483.
    Levin, A.S., Fudenberg, H.H., Hopper, J.E., Wilson, S.K., Nisonoff, A.: Immunofluorescent evidence for cellular control of synthesis of variable regions of light and heavy chains of immunoglobulins G and M by the same gene. Proc. Nat. Acad. Sci. USA 68: 169–171, 1971PubMedCrossRefGoogle Scholar
  484. 484.
    Levin, H.S., Mostofi, F.K.: Symptomatic plasmacytoma of the testis. Cancer 25: 1193–1203, 1970PubMedCrossRefGoogle Scholar
  485. 485.
    Lewinski, U.H., Klein, B., Gafter, U., Djaldetti, M.: Acute plasma cell leukemia followed by extramedullary plasmacytoma. Scand. J. Haematol. 24: 131–136, 1980PubMedCrossRefGoogle Scholar
  486. 486.
    Lewis, E. B.: Leukemia, multiple myeloma, and anaplastic anemia in American radiologists. Science 142: 1492–1494, 1963PubMedCrossRefGoogle Scholar
  487. 487.
    Lewis, L.A., Page, I.H.: Serum proteins and lipoproteins in multiple myelomatosis. Amer. J. Med. 17: 670–673, 1954PubMedCrossRefGoogle Scholar
  488. 488.
    Liang, W., Hopper, J. E., Rowley, J. D.: Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders. Cancer 44: 630–644, 1979PubMedCrossRefGoogle Scholar
  489. 489.
    Lichtenstein, L., Jaffe, H.L.: Multiple myeloma. A survey based on 35 cases, 18 of which came to autopsy. Arch. Pathol. 44: 207–246, 1947Google Scholar
  490. 490.
    Liebling, M. E., Grizzle, J., Hammack, W., Rundles, R. W.: Comparison of chlorambucil and prednisone with urethane and prednisone regimens in the treatment of multiple myeloma. Cancer Chemother. Rep. 16: 253–255, 1962Google Scholar
  491. 491.
    Lin, K.T.: Myeloma proteins in adult Chinese patients. Chin. J. Microbiol. 10: 28–36, 1977Google Scholar
  492. 492.
    Lindgarde, F., Zettervall, O.: Hypercalcemia and normal ionized serum calcium in a case of myelomatosis. Ann. Intern. Med. 78: 396–399, 1973PubMedGoogle Scholar
  493. 493.
    Lindström, F.D., Dahlström, U.: Multiple myeloma or benign monoclonal gammopathy? A study of differential diagnostic criteria in 44 cases. Clin. Immunol. Immunopathol. 10: 168–174, 1978PubMedCrossRefGoogle Scholar
  494. 494.
    Lindström, F.D., Hardy, W.R., Eberle, B.J., Williams, R.C.Jr.: Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes. Ann. Intern. Med. 78: 837–844, 1973PubMedGoogle Scholar
  495. 495.
    Lindström, F.D., Williams, R.C.Jr.: Serum antiimmunoglobulin in multiple myeloma and benign monoclonal gammopathy. Clin. Immunol. Immunopathol. 3: 503–513, 1975PubMedCrossRefGoogle Scholar
  496. 496.
    Lindström, F.D., Williams, R.C.Jr., Swaim, W.R., Freier, E.F.: Urinary light-chain excretion in myeloma and other disorders — an evaluation of the Bence-Jones test. J. Lab. Clin. Med. 71: 812–815, 1968PubMedGoogle Scholar
  497. 497.
    Löffler, H.: Unspezifische Esterasen und saure Phosphatase bei Plasmozytomen. Blut 15: 330–335, 1967PubMedCrossRefGoogle Scholar
  498. 498.
    Löffler, H., Knopp, A., Krecke, H.J.: Falle von multiplem Myelom (Plasmocytom) „ohne Paraprotein“. Dtsch. med. Wschr. 12: 226–229, 1967Google Scholar
  499. 499.
    Löffler, H., Schubert, J.C.F.: Cytochemische Unterschiede zwischen Plasmazellen und Myelomzellen. Klin. Wschr. 41: 484–490, 1963CrossRefGoogle Scholar
  500. 500.
    Longsworth, L.G., Shedlovsky, T., Macinnes, D. A.: Electrophoretic patterns of normal and pathological human blood serum and plasma. J. Exp. Med. 70: 399–413, 1939PubMedCrossRefGoogle Scholar
  501. 501.
    Luben, R. A., Mundy, G.R., Trummel, C.L., Raisz, L.G.: Partial purification of osteoclast activating factor from phytohemagglutinin-stimulated leukocytes. J. Clin. Invest. 53: 1473–1480, 1974PubMedCrossRefGoogle Scholar
  502. 502.
    Lüdin, H.: Die Plasmozytome. In: Handbuch der gesamten Hämatologie. Band V. Urban & Schwarzenberg, München-Berlin-Wien, SS. 381–420, 1969Google Scholar
  503. 503.
    Ludwig, H.: Neue Aspekte in der Therapie des multiplen Myeloms: Kultur und Zyto- statikasensitivitätstestung von Myelomstammzellen. Verh. dtsch. Ges. inn. Med. 86: 1101–1105, 1980Google Scholar
  504. 504.
    Ludwig, H., Fritz, E.: Individualized chemotherapy in multiple myeloma by cytostatic drug sensitivity testing of colony–forming stem cells. Anticancer Res. 1: 329–334, 1982Google Scholar
  505. 505.
    Ludwig, H., Fritz, E., Friedl, H.P.: Epidemiologic and age-dependent data on multiple myeloma in Austria. J. Natl. Cancer Inst. 68: 729–733, 1982PubMedGoogle Scholar
  506. 506.
    Ludwig, H., Fritz, E., Pötzi, P.: Cytostatic drug sensitivity testing of myeloma colony- forming stem cells: An approach to individualize chemotherapy. In: Current Chemotherapy and Immunotherapy. Hrsg.: Periti, P., Grassi, G. G., American Society for Microbiology, Washington, SS. 1272–1274, 1982Google Scholar
  507. 507.
    Ludwig, H., Kumpan, W., Sinzinger, H.: Radiography and bone scintigraphy in multiple myeloma: A comparative analysis. Brit. J. Radiol. 55: 173–181, 1982PubMedCrossRefGoogle Scholar
  508. 508.
    Ludwig, H., Mayr, W. R.: Genetic aspects of susceptibility to multiple myeloma. Blood 59: 1286–1291, 1982PubMedGoogle Scholar
  509. 509.
    Ludwig, H., Pavelka, M.: Phagocytic plasma cells in a patient with multiple myeloma. Blood 56: 173–176, 1980PubMedGoogle Scholar
  510. 510.
    Ludwig, H., Schernthaner, G., Knapp, W.: Zelluläre Immunreaktivität bei Patienten mit multiplem Myelom. Acta Med. Austriaca 5: 167–169, 1978PubMedGoogle Scholar
  511. 511.
    Ludwig, H., Swetly, P.: In vitro inhibitory effect of interferon on colony formation of myeloma stem cells. Cancer Immunol. Immunother. 9: 139–143, 1980CrossRefGoogle Scholar
  512. 512.
    Ludwig, H., Vormittag, W.: „Benign“ monoclonal IgE gammopathy. Brit. Med. J. 2: 539–540, 1980CrossRefGoogle Scholar
  513. 513.
    Luttgens, W.F., Bayrd, E.D.: Treatment of multiple myeloma with urethane. J. Amer. Med. Ass. 147: 824–827, 1951CrossRefGoogle Scholar
  514. 514.
    Lynch, P. J., Winkelmann, R.K.: Generalized plane xanthoma and systemic disease. Arch. Dermatol. 93: 639–646, 1966PubMedCrossRefGoogle Scholar
  515. 515.
    Maeda, K., Abesamis, C., Kuhn, L.M., Hyun, B.H.: Multiple myeloma in childhood: Report of a case with breast tumors as presenting manifestation. Amer. J. Clin. Pathol. 60: 552–558, 1973Google Scholar
  516. 516.
    Magnus-Levy, A.: Bence-Jones-Eiweiβ und Amyloid. Z. klin. Med. 116: 510–531, 1931Google Scholar
  517. 517.
    Magnus-Levy, A.: Multiple myeloma (XII). Acta Med. Scand. 95: 218–280, 1938Google Scholar
  518. 518.
    Mähr, G., Rommel, K., Knoth, W.: Paramyloidose mit Karpaltunnelsyndrom bei Bence-Jones-Plasmocytom. Dtsch. med. Wschr. 2166–2170, 1966Google Scholar
  519. 519.
    Maldonado, J.E., Brown, A.L.Jr., Bayrd, E.D., Pease, G.L.: Cytoplasmic and intranuclear electron-dense bodies in the myeloma cell. Light and electron microscopy observations. Arch. Pathol. 81: 484–500, 1966PubMedGoogle Scholar
  520. 520.
    Maldonado, J. E., Brown, A. L., Bayrd, E. D., Pease, G. L.: Ultrastructure of the myeloma cell. Cancer 19: 1613–1627, 1966PubMedCrossRefGoogle Scholar
  521. 521.
    Maldonado, J.E., Kyle, R. A.: Familial myeloma. Report of eight families and a study of serum proteins of their relatives. Amer. J. Med. 57: 875–884, 1974PubMedCrossRefGoogle Scholar
  522. 522.
    Maldonado, J.E., Velosa, J. A., Kyle, R.A., Wagoner, R.D., Holley, K.E., Salassa, R.M.: Fanconi syndrome in adults: a manifestation of a latent form of myeloma. Amer. J. Med. 58: 354–364, 1975PubMedCrossRefGoogle Scholar
  523. 523.
    Mancilla, R., Davies, G.L.: Non-secretory multiple myeloma. Amer. J. Med. 63: 1015–1022, 1977PubMedCrossRefGoogle Scholar
  524. 524.
    Manolova, Y., Manolov, G., Apostolov, P., Levan, A.: The same marker chromosome, mar17p +, in four consecutive cases of multiple myeloma. Hereditas 90: 307–310, 1979PubMedCrossRefGoogle Scholar
  525. 525.
    Marconcelli, P., Casalino, C.: Cytomorphological, immunochemical, and therapeutic aspects of multiple myeloma. Minerva Med. 64: 337–357, 1973Google Scholar
  526. 526.
    Marras, S., Magri, D.: Primi dati su una possible associazione tra HLA-A9 e mieloma in Campania. La Trasfusione del Sangue 23: 307–310, 1978Google Scholar
  527. 527.
    Marschalko, T. V.: Über die sogenannten Plasmazellen; Ein Beitrag zur Kenntnis der Herkunft der entzündlichen Infiltrationszellen. Arch. Dermatol. Syphiol. 30: 1–52, 1895Google Scholar
  528. 528.
    Marshall, M. O.: Comparison of immunofixation and immunoelectrophoresis methods in the identification of monoclonal immunoglobulins in serum. Clin. Chim. Acta 104: 1–9, 1980PubMedCrossRefGoogle Scholar
  529. 529.
    Martin, W.J., Mathieson, D.R.: Pyroglobulinemia (heatcoagulable globulin in the blood). Proc. Staff Meet. Mayo Clin. 28: 545–554, 1953PubMedGoogle Scholar
  530. 530.
    Martin, N. H., Schultorpe, H.: The non-protein constituents of the plasma in myelomatosis. J. Clin. Pathol. 11: 330–333, 1958PubMedCrossRefGoogle Scholar
  531. 531.
    Martinez-Maldonado, M., Yium, J., Suki, W.N., Eknoyan, G.: Renal complications in multiple myeloma: Pathophysiology and some aspects of clinical management. J. Chronic. Dis. 24: 221–237, 1971PubMedCrossRefGoogle Scholar
  532. 532.
    Mason, D. Y., Cullen, P.: HL-A antigen frequencies in myeloma. Tissue Antigens 5: 238–245, 1975PubMedCrossRefGoogle Scholar
  533. 533.
    Mason, T.J.: Cancer mortality in U. S. counties with plastic and related industries. Environ. Health Perspect. 11: 79–84, 1975PubMedCrossRefGoogle Scholar
  534. 534.
    Mass, R. E.: A comparison of the effect of prednisone and placebo in the treatment of multiple myeloma. Cancer Chemother. Rep. 16: 257–259, 1962PubMedGoogle Scholar
  535. 535.
    Mass, R.E., MacKenzie, M., Irwin, L.E.: High dose cyclophosphamide vs. CCNU treatment of melphalan resistant myeloma. Proc. Amer. Soc. Clin. Oncol. 17: 250, 1976Google Scholar
  536. 536.
    Matanoski, G. M., Seltser, R, Sartwell, P. E., Diamond, L., Elliot, E. A.: The current mortality rates of radiologists and other physician specialists: specific causes of death. Amer. J. Epidemiol. 101: 199–210, 1975Google Scholar
  537. 537.
    Matthias, J.Q., Misiewicz, J. J., Scott, R.B.: Cyclophosphamide in Hodgkin’s disease and related disorders. Brit. Med. J. 2: 1837–1840, 1960PubMedCrossRefGoogle Scholar
  538. 538.
    Matzner, Y., Benbassat, J., Polliack, A.: Prognostic factors in multiple myeloma. A retrospective study using conventional statistical methods and a computer program. Acta Haematol. 60: 257–268, 1978PubMedCrossRefGoogle Scholar
  539. 539.
    Matzner, Y., Polliack, A.: Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy. Isr. J. Med. Sci. 14: 1265–1267, 1978PubMedGoogle Scholar
  540. 540.
    Mauch, H., Hammer, H. J.: Die differenzierende Diagnostik monoklonaler und poly- klonaler Immunglobuline mit der Immunfixation. Lab. Med. 5: 227–230, 1981Google Scholar
  541. 541.
    Mauch, H., Hammer, H.J., Uhl, U.J., Scheurlen, P.G.: IgD-Plasmozytom. Dtsch. med. Wschr. 106: 678–681, 1981PubMedCrossRefGoogle Scholar
  542. 542.
    McArthur, J.R., Athens, J.W., Wintrobe, M.M., Cartwright, G.E.: Melphalan and myeloma: Experience with a low-dose continuous regimen. Ann. Intern. Med. 72: 665–670, 1970PubMedGoogle Scholar
  543. 543.
    McGregor, R.B., Negendank, W.G., Schreiber, A.D.: Impaired granulocyte adherence in multiple myeloma: Relationship to complement system, granulocyte delivery and infection. Blood 51: 591–599, 1978Google Scholar
  544. 544.
    Mclntire, K. R, Princler, G. L.: Prolonged adjuvant stimulation in germ-free BALB/c mice: Development of plasma cell neoplasia. Immunology 17: 481–487, 1969Google Scholar
  545. 545.
    Mclntyre, O. R, Leone, L., Pajak, T. F.: The use of intravenous melphalan (L-PAM) in the treatment of multiple myeloma. Blood Suppl. I, 52: 274, 1978Google Scholar
  546. 546.
    Mclntyre, W.: Case of mollities and fragilitas ossium accompanied with urine strongly charged with animal matter. Med. Chir. Trans. (London) 33: 211–232, 1850Google Scholar
  547. 547.
    McKelvey, E.M., Fahey, J.L.: Immunoglobulin changes in disease: Quantitation on the basis of heavy polypeptide chains, IgG (gammaG), IgA (gammaA) and IgM (gam– maM), and of light polypeptide chains, type kappa (I) and type L (II). J. Clin. Invest. 44: 1778–1786, 1965PubMedCrossRefGoogle Scholar
  548. 548.
    McKissock, W., Bloom, W. H., Chynn, K. Y.: Spinal cord compression caused by plasma-cell tumours. J. Neurosurg. 18: 68–73, 1961PubMedCrossRefGoogle Scholar
  549. 549.
    McLauchlan, J.: Solitary myeloma of the clavicle with long survival after total excision. Report of a case. J. Bone Joint Surg. 55: 357–358, 1973Google Scholar
  550. 550.
    McMahon, B., Clark, D.W.: The incidence of multiple myeloma. J. Chronic Dis. 4: 508–515, 1956CrossRefGoogle Scholar
  551. 551.
    McPhedran, P., Finch, S.C., Nemerson, Y.R., Barnes, M.G.: Alpha-2 globulin „spike“in renal carcinoma. Ann. Intern. Med. 76: 439–441, 1972PubMedGoogle Scholar
  552. 552.
    McPhedran, P., Heath, C.W.Jr., Garcia, J.: Multiple myeloma incidence in metropolitan Atlanta, Georgia: racial and seasonal variations. Blood 39: 866–873, 1972PubMedGoogle Scholar
  553. 553.
    Medical Research Council’s Working Party for Therapeutic Trials in Leukaemia: Myelomatosis: Comparison of melphalan and cyclophosphamide therapy. Brit. Med. J. 1: 640–641, 1971CrossRefGoogle Scholar
  554. 554.
    Medical Research Council’s Working Party for Therapeutic Trials in Leukaemia: Report of the first myelomatosis trial. Part I. Analysis of presenting features of prognostic significance. Brit. J. Haematol. 24: 123–139, 1973CrossRefGoogle Scholar
  555. 555.
    Medical Research Council’s Working Party on Leukaemia in Adults: Report on the second myelomatosis trial after five years of follow–up. Brit. J. Cancer 42: 813–822, 1980CrossRefGoogle Scholar
  556. 556.
    Medical Research Council’s Working Party on Leukaemia in Adults: Prognostic features in the third MRC myelomatosis trial. Brit. J. Cancer 42: 831–840, 1980CrossRefGoogle Scholar
  557. 557.
    Medinger, F. G., Craver, L. F.: Total body irradiation with review of cases. Amer. J. Roentgenol. 48: 651–671, 1942Google Scholar
  558. 558.
    Medini, E., Levitt, S. H.: Solitary extramedullary plasmacytoma of the upper respiratory and digestive tracts. Cancer 45: 2893–2896, 1980PubMedCrossRefGoogle Scholar
  559. 559.
    Melchers, F.: Biosynthesis of the carbohydrate portion of immunoglobulins. Biochem. J. 119: 765–772, 1970PubMedGoogle Scholar
  560. 560.
    Mellstedt, H., Ahre, A., Björkholm, M., Holm, G., Johansson, B., Strander, H.: Interferon therapy in myelomatosis. Lancet 1: 245–247, 1979PubMedCrossRefGoogle Scholar
  561. 561.
    Mellstedt, H., Björkholm, M., Holm, G.: Intermittent melphalan and prednisolone therapy in plasma cell myeloma. Acta. Med. Scand. 202: 5–9, 1977PubMedCrossRefGoogle Scholar
  562. 562.
    Mellstedt, H., Hammarström, S., Holm, G.: Monoclonal lymphocyte population in human plasma cell myeloma. Clin. Exp. Immunol. 17: 371–384, 1974PubMedGoogle Scholar
  563. 563.
    Mellstedt, H., Holm, G.: In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities. Clin. Exp. Immunol. 15: 309–320, 1973PubMedGoogle Scholar
  564. 564.
    Meltzer, M., Franklin, E.C.: Cryoglobulinemia: A study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Amer. J. Med. 40: 828–836, 1966PubMedCrossRefGoogle Scholar
  565. 565.
    Merigan, T.C., Hayes, R.E.: Treatment of hypercalcemia in multiple myeloma. Arch. Intern. Med. 107: 389–394, 1961PubMedCrossRefGoogle Scholar
  566. 566.
    Merlini, G., Riccardi, A., Gobbi, P., Perugini, S.: Trattamento des plasmocitoma con peptichemio. ATTI del XXVI Congresso Nazionale della Società Italiana di Ematologia, Tipografia Viscontea, Pavia, 554–560, 1977Google Scholar
  567. 567.
    Merlini, G., Waldenström, J.G., Jayakar, S.D.: A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55: 1011–1018, 1980PubMedGoogle Scholar
  568. 568.
    Mervin, R. M., Algire, G. H.: Induction of plasma–cell neoplasms and fibrosarcomas in BALB/c mice carrying diffusion chambers. Proc. Soc. Exp. Biol. Med. 101: 437–439, 1959Google Scholar
  569. 569.
    Meshkinpour, H., Mynne, C. G., Kramer, L. S.: A unique multi-systemic syndrome of unknown origin. Arch. Intern. Med. 137: 1719–1721, 1977PubMedCrossRefGoogle Scholar
  570. 570.
    Meyer, J.E., Schulz, M.D.: „Solitary“myeloma of bone: A review of twelve cases. Cancer 34: 438–440, 1974PubMedCrossRefGoogle Scholar
  571. 571.
    Meyers, B.R., Hirschman, S.L., Axelrod, J. A.: Current patterns of infection in multiple myeloma. Amer. J. Med. 52: 87–92, 1972PubMedCrossRefGoogle Scholar
  572. 572.
    Milham, S.Jr.: Leukemia and multiple myeloma in farmers. Amer. J. Epidemiol. 94: 307–310, 1971Google Scholar
  573. 573.
    Milham, S.Jr.: Occupational Mortality in Washington State 1950–1971. DHEW Publication No. (NIOSH) 76–175, Washington DC, US Government Printing Office, 1976Google Scholar
  574. 574.
    Mill, W.B.: Radiation therapy in multiple myeloma. Radiology 115: 175–178, 1975PubMedGoogle Scholar
  575. 575.
    Mill, W.B., Griffith, R.: The role of radiation therapy in the management of plasma cell tumors. Cancer 45: 647–652, 1980PubMedCrossRefGoogle Scholar
  576. 576.
    Miller, R. W.: Cancer epidemics in the People’s Republic of China. J. Natl. Cancer Inst. 60: 1195–1203, 1978PubMedGoogle Scholar
  577. 577.
    Miller, S., Perrota, A.: Multiple myeloma: Results with the M-2 protocol in a community hospital. J. Amer. Osteopathol. Ass. 78: 857–864, 1979Google Scholar
  578. 578.
    Mitchel, D.N., Rees, R.J.W., Salsbury, A. J.: Possible transmissibility of human myelomatosis in immunologically deficient mice. Lancet 2: 1009–1012, 1971CrossRefGoogle Scholar
  579. 579.
    Miturzynska, H.: Niedoczynnośc przedniego plata przysadki w przebiegu szpiczaka mnogiego. Pol. Typ. Lek. 17: 224–226, 1962Google Scholar
  580. 580.
    Mohr, R.: Das Paraprotein als tumorspeziflseher Marker beim Plasmozytom. Vhdl. dtsch. Ges. inn. Med. 84: 196–198, 1982Google Scholar
  581. 581.
    Möller, H., Waldenström, J.G., Zettervall, O.: Pyoderma gangraenosum (dermatitis ulcerosa) and monoclonal (IgA) globulin healed after melphalan treatment. Acta Med. Scand. 203: 293–296, 1978PubMedCrossRefGoogle Scholar
  582. 582.
    Monson, R. R., Nakano, K. K.: Mortality among rubber workers. II. Other employees. Amer. J. Epidemiol. 103: 297–303, 1976Google Scholar
  583. 583.
    Moon, J.H., Edmonson, J.H.: Procarbazine (NSC-77213) and multiple myeloma. Cancer Chemother. Rep. 54: 245–247, 1970PubMedGoogle Scholar
  584. 584.
    Morell, A., Maurer, W., Skvaril, F., Barandun, S.: Differentiation between benign and malignant monoclonal gammopathies by discriminant analysis on serum and bone marrow parameters. Acta Haematol. 60: 129–136, 1978PubMedCrossRefGoogle Scholar
  585. 585.
    Morell, A., Skvaril, F.: Correlations between the serum concentrations of IgG myeloma proteins and background IgG. In: Protides of the Biological Fluids. Hrsg.: Peeter, H., Pergamon Press, Oxford-New York, 1973Google Scholar
  586. 586.
    Morell, A., Terry, W.D., Waldmann, T. A.: Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49: 673–680, 1970PubMedCrossRefGoogle Scholar
  587. 587.
    Morgan, C., Hammack, W. J.: Intravenous urography in multiple myeloma. N. Engl. J. Med. 275: 77–79, 1966PubMedCrossRefGoogle Scholar
  588. 588.
    Morris, R.C., Fudenberg, H.H.: Impaired renal acidification in patients with hyper-gammaglobulinemia. Medicine 46: 57–69, 1967PubMedCrossRefGoogle Scholar
  589. 589.
    Morse, D., Dailey, R.C., Bunn, J.: Prehistoric multiple myeloma. Bull. N. Y. Acad. Med. 50: 447–458, 1974PubMedGoogle Scholar
  590. 590.
    Moseley, J. E.: Bone Changes in Hematologic Disorders. Grune & Stratton, New York-London, 1963Google Scholar
  591. 591.
    Mottot, C., Bastien, H., Guerrin, J., Justrabo, E., Knopf, J.F., Cayot, F., Aupecle, P.: Localisation mammaire bilaterale d’une maladie de Kahler. Sem. Hop. Paris 54: 1393–1397, 1978PubMedGoogle Scholar
  592. 592.
    Moya-Mir, M. S., Martin-Martin, F., Barbadillo, R, Cuervas-Mons, V., Martin-Jimenez, T., Sanchez-Miro, I., Garcia-Merino, J. A.: Plasma cell dyscrasia with polyneuritis and dermato-endocrine alterations. Report of a new case outside Japan. Postgrad. Med. J. 56: 427–430, 1980PubMedCrossRefGoogle Scholar
  593. 593.
    Mundy, G.R., Raisz, L.G., Cooper, R.A., Schlechter, G.P., Salmon, S.E.: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med. 291: 1041–1046, 1974PubMedCrossRefGoogle Scholar
  594. 594.
    Murphy, W. M., Deodhar, S. D.: Studies in multiple myeloma. I. Characteristics by immunoglobulin class. Cleve. Clin. Q. 40: 1–7, 1973PubMedGoogle Scholar
  595. 595.
    Najarian, T., Castleman, B.: Is low-dose radiation associated with myeloma ? N. Engl. J. Med. 300: 1278, 1978Google Scholar
  596. 596.
    Namba, Y., Hanaoko, M.: Immunoglobulin synthesis by cultured mouse myeloma cells. J. Immunol. 102: 1486–1497, 1969PubMedGoogle Scholar
  597. 597.
    Navarro, V., Rapado, A., Capote, L., Ruiz, F., de la Barreda, P.: Leucoencefalopatia multifocal progressiva en un mieloma. Rev. Clin. Espan. 131: 319–326, 1973PubMedGoogle Scholar
  598. 598.
    Nestler, J.E.: Immunoglobulin D multiple myeloma with thrombocytosis. Ann. Intern. Med. 94: 412, 1981PubMedGoogle Scholar
  599. 599.
    Newell, G.R., Kremetz, E.T., Roberts, J.D., Kinnear, B.K.: Multiple primary neoplasms in blacks compared to whites. I. Further cancers in patients with Hodgkin’s disease, leukemia, and myeloma. J. Natl. Cancer Inst. 52: 635–638, 1974PubMedGoogle Scholar
  600. 600.
    Nicholls, M., Vincent, P.C., Repka, E., Saunders, J., Gunz, F. W.: Isotypic discordance of paraproteins and lymphocyte surface immunoglobulins in myeloma. Blood 57: 192–195, 1981PubMedGoogle Scholar
  601. 601.
    Niell, H.B., Neely, C.L., Palmieri, G.M.: The postabsorptive urinary hydroxyproline (Spot-HYPRO) in patients with multiple myeloma. Cancer 48: 783–787, 1981PubMedCrossRefGoogle Scholar
  602. 602.
    Nishiyama, H., Anderson, R. E., Ishimura, T., Ihidak, Y. I., Okabe, N.: The incidence of malignant lymphoma and multiple myeloma in Hiroshima and Nagasaki atomic bomb survivors 1945–1965. Cancer 32: 1301–1309, 1973PubMedCrossRefGoogle Scholar
  603. 603.
    Norden, C. W.: Infections in patients with multiple myeloma. Arch. Intern. Med. 140: 1150–1151, 1980PubMedCrossRefGoogle Scholar
  604. 604.
    Nordenson, N.G.: Myelomatosis: A clinical review of 310 cases. Acta Med. Scand. (Suppl. 445 ), 179: 178, 1966CrossRefGoogle Scholar
  605. 605.
    Nørgaard, O.: Three cases of multiple myeloma in which the preclinical asymptomatic phases persisted throughout 15 to 24 years. Brit. J. Cancer 25: 417–422, 1971PubMedCrossRefGoogle Scholar
  606. 606.
    Norton, L., Simon, R.: Tumor size, sensitivity to therapy, and a design of treatment schedules. Cancer Treat. Rep. 61: 1307–1317, 1977PubMedGoogle Scholar
  607. 607.
    Ockhuizen, T., Steen, G., Muilerman, H.G., Smit, J.W., Wietzes, P., Mandema, E., Marrink, J.: A biclonal origin of two monoclonal proteins, IgG3(kappa) and IgA1 (lambda), from a single patient. Immunology 37: 863–868, 1979PubMedGoogle Scholar
  608. 608.
    Ogawa, M., Kochwa, S., Smith, C., Ishizaka, K., Mclntyre, O.R.: Clinical aspects of IgE myeloma. N. Engl. J. Med. 281: 1217–1220, 1969PubMedCrossRefGoogle Scholar
  609. 609.
    Ogawa, M., Mclntyre, O. R., Ishizaka, K., Ishizaka, T., Terry, W. D., Waldmann, T. A.: Biologic properties of E myeloma proteins. Amer. J. Med. 51: 193–199, 1971PubMedCrossRefGoogle Scholar
  610. 610.
    Ohnishi, K., Hayakawa, M., Koyama, O., Fukuhara, M., Hinami, F., Saito, K., Toyokawa, S., Adachi, K., Takao, N., Tanemoto, K.: A case of multiple myeloma with alveolar calcification in lung showing diffuse disseminated miliary shadows. Jpn. Thorac. Dis. 16: 279–283, 1978Google Scholar
  611. 611.
    Orf, G.: Das Plasmozytom als neurochirurgisches Krankheitsbild. Acta Neurochir. 22: 91–108, 1970CrossRefGoogle Scholar
  612. 612.
    Ohtani, H.: Myeloma and immunoglobulins. Jpn. J. Cin. Pathol. 24: 287–293, 1976Google Scholar
  613. 613.
    Ösby, E., Carlmark, B., Reizenstein, P.: Staging of myeloma: A preliminary study of staging factors and treatment in different stages. In: Recent Results in Cancer Research. Lymphoid Neoplasias. II. Clinical and Therapeutic Aspects. Hrsg.: Mathé, G., Seligmann, M., Tubiana, M., Springer Verlag, Berlin-Heidelberg-New York, SS. 21–27, 1978Google Scholar
  614. 614.
    Osgood, E.E.: The survival time of patients with plasmocytic myeloma. Cancer Chemother. Rep. 9: 1–10, 1960PubMedGoogle Scholar
  615. 615.
    Osserman, E.F.: Plasma-cell myeloma. II. Clinical aspects. N. Engl. J. Med. 261: 952–960, 1959PubMedCrossRefGoogle Scholar
  616. 616.
    Osserman, E.F.: Melphalan and antigenic type of Bence Jones proteins in myeloma. Science 149: 564, 1965CrossRefGoogle Scholar
  617. 617.
    Osserman, E.F.: Multiple myeloma and related plasma cell dyscrasias. In: Immunological Diseases. Hrsg.: Samter, M., Talmage, D.W., Rose, B., Little Brown & Co, Boston, SS. 520–547, 1971Google Scholar
  618. 618.
    Osserman, E.F., Fahey, J.L.: Plasma cell myeloma. In: Hematology. Hrsg.: Williams, W.Jr., Beutler, E., Ersler, A. J., Rundles, W., McGraw-Hill, New York, SS. 956–968, 1972Google Scholar
  619. 619.
    Osserman, E.F., Sherman, W.H., Alexanian, R., Gutterman, J.U., Humphrey, R.L.: Preliminary results of the American Cancer Society (ACS)-sponsored trial of human leukocyte interferon (IF) in multiple myeloma (MM). Proc. Amer. Assoc. Cancer Res. 21: 161, 1980Google Scholar
  620. 620.
    Osserman, E.F., Takatsuki, K.: Plasma cell myeloma: Gammaglobulin synthesis and structure. Medicine 42: 357–384, 1963PubMedCrossRefGoogle Scholar
  621. 621.
    Osserman, E. F., Takatsuki, K.: Considerations regarding the pathogenesis of the plasmacytic dyscrasias. Scand. J. Haematol. 4: Suppl., 28, 1965Google Scholar
  622. 622.
    Otieno, L.S., Ogada, T.: Multiple myeloma at Kenyatta National Hospital 1973–1976. East Afr. Med. J. 54: 574–578, 1977PubMedGoogle Scholar
  623. 623.
    Otto, S., Puskas, E., Medgyesi, G. A., Gergely, J.: Diclonal and multiple gammopathies. Haematologica (Budapest) 6: 471–487, 1972Google Scholar
  624. 624.
    Ottolander, G. J., Den, H., Perret, J.: Verworven hemorragische idathese ten gevolge van geisoleerde factor X-deficientie. Med. Tijdschr. Geneeskd. 109: 852–854, 1965Google Scholar
  625. 625.
    Ottosen, P.D., Courtoy, P. J., Farquhar, M.G.: Pathways followed by membrane recovered from the surface of plasma cells and myeloma cells. J. Exp. Med. 152: 1–19, 1980PubMedCrossRefGoogle Scholar
  626. 626.
    Outeirino, J., Sanchez, F.J., Ortiz, M.F.: Non-macroglobulinaemic plasma cell dyscrasias in haematological analysis in 100 cases. Sangre (Barcelona) 21: 296–310, 1976Google Scholar
  627. 627.
    Ozer, H., Han, T., Henderson, E. S., Nussbaum, A., Sheedy, D.: Immunoregulatory T cell function in multiple myeloma. J. Clin. Invest. 67: 779–789, 1981PubMedCrossRefGoogle Scholar
  628. 628.
    Pachter, M. R., Johnson, S. A., Basinki, D. H.: The effect of macroglobulins and their dissociation units on release of platelet factor 3. Thromb. Diath. Haemorrh. 3: 501–509, 1959PubMedGoogle Scholar
  629. 629.
    Paglieroni, T., McKenzie, M. R.: Studies on the pathogenesis of an immune defect in multiple myeloma. J. Clin. Invest. 59: 1120–1133, 1977PubMedCrossRefGoogle Scholar
  630. 630.
    Paglieroni, T., McKenzie, R.M.: Multiple myeloma: An immunologic profile. III.Cytotoxic and suppressive effects of the EA rosette-forming cell. J. Immunol. 124: 2563–2570, 1980PubMedGoogle Scholar
  631. 631.
    Palade, G.: Intracellular aspects of the process of protein secretion. Science 189: 347–358, 1975PubMedCrossRefGoogle Scholar
  632. 632.
    Papadimitriou, J. M., Matz, L. R.: The origin of multinucleate giant cells in myeloma kidney from mononuclear phagocytes: An untrastructural study. Pathology 11: 583–593, 1979PubMedCrossRefGoogle Scholar
  633. 633.
    Pappenheim, A.: Wie verhalten sich die Unnaschen Plasmazellen zu Lymphozyten? Virchow’s Arch, pathol. Anat. 166: 424–453, 1901Google Scholar
  634. 634.
    Parr, D.M., Conell, G.E., Powell, A. J., Pruzanski, W.: A pathologic IgM occurring in serum as pentamer, dimer, and monomer. J. Immunol. 113: 2020–2026, 1974PubMedGoogle Scholar
  635. 635.
    Pasmantier, M. W., Azar, H. A.: Extraskeletal spread in multiple plasma cell myeloma: A review of 57 autopsied cases. Cancer 23: 167–174, 1969PubMedCrossRefGoogle Scholar
  636. 636.
    Patterson, R., Roberts, M., Pruzansky, J. J.: Localization of thermoprecitipable activity to the „heavy“polypeptide chain of a G myeloma pyroglobulin. Proc. Soc. Exp. Biol. (N. Y.) 120: 275–278, 1965Google Scholar
  637. 637.
    Paul, L.W., Pohle, E.A.: Solitary myeloma of bone: Review of roentgenologic features, with report of 4 additional cases. Radiology 35: 651–666, 1940Google Scholar
  638. 638.
    Pavlovsky, S., Saslavsky, J., Tezanos Pinto, M., Cavagnaro, F., Curutchet, M., Lein, J.M., Garay, G., Dragosky, M., Bergna, L.: Assessment of melphalan and prednisone (MP) versus the same drugs plus cyclophosphamide, MeCCNU and vincristine (MPCCV) in the treatment of multiple myeloma. (Abstract C-795), Proc. Amer. Assoc. Cancer Res. 22: 536, 1981Google Scholar
  639. 639.
    Payne, R. B.: A red herring in the detection of Bence-Jones protein (Letter). J. Clin. Pathol. 25: 183, 1972PubMedCrossRefGoogle Scholar
  640. 640.
    Pederson, N. S., Axelsen, N. H.: Detection of M-components by an easy immunofixation procedure: Comparison with agarose gel electrophoresis and classical immuno-electrophoresis. J. Immunol. Meth. 30: 257–262, 1979CrossRefGoogle Scholar
  641. 641.
    Pehamberger, H., Diem, E., Konrad, K.: Systemic lupus erythematosus with multiple myeloma. Acta Dermatol.-Venereol. 58: 527–530, 1978Google Scholar
  642. 642.
    Pengelly, C. D. R., Mondal, B. K., Barna, A. R.: Haemolytic anaemia in myelomatosis. Postgrad. Med. J. 49: 279–281, 1973PubMedCrossRefGoogle Scholar
  643. 643.
    Penny, R., Castaldi, P. A., Whitsed, H.M.: Inflammation and haemostasis in paraproteinaemias. Brit. J. Haematol. 20: 35–44, 1971CrossRefGoogle Scholar
  644. 644.
    Penny, R., Galton, D.A.G.: Studies on neutrophil function. II. Pathological aspects. Brit. J. Haematol. 12: 633–645, 1966CrossRefGoogle Scholar
  645. 645.
    Penny, R., Hughes, S.: Repeated stimulation of the reticuloendothelial system and the development of plasma-cell dyscrasias. Lancet 1: 77–78, 1970PubMedCrossRefGoogle Scholar
  646. 646.
    Pentimone, F., Camici, M., Cini, G., Levorato, D.: Duodenal plasmocytoma. A rare primary extramedullary localization simulating a carcinoma. Acta Haematol. 61: 155–160, 1979PubMedCrossRefGoogle Scholar
  647. 647.
    Perez-Gutierrez, A., Prieto, S., Espinos, D., Tamarit, J.: Calcitonin in multiple myeloma. Sangre 25: 334–338, 1980PubMedGoogle Scholar
  648. 648.
    Perkins, H. A., McKenzie, M. R., Fudenberg, H. H.: Hemostatic defects in dysproteinemias. Blood 35: 695–707, 1970PubMedGoogle Scholar
  649. 649.
    Perlzweig, W. A., Delrue, G., Gesehickter, C.: Hyperproteinemia associated with multiple myelomas: report of an unusual case. J. Amer. Med. Ass. 90: 755–757, 1928CrossRefGoogle Scholar
  650. 650.
    Perry, M. C., Kyle, R. A.: The clinical significance of Bence Jones proteinuria. Mayo Clin. Proc. 50: 234–238, 1975PubMedGoogle Scholar
  651. 651.
    Pettersen, D., Mellstedt, H., Holm, G.: Immunoglobulin isotypes on monoclonal blood lymphocytes in human plasma cell myeloma. J. Clin. Lab. Immunol. 3: 93–98, 1980Google Scholar
  652. 652.
    Pezzutto, A., Semenzato, G., Agostini, C., Raimondi, R., Gasparotto, G.: Subpopulations of T-lymphocytes in multiple myeloma. Scand. J. Haematol. 26: 333–338, 1981PubMedCrossRefGoogle Scholar
  653. 653.
    Philip, P., Drivsholm, A., Hansen, N.E., Jensen, M.K., Killmann, S. A.: Chromosomes and survival in multiple myeloma: A banding study of 25 cases. 18th Congress Internat. Soc. Haematol., Montreal, Abstract 458, 1980Google Scholar
  654. 654.
    Philips. E.D., El–Mahdi, A.M., Humphrey, R.L., Furlong, M.B. Jr.: The effect of the radiation treatment on the polyneuropathy of multiple myeloma. J. Can. Ass. Radiol. 23: 103–106, 1972Google Scholar
  655. 655.
    Pick, A.I., Fröhlichmann, R., Lavie, G., Duczyminer, M., Skvaril, F.: Clinical and immunochemical studies of 20 patients with amyloidosis and plasma cell dyscrasia. Acta Haematol. 66: 154–167, 1981PubMedCrossRefGoogle Scholar
  656. 656.
    Pick, A.I., Osserman, E.F.: Amyloidosis associated with plasma cell dyscrasias. In: Amyloidosis. Hrsg.: Mandema, E., Ruinen, L., Scholten, J. H., Exerpta Medica, Amsterdam, SS. 100–109, 1968Google Scholar
  657. 657.
    Pietruszka, M., Rabin, B. S., Srodes, C.: Multiple myeloma in husband and wife. Lancet 1: 314, 1976PubMedCrossRefGoogle Scholar
  658. 658.
    Pileri, A., Boccadoro, M., Mandelli, F., Amadori, S.: Growth kinetics of minimal tumour masses: Implications for rational chemotherapy. Haematologica 66: 545–553, 1981PubMedGoogle Scholar
  659. 659.
    Pilgrim, H. I.: The relationship of chronic ulceration of the ileocecal junction to the development of reticuloendothelial tumors in C3H mice. Cancer Res. 25: 53–65, 1965PubMedGoogle Scholar
  660. 660.
    Pinsky, C.M., Lee, B.J.: Melphalan treatment of multiple myeloma. Memorial Sloan Kettering Cancer Center Bull. 6: 142–146, 1976Google Scholar
  661. 661.
    Plenk, A., Pretl, K.: Peripheres endobronchiales Plasmozytom der Lunge mit Osteopathia hypertrophicans. Wien. med. Wschr. 25 /26: 450–451, 1953Google Scholar
  662. 662.
    Poger, M.E., Lamm, M.E.: Localization of free and bound secretory component in human intestinal epithelial cells: A model for the assembly of secretory IgA. J. Exp. Med. 139: 629–642, 1974PubMedCrossRefGoogle Scholar
  663. 663.
    Polednak, A. P., Stehney, A. F., Rowland, R. E.: Mortality among women first employed before 1930 in the US radium dial-painting industry. Amer. J. Epidemiol. 107: 179–195, 1978Google Scholar
  664. 664.
    Polliak, A., Nilsson, K., Laskov, R, Biberfeld, P.: Characteristic surface morphology of human and murine myeloma cells: a scanning and trasmission electron microscopic study. Brit. J. Haematol. 39: 25–32, 1978CrossRefGoogle Scholar
  665. 665.
    Port, C.D., Maschgan, E.R, Pond, J., Scarpelli, D.G.: Multiple neoplasia in a jaguar (panthera onca). J. Comp. Pathol. 91: 115–122, 1981PubMedCrossRefGoogle Scholar
  666. 666.
    Poth, J. L., George, R. P.: Hemorrhagic ascites: An unusual complication of multiple myeloma. Calif. Med. 115: 61–64, 1971PubMedGoogle Scholar
  667. 667.
    Potter, M.: Antigen binding M-components in man and mouse. In: Multiple Myeloma and Related Disorders. Hrsg.: Azar, H.A., Potter, M., Harper & Row, New York, SS. 195–246, 1973Google Scholar
  668. 668.
    Potter, M.: The developmental history of the neoplastic plasma cell in mice: A brief review of recent developments. Semin. Hematol. 10: 19–32, 1973PubMedGoogle Scholar
  669. 669.
    Potter, M., Boyce, C. R.: Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 193: 1086–1087, 1962PubMedCrossRefGoogle Scholar
  670. 670.
    Potter, M., Robertson, C.L.: Development of plasma cell neoplasms in BALB/c mice after intraperitoneal injection of paraffin oil adjuvant, heat killed Staphylococcus mixtures. J. Natl. Cancer Inst. 25: 847–861, 1960PubMedGoogle Scholar
  671. 671.
    Prange, H., Kaboth, U., Spaar, F. W., Gremse, B.: Neurologische Komplikationen bei paraproteinämischen Hämoblastosen: Klinische Beobachtungen und Liquorbefunde. Fortschr. Neurol. Psychiat. 47: 387–398, 1979Google Scholar
  672. 672.
    Presant, C.A., Klahr, C: Adriamycin, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, NSC #409962), cyclophosphamide plus prednisone (ABC-P) in melphalan-resistant multiple myeloma. Cancer 42: 1222–1227, 1978PubMedCrossRefGoogle Scholar
  673. 673.
    Preston, F.E., Cooke, K.B., Foster, M.E., Winfield, D. A., Lee, D.: Myelomatosis and the hyperviscosity syndrome. Brit. J. Haematol. 38: 517–530, 1978CrossRefGoogle Scholar
  674. 674.
    Preud’Homme, J. L., Hurez, D., Danon, F., Seligmann, M.: Intracytoplasmic and surface-bound immunoglobulins in,nonsecretory‘and Bence-Jones myeloma. Clin. Exp. Immunol. 25: 428–436, 1976PubMedGoogle Scholar
  675. 675.
    Preud’Homme, J.L., Klein, M., Labaume, S., Seligman, M.: Idiotype-bearing and antigen-binding receptors produced by blood T lymphocytes in a case of human myeloma. Eur. J. Immunol. 7: 840–846, 1977PubMedCrossRefGoogle Scholar
  676. 676.
    Preuss, H.G., Weiss, F.R., Iammarino, R.M., Hammack, W.J., Murdaugh, H.V.: Effects of rat kidney slice function in vitro of proteins from the urines of patients with myelomatosis and nephrosis. Clin. Sci. Mol. Med. 46: 283–294, 1974PubMedGoogle Scholar
  677. 677.
    Pribilla, W. G., Stecher, G., Kanzow, U.: Untersuchungen über die Pathogenese der Anämie bei Plasmocytom und Makroglobulinämie Waldenström. Dtsch. med. Wschr. 90: 988–995, 1965PubMedCrossRefGoogle Scholar
  678. 678.
    Price, H. I., Danziger, A., Wainwright, H.C., Batnitzky, S.: CT of orbital multiple myeloma. Amer. J. Neuroradiol. 1: 573–575, 1980Google Scholar
  679. 679.
    Prost, A., Soulilou, J. P., Gardais, J., Hurez, D., Cottin, S.: Deux nouvelles observations de myélomes á plasmocytes d’emblée on secondairement non-excrétant. Rev. Rheum. Malad. Osteoart. 40: 151–157, 1973Google Scholar
  680. 680.
    Pruzanski, W.: Clinical manifestation of multiple myeloma: Relation to class and type M component. Can. Med. Ass. J. 114: 896–897, 1976PubMedGoogle Scholar
  681. 681.
    Pruzanski, W., Gidon, M.S., Roy, A.: Suppression of polyclonal immunoglobulins in multiple myeloma: Relationship to the staging and other manifestations at diagnosis. Clin. Immunol. Immunopathol. 17: 280–286, 1980PubMedCrossRefGoogle Scholar
  682. 682.
    Pruzanski, W., Platts, M.E., Ogryzolo, M. A.: Leukemic form of immunocytic dyscrasia (plasma cell leukemia). A study of 10 cases and a review of the literature. Amer. J. Med. 47: 60–74, 1969PubMedCrossRefGoogle Scholar
  683. 683.
    Pruzanski, W., Underdown, B., Silver, E.H., Katz, A.: Macroglobulinemia-myeloma double gammopathy: A study of four cases and a review of the literature. Amer. J. Med. 57: 259–266, 1974PubMedCrossRefGoogle Scholar
  684. 684.
    Pruzanski, W., Watt, J. G.: Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Ann. Intern. Med. 77: 853–860, 1972PubMedGoogle Scholar
  685. 685.
    Püschel, W., Kunath, K.: Statistische Ergebnisse von Autopsiebefunden beim multiplen Myelom. Zentralbl. Allg. Pathol. 121: 381–388, 1977PubMedGoogle Scholar
  686. 686.
    Putnam, F.W.: Aberrations of protein metabolism in multiple myeloma. Interrelationship of abnormal serum globulin and Bence-Jones protein. Physiol. Rev. 37: 512–538, 1957PubMedGoogle Scholar
  687. 687.
    Putnam, F.W., Easley, C. W., Lynn, L.T., Ritchie, A.E., Phelps, R. A.: The heat precipitation of Bence-Jones proteins. I. Optimum conditions. Arch. Biochem. Biophys. 83: 115–130, 1959PubMedCrossRefGoogle Scholar
  688. 688.
    Queisser, W., Hoelzer, D., Queisser, U.: Cytophotometrisch-autoradiographische Untersuchung der Zellproliferation bei paraproteinämischen Hämoblastosen mit leukämischen Blutbildveränderungen. Klin. Wschr. 51: 230–234, 1973PubMedCrossRefGoogle Scholar
  689. 689.
    Rabbits, T. H.: Evidence for splicing of interrupted immunoglobulin variable and constant region sequences in nuclear RNA. Nature 275: 291–296, 1978CrossRefGoogle Scholar
  690. 690.
    Raisz, L. G., Luben, R. A., Mundy, G. R., Dietrich, J. W., Horton, J. E., Trummel, G. L.: Effect of osteoclast activating factor from human leukocytes on bone metabolism. J. Clin. Invest. 56: 408–413, 1975PubMedCrossRefGoogle Scholar
  691. 691.
    Ramon Y Cajal, S.: Manual de anatomia patológia general. Barcelona, 1890Google Scholar
  692. 692.
    Rautenstrauch, H.: Analyse der Urinproteine von 50 Patienten mit Plasmozytom durch die Diskelektrophorese. Blut 38: 337–341, 1979PubMedCrossRefGoogle Scholar
  693. 693.
    Ray, P.K., Besa, E., Idiculla, A., Rhoads, J.E., Basset, J.G., Cooper, D.R.: Efficient removal of abnormal immunoglobulin G from plasma of a multiple myeloma patient. Description of a new method for treatment of the hyperviscosity syndrome. Cancer 45: 2633–2638, 1980PubMedCrossRefGoogle Scholar
  694. 694.
    Registrar General’s Decennial Supplement: England and Wales 1951: Occupational Mortality Tables. HM Stat. Off., London, 1958Google Scholar
  695. 695.
    Reverberi, R., Scapoli, G.L., Menini, C.: Terapia con plasmaferesi in casi di gammapatie monoclonali con sindrome di iperviscosita. Revisione di dieci casi. La Trasf. del Sangue 1: 84–91, 1980Google Scholar
  696. 696.
    Riccardi, A., Merlini, G., Montecucco, D., Perugini, S.: Vincristine in the treatment of multiple myeloma. Haematologica 65: 595–611, 1980PubMedGoogle Scholar
  697. 697.
    Rice, N.T., Woodring, J.H., Mostowycz, L., Purcell, M.: Pancreatic plasmacytoma: Sonographic and computerized tomographic findings. J. Clin. Ultrasound 9: 46–48, 1981PubMedCrossRefGoogle Scholar
  698. 698.
    Richter, G. W.: The resorption of amyloid under experimental conditions. Amer. J. Pathol. 30: 239–251, 1954Google Scholar
  699. 699.
    Rigoletti, L.: Plasmocitoma della lingua. Arch. Sci. Med. 61: 600–604, 1936Google Scholar
  700. 700.
    Ritchie, R. F., Smith, R.: Immunofixation. III. Application to the study of monoclonal protein. Clin. Chem. 22: 1982–1985, 1976PubMedGoogle Scholar
  701. 701.
    Ritchie, W. A., Warren, S.L.: The occurrence of multiple bony lesions suggesting myeloma in the skeleton of a pre-Columbian Indian. Amer. J. Roentgenol. 28: 622–628, 1932Google Scholar
  702. 702.
    Riva, G.: Das Serumeiweiβbild. H. Huber Verlag, Bern-Stuttgart, 1957Google Scholar
  703. 703.
    Rivat, M.H., Colomb, D., Normand, J., Cavailles, M.: Xanthomes et dysglobuliné- mies myélomateuses. A propos d’un cas associé également à une amyloidose systématisée, dite primitive, type Lubarsch-Pick. Revue de 42 cas de la littérature. Ann. Dermatol. Venereol. (Paris) 106: 755–766, 1979Google Scholar
  704. 704.
    River, G.L., Tewksbury, D.A., Fudenberg, H.: Non-secretory myeloma. Blood 40: 204–206, 1972PubMedGoogle Scholar
  705. 705.
    Rivers, S.L., Patno, M.E.: Cyclophosphamide vs. melphalan in treatment of plasma cell myeloma. J. Amer. Med. Ass. 207: 1328–1334, 1969CrossRefGoogle Scholar
  706. 706.
    Rivers, S. L., Whittington, R. M., Patno, M. E.: Comparison of the effects of cyclophosphamide and a placebo in the treatment of multiple myeloma. Cancer Chemother. Rep. 29: 115–119, 1963PubMedGoogle Scholar
  707. 707.
    Rogentine, G.N., Rowe, D.S., Bradley, J., Waldmann, T. A., Fahey, J.L.: Metabolism of human immunoglobulin D (IgD). J. Clin. Invest. 45: 1467–1478, 1966PubMedCrossRefGoogle Scholar
  708. 708.
    Rogers, J. S. II, Shah, S.: Spontaneous splenic rupture in plasma cell leukemia. Cancer 46: 212–214, 1980PubMedCrossRefGoogle Scholar
  709. 709.
    Rogers, J. S. II, Spahr, J., Judge, D. M., Varano, L. A., Eyster, M. E.: IgE myeloma with osteoblastic lesions. Blood 49: 295–299, 1977PubMedGoogle Scholar
  710. 710.
    Roof, B.S.: Tumor hypercalcemia. Calif. Med. 118: 35–36, 1973PubMedGoogle Scholar
  711. 711.
    Ropartz, C., Rivat, L., Rousseau, P.Y., Fine, J.M.: Myélomes, maladies de Waldenström et groupes de gammaglobulines Gm et Inv. Rev. Franc. Etudes Clin. Biol. 10: 507–513, 1965PubMedGoogle Scholar
  712. 712.
    Rosenberg, B., Attie, J. N., Mandelbaum, H. L.: Breast tumor as the presenting sign of multiple myeloma. N. Engl. J. Med. 269: 359–361, 1963PubMedCrossRefGoogle Scholar
  713. 713.
    Rosenthal, C.F., Franklin, E.C., Frangione, B., Greenspan, J.: Isolation and partial characterization of SAA — an amyloid-related protein from human serum. J. Immunol. 116: 1415–1418, 1976PubMedGoogle Scholar
  714. 714.
    Rosner, F., Grünwald, H.: Multiple myeloma terminating in acute leukemia: Report of 12 cases and review of the literature. Amer. J. Med. 57: 927–939, 1974PubMedCrossRefGoogle Scholar
  715. 715.
    Rosner, F., Grünwald, H. W.: Multiple myeloma and Waldenström’s macroglobulinemia terminating in acute leukemia. N. Y. State J. Med. 80: 558–570, 1980PubMedGoogle Scholar
  716. 716.
    Rowe, D.S., Fahey, J.L.: A new class of human immunoglobulins. I. A unique myeloma protein. J. Exp. Med. 121: 171–184, 1965PubMedCrossRefGoogle Scholar
  717. 717.
    Russel, W.: An address on a characteristic organism of cancer. Brit. Med. J. 2: 1356–1360, 1890CrossRefGoogle Scholar
  718. 718.
    Russell, J. A., Powles, R.L.: The relationship between serum viscosity, hypervolemia and clinical manifestations associated with circulating paraprotein. Brit. J. Haematol. 39: 163–175, 1978CrossRefGoogle Scholar
  719. 719.
    Rustizky, J.: Multiples Myelom. Dtsch. Z. Chir. 3: 162–172, 1873CrossRefGoogle Scholar
  720. 720.
    Saha, A., Edwards, M. A., Sargent, A.U.: Mechanism of cryoprecipitation. I. Characteristics of a human cryoglobulin. Immunochemistry 5: 341–356, 1968PubMedCrossRefGoogle Scholar
  721. 721.
    Saleün, J. P., Youinou, P., Le Goff, P., Le Menn, G., Morin, J.F.: HLA antigens and monoclonal gammopathy. Tissue Antigens 12: 233–235, 1979Google Scholar
  722. 722.
    Salmon, S. E.: Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin. Hematol. 10: 135–147, 1973PubMedGoogle Scholar
  723. 723.
    Salmon, S.E.: Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood 45: 119–129, 1975PubMedGoogle Scholar
  724. 724.
    Salmon, S.E.: Nitrosoureas in multiple myeloma. Cancer Treat. Rep. 60: 789–794, 1976PubMedGoogle Scholar
  725. 725.
    Salmon, S. E., Fudenberg, H. H.: Abnormal nucleic acid metabolism of lymphocytes in plasma cell myeloma and macroglobulinemia. Blood 33: 300–312, 1969PubMedGoogle Scholar
  726. 726.
    Salmon, S.E., Seligman, M.: B-cell neoplasia in man. Lancet 2: 1230–1233, 1974PubMedCrossRefGoogle Scholar
  727. 727.
    Salmon, S.E., Samal, B. A, Hayes, D.M., Hosley, H, Miller, S.P., Schilling, A.: Role of gamma globulin for immune prophylaxis in multiple myeloma. N. Engl. J. Med. 277: 1336–1340, 1967PubMedCrossRefGoogle Scholar
  728. 728.
    Salmon, S. E., Shadduck, R. K., Schilling, A.: Intermittent high-dose prednisone (NSL-10023) therapy for multiple myeloma. Cancer Chemother. Rep. 51: 179–187, 1967PubMedGoogle Scholar
  729. 729.
    Salmon, S.E., Smith, B. A.: Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J. Clin. Invest. 49: 1114–1121, 1970PubMedCrossRefGoogle Scholar
  730. 730.
    Salzer, M., Knahr, K.: Die operative Therapie der malignen Knochentumoren. Z. Orthop. 116: 517–525, 1978PubMedGoogle Scholar
  731. 731.
    Sanchez, L.M., Domz, C. A.: Renal patterns in myeloma. Ann. Intern. Med. 52: 44–54, 1960PubMedGoogle Scholar
  732. 732.
    Sanchez-Avalos, J., Soong, B. C. F., Miller, S. P.: Coagulation disorders in cancer. II. Multiple myeloma. Cancer 23: 1388–1398, 1969PubMedCrossRefGoogle Scholar
  733. 733.
    Sanders, J.H., Fahey, J.L., Finegold, I., Ein, E., Reisfeld, R., Berard, C.: Multiple anomalous immunoglobulins: Clinical, structural and cellular studies in three patients. Amer. J. Med. 47: 43–59, 1969PubMedCrossRefGoogle Scholar
  734. 734.
    Sandkühler, S.: Das heutige Bild des Plasmocytoms. Dtsch. med. Wschr. 76: 168–171, 1951PubMedCrossRefGoogle Scholar
  735. 735.
    Sato, I., Abo, T., Onadera, S., Kumagai, K.: Detection of monoclonal lymphocytes in multiple myeloma by immunofluorescence tests of surface immunoglobulins. Scand. J. Haematol. 21: 433–444, 1978PubMedCrossRefGoogle Scholar
  736. 736.
    Schafer, A. I., Miller, J. B.: Association of IgA multiple myeloma with pre-existing disease. Brit. J. Haematol. 41: 19–24, 1979CrossRefGoogle Scholar
  737. 737.
    Schecter, G.P., Wahl, L.M., Horton, J.E.: In vitro bone resorption by human myeloma cells. In: Progress in Myeloma. Hrsg.: Potter, M., Elsevier/North Holland, New York-Oxford-Amsterdam, 1980Google Scholar
  738. 738.
    Schedel, I., Fink, P.C., Schöner, W., Kalden, J.R., Peter, H.H., Deicher, H.: Serum anti-immunoglobulins in multiple myeloma and benign monocolonal hyperglobulin– emia. Clin. Immunol. Immunopathol. 15: 586–599, 1980PubMedCrossRefGoogle Scholar
  739. 739.
    Schedel, I., Peest, D., Stünkel, K., Fricke, M., Eckert, G., Deicher, H.: Idiotype- bearing peripheral blood lymphocytes in human multiple myeloma and Waldenström’s macroglobulinaemia. Scand. J. Immunol. 11: 437–444, 1980PubMedCrossRefGoogle Scholar
  740. 740.
    Schernthaner, G., Erd, W., Ludwig, H., Höfer, R.: „Normalwerte“der renalen Clearance in Abhängigkeit vom Lebensalter. In: Nuklearmedizin. Hrsg.: Schmidt, H. A.E., F. K. Schattauer Verlag, Stuttgart-New York, SS. 316–319, 1975Google Scholar
  741. 741.
    Schernthaner, G., Ludwig, H., Silberbauer, K.: Elevated plasma β-thromboglobulin levels in multiple myeloma and in polycythaemia vera. Acta Haematol. 62: 219–222, 1979PubMedCrossRefGoogle Scholar
  742. 742.
    Schilling, A., Finkel, H. E.: Ancillary measures in treatment of myeloma. Arch. Intern. Med. 135: 193–196, 1975PubMedCrossRefGoogle Scholar
  743. 743.
    Schlossberg, M., Hollander, V.P.: Immuran induced regression of plasma cell tumor. MOPC-315. Cancer Res. 33: 1953–1956, 1973PubMedGoogle Scholar
  744. 744.
    Schnur, M.J., Appel, G.B., Bilezikian, J.P.: Primary hyperparathyroidism and benign monoclonal gammopathy. Arch. Intern. Med. 137: 1201–1203, 1977PubMedCrossRefGoogle Scholar
  745. 745.
    Schubert, G. E., Veigel, J., Lennert, K.: Structure and function of the kidneys of patients with multiple myeloma. Virchow’s Arch, pathol. Anat. 355: 135–157, 1972CrossRefGoogle Scholar
  746. 746.
    Schubert, J. C. F., Rinneberg, H.: Der zytochemische Nachweis von Adenosin-Tri- phosphate-spaltenden Fermenten bei pH 7,2 in menschlichen Knochenmarksausstrichen. Blut 8: 282–288, 1962PubMedCrossRefGoogle Scholar
  747. 747.
    Schubert, J. C. F., Schubert, H.: Die zytologische Diagnose des Plasmozytoms am Knochenmarksausstrich mit Hilfe der Adenosin-Triphosphatase-Reaktion. Blut 19: 78–98, 1969PubMedCrossRefGoogle Scholar
  748. 748.
    Schulz, U., Löer, F.: Die Rolle der Strahlentherapie und der Chirurgie beim ossären Plasmozytom. Dtsch. med. Wschr. 20: 719–721, 1979CrossRefGoogle Scholar
  749. 749.
    Schur, P.H., Kyle, R.A., Bloch, K.J., Hammack, W.J., Rivers, S.L., Sargent, A., Ritchie, R.F., Mclntyre, O.R., Moloney, W.C., Wolfson, L.: IgG subclasses: Relationship to clinical aspects of multiple myeloma and frequency distribution among M- components. Scand. J. Haematol. 12: 60–68, 1974PubMedCrossRefGoogle Scholar
  750. 750.
    Schweers, C.A., Shaw, M.T., Nordquist, R.E., Rose, D.D., Kell, T.: Solitary cecal plasmacytoma. Electron microscopic, immunologic, and cytochemical studies. Cancer 37: 2220–2223, 1976PubMedCrossRefGoogle Scholar
  751. 751.
    Scolari, L., Vaerman, J. P., Castigli, E., Voliani, D., Salsano, F., Masala, G., DiGuglielmo R.: Late appearance of an IgA(k) monoclonal protein in a patient with IgG(k) multiple myeloma: Sharing of idiotypic specificities between the two serum proteins. Scand. J. Immunol. 8: 201–206, 1978PubMedCrossRefGoogle Scholar
  752. 752.
    Seigneurin, D., David, J., Sotto, J. J., Hollard, D.: β -Glucuronidases plasmocytaires dans les dysglobulinémies. Intérêt diagnostique de leur mise en evidence. Pathol. Biol. 27: 467–479, 1979PubMedGoogle Scholar
  753. 753.
    Sekulich, M., Pandola, G., Simon, T.: A solitary pulmonary mass in multiple myeloma: Report of a case. Dis. Chest. 48: 100–103, 1965PubMedCrossRefGoogle Scholar
  754. 754.
    Seligmann, M., Danon, F., Mihaesco, C.: Family studies in Waldenström’s macroglobulinemia. Scand. J. Haematol. 4: 50–64, 1965Google Scholar
  755. 755.
    Seligmann, M., Preud’Homme, J. L., Brouet, J. C.: B and T cell markers in human pro-liferative blood diseases and primary immunodeficiencies with specific references of membrane bound immunoglobulins. Transpl. Rev. 85–113, 1973Google Scholar
  756. 756.
    Seligmann, M., Sassy, C., Chevalier, A.: A human IgG myeloma protein with anti– alpha2 macroglobulin antibody activity. J. Immunol. 110: 85–90, 1973PubMedGoogle Scholar
  757. 757.
    Seon, B. K., Yagi, Y., Pressman, D.: Monoclonal IgA and IgM in the serum of a single patient (SC). II. Identity of light chains from IgA(k) and IgM(k). J. Immunol. 110: 345–349, 1973PubMedGoogle Scholar
  758. 758.
    Sewell, R.L.: Lymphocyte abnormalities in myeloma. Brit. J. Haematol. 36: 545–551, 1977CrossRefGoogle Scholar
  759. 759.
    Shalit, M., Bar-Sela, S., Leviaton, A., Naparstek, Y.: Hyperglobulinemic purpura in the course of multiple myeloma. Acta Haematol. 64: 331–334, 1980PubMedCrossRefGoogle Scholar
  760. 760.
    Shaw, M.T., Twele, T.W., Nordquist, R.E.: Plasma cell leukemia: Detailed studies and response to therapy. Cancer 33: 619–625, 1974PubMedCrossRefGoogle Scholar
  761. 761.
    Shigematsu, T.: The fine structure of various types of myeloma cells as revealed by electron microscopy. Arch. Hist. Jap. 30: 375–400, 1969CrossRefGoogle Scholar
  762. 762.
    Shildt, R.A., Rubin, R.R., Schiffman, G., Giolma, P.: Polyvalent pneumococcal immunization of patients with plasma cell dyscrasias. Cancer 48: 1377–1380, 1981PubMedCrossRefGoogle Scholar
  763. 763.
    Shirakura, T., Takekoshi, K., Umi, M., Kanazawa, K., Okabe, H., Inoue, T., Imamura, Y.: Waldenstrom’s macroglobulinaemia with IgE M-component. Scand. J. Haematol. 21: 292–298, 1978PubMedCrossRefGoogle Scholar
  764. 764.
    Shulman, G., Lynch, S. R., Bezwoda, W. R., Gilich, G. C.: Serum beta-lipoprotein and other specific protein concentrations in patients with immunocytoma. J. Clin. Pathol. 29: 458–461, 1976PubMedCrossRefGoogle Scholar
  765. 765.
    Shustik, C., Bergsagel, D.E., Pruzanski, W.: Kappa and lambda light chain disease: Survival rates and clinical manifestations. Blood 48: 41–51, 1976PubMedGoogle Scholar
  766. 766.
    Sikora, K.: Does interferon cure cancer? Brit. Med. J. 281: 855–858, 1980PubMedCrossRefGoogle Scholar
  767. 767.
    Silberbauer, K., Pietschmann, H., Ring, F., Sinzinger, H.: Monoclonale Gammopathie und Thrombozytenfunktion. Wien. klin. Wschr. 22: 755–758, 1979Google Scholar
  768. 768.
    Silverstein, A., Doninger, D.E.: Neurologic complications of myelomatosis. Arch. Neurol. (Chicago) 9: 534–544, 1963CrossRefGoogle Scholar
  769. 769.
    Siris, E. S., Sherman, W. H., Baquiran, D. C., Schlatterer, J. P., Osserman, E. F., Canfield, R. E.: Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N. Engl. J. Med. 302: 310–314, 1980PubMedCrossRefGoogle Scholar
  770. 770.
    Sirot, G.: Cutaneous manifestations of multiple myeloma. Cutis 23: 174–177, 1979PubMedGoogle Scholar
  771. 771.
    Skoog, W. A., Adams, W.S.: Clinical and metabolic investigation of eight cases of multiple myeloma during prolonged cyclophosphamide administration. Amer. J. Med. 41: 76–95, 1966CrossRefGoogle Scholar
  772. 772.
    Skvaril, F., Morell, A., Barandun, S.: The IgG subclass distribution in 659 myeloma sera. Vox Sang. 23: 546–551, 1972PubMedCrossRefGoogle Scholar
  773. 773.
    Slager, U.T., Taylor, W.F., Opfell, R. W., Myers, A.: Leptomeningeal myeloma. Arch. Pathol. Lab. Med. 103: 680–683, 1979PubMedGoogle Scholar
  774. 774.
    Smetana, K., Hermansky, F., Koblizkova, H., Pospisil, V.: A further note on the ultra- structure of myeloma plasmacytes. Neoplasma 18: 3–13, 1971PubMedGoogle Scholar
  775. 775.
    Smetana, K., Gyorkey, F., Gyorkey, P., Busch, H.: Ultrastructural studies in human myeloma plasmacytosis. Cancer Res. 33: 2300–2309, 1973PubMedGoogle Scholar
  776. 776.
    Smith, G., Walford, R. L., Fishkin, B., Carter, P. K., Tanaka, K.: HL–A phenotypes, im¬munoglobulins and kappa and lambda chain in multiple myeloma. Tissue Antigens 4: 374–377, 1974PubMedCrossRefGoogle Scholar
  777. 777.
    Smith, P. G., Doll, R.: Late effects of X irradiation in patients treated for metropathia haemorrhagica. Brit. J. Radiol. 49: 224–232, 1976PubMedCrossRefGoogle Scholar
  778. 778.
    Snapper, I., Kahn, A.I.: Multiple myeloma. Semin. Hematol. 1: 87–143, 1964PubMedGoogle Scholar
  779. 779.
    Snapper, I., Kahn, A.: Myelomatosis. Fundamentals and Clinical Features. S. Karger Verlag, Basel-New York, 1971Google Scholar
  780. 780.
    Snapper, I., Schneid, B.: On the influence of stilbamidine upon myeloma cells. Blood 1: 534–536, 1946PubMedGoogle Scholar
  781. 781.
    Snapper, I., Turner, L.B., Moscovity, H.L.: Multiple Myeloma. Grune & Stratton, New York, 1953Google Scholar
  782. 782.
    Sod, L. M., Lewis, M., Wiener, M. D.: Intradural extramedullary plasmacytoma. J. Neurosurg. 16: 107–109, 1959PubMedCrossRefGoogle Scholar
  783. 783.
    Solis, O.J., Gonzales, R., Deluca, S.: Evaluation del mieloma con cintilografia osea usando 99mTc-diphosphonate. Revision de la literatura. Rev. Interamer. Radiol. 2: 71–75, 1977Google Scholar
  784. 784.
    Solly, S.: Remarks on the pathology of mollities ossium: With cases. Med. Chir. Trans. (London) 27: 435–461, 1844Google Scholar
  785. 785.
    Somer, T.: Hyperviscosity symdrome in plasma cell dyscrasias. Adv. Microcirc. 6: 1–55, 1975Google Scholar
  786. 786.
    Sorensen, G. D.: Electron microscopic observations of bone marrow from patients with multiple myeloma. Laboratory Invest. 13: 196–213, 1964Google Scholar
  787. 787.
    Sorenson, G. D.: Virus-like particles in myeloma cells of man. Proc. Soc. Exp. Biol. Med. 118: 250–252, 1965PubMedGoogle Scholar
  788. 788.
    Southeastern Cancer Study Group: Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine. Arch. Intern. Med. 135: 157–162, 1975CrossRefGoogle Scholar
  789. 789.
    Southwest Oncology Group Study: Remission maintenance therapy for multiple myeloma. Arch. Intern. Med. 135: 147–152, 1975CrossRefGoogle Scholar
  790. 790.
    Sovia, J., Sovia, C., Samama, M., Fine, J. M., Bousser, J.: Analysis of fibrin abnormalities in a case of multiple myeloma. Scand. J. Haematol. 15: 207–218, 1975Google Scholar
  791. 791.
    Spain, D.M., Greenblatt, I. J., Snapper, I., Cohn, T.: Degree of coronary and aortic arteriosclerosis in necropsied cases of multiple myeloma. Amer. J. Med. Sci. 231: 165–167, 1956PubMedGoogle Scholar
  792. 792.
    Speed, D.E., Galton, D. A.G., Swan, A.: Melphalan in the treatment of myelomatosis. Brit. Med. J. 1: 1664–1669, 1964PubMedCrossRefGoogle Scholar
  793. 793.
    Spence, R.K., Hill, G.S., Goldwein, M.I., Grossman, R. A., Barker, C.F., Perloff, L.J.: Renal transplantation for end-stage myeloma kidney: Report of a patient with long term survival. Arch. Surg. 114: 950–952, 1979PubMedCrossRefGoogle Scholar
  794. 794.
    Spiegelberg, H.L.: Biological activities of immunoglobulins of different classes and subclasses. Adv. Immunol. 19: 259–294, 1974PubMedCrossRefGoogle Scholar
  795. 795.
    Spiers, A.S.D., Halpern, R., Ross, S.C., Neiman, R.S., Harawi, S., Zipoli, T.E.: Meningeal myelomatosis. Arch. Intern. Med. 140: 256–259, 1980PubMedCrossRefGoogle Scholar
  796. 796.
    Spitler, L.E., Spath, P., Petz, L., Cooper, N., Fudenberg, H.H.: Phagocytes and C4 in paraproteinaemia. Brit. J. Haematol. 29: 279–292, 1975CrossRefGoogle Scholar
  797. 797.
    Spjut, H. J., Dorfman, H. D., Fechner, R. E., Ackerman, L. V.: Tumors of bone and cartillage. In: Atlas of Tumor Pathology. Armed Forces Inst, of Pathol., Washington, D.C., 1970Google Scholar
  798. 798.
    Stalsberg, H.: Lymphoreticular tumors in Norway and in other European countries. J. Natl. Cancer Inst. 50: 1685–1702, 1973PubMedGoogle Scholar
  799. 799.
    Stamp, T.C.B., Child, J. A., Walker, P.G.: Treatment of osteolytic myelomatosis with mithramycin. Lancet 1: 719–722, 1975PubMedCrossRefGoogle Scholar
  800. 800.
    Stavem, P., Froland, S. S., Haugen, H. F., Lislerud, A.: Nonsecretory myelomatosis without intracellular immunoglobulin. Immunofluorescent and ultramicroscopic stu¬dies. Scand. J. Haematol. 17: 89–95, 1976PubMedCrossRefGoogle Scholar
  801. 801.
    Stegman, R., Alexanian, R.: Solid tumors in multiple myeloma. Ann. Intern. Med. 90: 780–782, 1979PubMedGoogle Scholar
  802. 802.
    Stobbe, H.: Zum Sekretionsmechanismus der Plasmazellen. Schweiz. med. Wschr. 90: 1265–1269, 1960Google Scholar
  803. 803.
    Suissa, L., La Rosa, J., Linn, B.: Plasmacytoma of lymph nodes. A case report. J. Amer. Med. Ass. 197: 294–296, 1966CrossRefGoogle Scholar
  804. 804.
    Suki, W.N., Yium, J. J., von Minden, M., Sallertterbeit, C., Eknoyan, G., Martinez-Maldonado, M.: Acute treatment of hypercalcemia with furosemide. N. Engl. J. Med. 283: 836–841, 1970PubMedCrossRefGoogle Scholar
  805. 805.
    Sullivan, P. W., Salmon, S.E.: Kinetics of tumor growth and regression in IgG multiple myeloma. J. Clin. Invest. 51: 1697–1708, 1972PubMedCrossRefGoogle Scholar
  806. 806.
    Sun, N. C., Fishkin, B. G., Nies, K. M., Glassy, E. F., Carpentier, C.: Lymphoplasma- cytic myeloma: An immunological, immunohistochemical and electron microscopic study. Cancer 43: 2268–2278, 1979PubMedCrossRefGoogle Scholar
  807. 807.
    Swash, M., Perrin, J., Schartz, M. S.: Significance of immunoglobulin deposition in peripheral nerve in neuropathies associated with paraproteinaemia. J. Neurol. Neuro- surg. Psychiat. 42: 179–183, 1979CrossRefGoogle Scholar
  808. 808.
    Szimigielski, A., Litwin, J. Zupanska, B.: Cyto-enzymatical differentiation of normal and neoplastic plasma cells. J. Clin. Pathol. 18: 345–346, 1965CrossRefGoogle Scholar
  809. 809.
    Taetle, R., Dickman, P.S., Feldman, P.S.: Pulmonary histopathologic changes associated with melphalan therapy. Cancer 42: 1239–1245, 1978PubMedCrossRefGoogle Scholar
  810. 810.
    Takatsuki, D., Yodoi, J., Wakisaka, G.: Plasma cell dyscrasia with polyneuritis and an endocrine anomaly: Endocrinological study of a new syndrome. Folia Endocrinol. Jpn. 50: 567, 1973Google Scholar
  811. 811.
    Talerman, A.: Clinico-pathological study of multiple myeloma in Jamaica. Brit. J. Cancer 23: 285–293, 1969PubMedCrossRefGoogle Scholar
  812. 812.
    Talerman, A.: Thrombembolic complications in myelomatosis. Brit. Med. J. 2: 709, 1970CrossRefGoogle Scholar
  813. 813.
    Tanaka, Y.: Fibrillar structures in the cells of blood–forming organs. J. Natl. Cancer Inst. 33: 467–475, 1964PubMedGoogle Scholar
  814. 814.
    Tattersall, M.H.N., Jarman, M., Newland, E.S., Holyhead, L., Milstead, R.A.V., Weinberg, A.: Pharmacokinetics of melphalan following oral or intravenous admini¬stration in patients with malignant disease. Eur. J. Cancer 14: 507–513, 1978PubMedCrossRefGoogle Scholar
  815. 815.
    Tavassoli, M., Baughan, M.: Virus like particle in human myeloma without paraproteinemia. Arch. Pathol. 96: 347–349, 1973PubMedGoogle Scholar
  816. 816.
    Taylor, J.S., Lewis, L. A., Battle, J.D., Butkus, A., Robertson, A.L., Deodhar, S., Roenigk, H.H.: Plane xanthoma and multiple myeloma with lipoprotein–paraprotein complexing. Arch. Dermatol. 114: 425–431, 1978PubMedCrossRefGoogle Scholar
  817. 817.
    Thiery, J.P.: Microcinematic contributions to the study of plasma cells. In: Ciba Foundation Symposium on Cellular Aspects of Immunity. Hrsg.: Wolstenholme, G.E.W., Connor, M, Churchill, London, SS. 59–91, 1960Google Scholar
  818. 818.
    Thomas, F.B., Clausen, K.P., Greenberger, N.J.: Liver disease in multiple myeloma. Arch. Intern. Med. 132: 195–202, 1973PubMedCrossRefGoogle Scholar
  819. 819.
    Thomas, J. J.: A case of myeloma of the spine with compression of the cord. Boston Med. Surg. J. 145: 367–373, 1901CrossRefGoogle Scholar
  820. 820.
    Thomas, T. L., Decoufle, P., Moure-Eraso, R.: Mortality among workers employed in petroleum refining and petrochemical plants. JOM 21: 619–623, 1979PubMedGoogle Scholar
  821. 821.
    Tichy, M., Hrncir, Z., Mracek, J., Hrncirova, L., Mateja, F.: Immunochemical and clinical characteristics of a series of 516 paraproteinemic patients. Neoplasma 25: 477–481, 1978PubMedGoogle Scholar
  822. 822.
    Toma, V. A.: A comparative electron microscopic study of plasma cells in plasma cell malignancy and reactive states. Thesis, Univ. of Bloemfontein, South Africa, 1976Google Scholar
  823. 823.
    Toma, V.A., Retief, F.P., Potgieter, G.M., Anderson, J.D.: Plasma cell leukaemia. Diagnostic problems in our experience with 11 cases. Acta Haematol. 63: 136–145, 1980PubMedCrossRefGoogle Scholar
  824. 824.
    Tomasi, T.B., Zigelbaum, S.: The selective occurrence of gamma-1A globulins in certain body fluids. J. Clin. Invest. 42: 1552–1560, 1963PubMedCrossRefGoogle Scholar
  825. 825.
    Tong, D., Griffin, T.W., Laramore, G.E., Kurtz, J.M., Russel, A.H., Groudine, M.T., Herron, T., Blasko, J.C., Tesh, D. W.: Solitary plasmacytoma of bone and soft tissues. Radiology 135: 195–198, 1980PubMedGoogle Scholar
  826. 826.
    Tong, E. C. K., Rubenfeld, S.: The strontium 85 bone scan in myeloma. Amer. J. Roentgenol. 103: 843–848, 1968PubMedGoogle Scholar
  827. 827.
    Tornyos, K., Silberman, H., Solomon, A.: Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma. Cancer Treat. Rep. 61: 785–787, 1977PubMedGoogle Scholar
  828. 828.
    Trecan, G., Dufier, J. L., Blatrix, C, Aftimos, G., Saranx, H., Thomas, M.: Exophthal– mie maligne bilatérale révélatrice d’un myélome multiple a IgM. Sem. Hôp. Paris 53: 1867–1871, 1977PubMedGoogle Scholar
  829. 829.
    Turesson, I., Grubb, A.: Non-secretory or low secretory myeloma with intracellular kappa chains. Report of six cases and review of the literature. Acta Med. Scand. 204: 445–451, 1978PubMedCrossRefGoogle Scholar
  830. 830.
    Twomey, J.J.: Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch. Intern. Med. 132: 562–565, 1973PubMedCrossRefGoogle Scholar
  831. 831.
    Underdown, B.J., Dorrington, K.J.: Studies on the structural and conformational basis for the relative resistance of serum and secretory immunoglobulin A to proteolysis. J. Immunol. 112: 949–959, 1974PubMedGoogle Scholar
  832. 832.
    Unna, P. G.: Über Plasmazellen insbesondere beim Lupus. Monatschr. prakt. Dermatol. 12: 296–317, 1891Google Scholar
  833. 833.
    Van Camp, B.G. K., Cole, J., Peetermans, M. E.: HLA antigens and homogeneous immunoglobulins. Clin. Immunol. Immunopathol. 7: 315–318, 1977PubMedCrossRefGoogle Scholar
  834. 834.
    Van Camp, B., Reynaert, P., Broodtaerts, L.: Studies on the origin of the precursor cell in multiple myeloma, Waldenström’s macroglobulinaemia and benign monoclonal gammopathy. Clin. Exp. Immunol. 44: 82–89, 1981PubMedGoogle Scholar
  835. 835.
    Van Camp, B. G. K., Shuit, H. R. E., Hijmans, W., Radl, J.: The cellular basis of double paraproteinemia in man. Clin. Immunol. Immunopathol. 9: 111–119, 1978PubMedCrossRefGoogle Scholar
  836. 836.
    Van den Berghe, H., Broeckart-Van Orshoven, A., David, G., Verwilghen, R., Michaux, J.L., Sokal, G.: Philadelphia chromosome in human multiple myeloma. J. Natl. Cancer Inst. 63: 11–16, 1979Google Scholar
  837. 837.
    Van Epps, D.E., Williams, R.C.: Suppression of leukocyte chemotaxis by human IgA myeloma components. J. Exp. Med. 144: 1227–1242, 1976PubMedCrossRefGoogle Scholar
  838. 838.
    Van Kaick, G., Lorenz, D., Muth, H., Kaul, A.: Malignancies in German Thorotrast patients and estimated tissue dose. Health Phys. 35: 127–136, 1978PubMedCrossRefGoogle Scholar
  839. 839.
    Vaerman, J. P.: A new case of IgE myeloma (Des) ending with renal failure. J. Clin. Lab. Immunol. 2: 343–348, 1979PubMedGoogle Scholar
  840. 840.
    Vaerman, J. P., Heremans, J. F., Laurell, C. B.: Distribution of alpha-chain subclasses in normal and pathological IgA-globulins. Immunology 14: 425–432, 1968PubMedGoogle Scholar
  841. 841.
    Valderrama, A.F., Bullough, P.G.: Solitary myeloma of the spine. J. Bone Joint. Surg. 50B: 82–90, 1968Google Scholar
  842. 842.
    Vercelli, D., Cozzolino, F., Di Guglielmo, R.: A comparison of two staging systems for myeloma. Nouv. Rev. Fr. Hematol. 23: 107–110, 1981PubMedGoogle Scholar
  843. 843.
    Vercelli, D.R., di Guglielmo, R., Guidi, G., Scolari, L., Buriechi, L., Cozzolino, F.: Bone marrow percentage of plasma cells in the staging of monoclonal gammopathies. Nouv. Rev. Fr. Hematol. 22: 139–145, 1980PubMedGoogle Scholar
  844. 844.
    Vitetta, E.S., Uhr, J. W.: IgD and B cell differentiation. Immunol. Rev. 37: 50–88, 1977PubMedCrossRefGoogle Scholar
  845. 845.
    Vix, V. A.: Intravenous pyelography in multiple myeloma. A review of 52 studies in 40 patients. Radiology 87: 896–902, 1966PubMedGoogle Scholar
  846. 846.
    Vogel, H., Niewisch, H., Matioli, G.: The self-renewal probability of hemopoietic stem cells. J. Cell. Physiol. 72: 221–228, 1968PubMedCrossRefGoogle Scholar
  847. 847.
    Vrana, M., Bunn, P. A. Jr.: A review of therapeutic trials in multiple myeloma and perspectives for future trials. In: Progress in Myeloma. Hrsg.: Potter, M., Elsevier/North Holland, New York-Oxford-Amsterdam, SS. 239–262, 1980Google Scholar
  848. 848.
    Wagoner, J.K.: Leukemia and other malignancies following radiotherapy for gynecological disease. (Thesis), Boston: Harvard School of Public Health, 1970Google Scholar
  849. 849.
    Wahner, H. W., Kyle, R. A., Beabout, J. W.: Scintigraphic evaluation of the skeleton in multiple myeloma. Mayo Clin. Proc. 55: 739–746, 1980PubMedGoogle Scholar
  850. 850.
    Waldbaum, B., Gelfand, M.: Myelomatosis in the Rhodesian African. Trop. Geogr. Med. 26: 26–30, 1974PubMedGoogle Scholar
  851. 851.
    Waldenstrom, J.: Clinical diagnosis and biochemical findings in material of 296 sera with M-type, narrow gamma-globulins. Acta. Med. Scand. (Suppl.) 367: 110–126, 1961Google Scholar
  852. 852.
    Waldenström, J.: Diagnosis and Treatment of Multiple Myeloma. Grune & Stratton, New York, 1970Google Scholar
  853. 853.
    Waldenström, J., Adner, G., Gydell, K., Zetterval, O.: Osteosclerotic „plasmacytoma“with polyneuropathy, hypertrichosis and diabetes. Acta Med. Scand. 203: 297–303, 1978PubMedCrossRefGoogle Scholar
  854. 854.
    Waldeyer, W.: Über Bindegewebszellen. Arch. Mikroskop. Anat. 11: 176–194, 1875CrossRefGoogle Scholar
  855. 855.
    Waldmann, T.A., Bull, J.M., Bruce, R.M., Broder, S., Balestra, S.T., Suer, M.E.: Serum immunoglobulin E levels in patients with neoplastic disease. J. Immunol. 113: 379–386, 1974PubMedGoogle Scholar
  856. 856.
    Waldmann, T. A., Ito, A., Ogawa, M., Mclntyre, O. R., Strober, W.: The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. J. Immunol. 117: 1139–1144, 1976PubMedGoogle Scholar
  857. 857.
    Waldmann, T.A., Strober, W.: Metabolism of immunoglobulins. Progr. Allergy 13: 1–110, 1969Google Scholar
  858. 858.
    Waldmann, T. A., Strober, W., Mogielnicki, R.P.: The renal handling of low molecular weight proteins. II. Disorder of serum protein catabolism with tubular proteinuria, the nephrotic syndrome, or uremia. J. Clin. Invest. 51: 2162–2173, 1972PubMedCrossRefGoogle Scholar
  859. 859.
    Wallgren, A.: Über die Natur der Myelomzellen. Virchow’s Arch. path. Anat. 232: 381–391, 1921CrossRefGoogle Scholar
  860. 860.
    Walsh, J.C.: The neuropathy of multiple myeloma. Arch. Neurol. 25:404–114,1971Google Scholar
  861. 861.
    Wang, A.C., Gergely, J., Fudenberg, H. H.: Amino acid sequences at constant and variable regions of heavy chains of monotypic immunoglobulins G and M of a single patient. Biochemistry 12: 528–534, 1973PubMedCrossRefGoogle Scholar
  862. 862.
    Warner, T.F.C.S., Krueger, R.G.: Circulating lymphocytes and the spread of myeloma. Lancet 1: 1174–1176, 1978PubMedCrossRefGoogle Scholar
  863. 863.
    Waxman, A.D., Siemsen, J.K., Levine, A.M., Holdorf, D., Suzuki, R., Singer, F.R., Bateman, J.: Radiographic and radionuclide imaging in multiple myeloma. The role of gallium scintigraphy: concise communication. J. Nucl. Med. 22: 232–236, 1981PubMedGoogle Scholar
  864. 864.
    Webb, H. E., Harrison, E. G., Masson, J. K., Remine, W. H.: Solitary extramedullary myeloma (plasmacytoma) of the upper part of the respiratory tract and oropharynx. Cancer 15: 1142–1155, 1962PubMedCrossRefGoogle Scholar
  865. 865.
    Weening, R.S., Schoorel, E.P., Roos, D., van Schaik, M.L.J., Voetman, A. A., Bot, A. A., Batenburg-Plenter, A. M., Willems, C., Zeijlemaker, W. P., Astaldi, A.: Effect of ascorbate on abnormal neutrophil, platelet, and lymphocyte function in a patient with the Chediak-Higashi syndrome. Blood 57: 856–865, 1981PubMedGoogle Scholar
  866. 866.
    Weiss, A. H., Smith, E., Christoff, N., Kochwa, S.: Cerebrospinal fluid paraproteins in multiple myeloma. J. Lab. Clin. Med. 66: 280–293, 1965PubMedGoogle Scholar
  867. 867.
    Weiss, H.J., Kochwa, S.: Antihaemophilic globulin (AHG) in multiple myeloma and macroglobulinaemia. Brit. J. Haematol. 14: 205–214, 1968CrossRefGoogle Scholar
  868. 868.
    Weitze, L., Hopper, J.E., Rowley, J.D.: Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders. Cancer 44: 630–644, 1979CrossRefGoogle Scholar
  869. 869.
    Weitzel, R. A.: Carcinoma coexistent with malignant disorders of plasma cells. An autopsy survey. Cancer 11: 546–549, 1958PubMedCrossRefGoogle Scholar
  870. 870.
    Westerhausen, M.: Die malignen Erkrankungen der Immunzellen der späten Diffe- renzierungsstufe: Plasmozytom, Morbus Waldenstrom u.a. In: Das Knochenmark. Hrsg.: Queiβer, W., Georg Thieme, Stuttgart 1978Google Scholar
  871. 871.
    Westerfield, B.T., Michalski, J. P., McCombs, C., Light, R. W.: Reversible melphalan- induced lung damage. Amer. J. Med. 68: 767–771, 1980PubMedCrossRefGoogle Scholar
  872. 872.
    Western Cancer Study Group: Sequential therapy compared with combination therapy in multiple myeloma. Arch. Intern. Med. 135: 163–171, 1975CrossRefGoogle Scholar
  873. 873.
    Wetter, O., Lindner, K.H.: Blood lymphocytes in myeloma patients: High percentage of complement receptor bearing cells is accompanied by decreased anti-immunoglobulin (Ig) binding capacity. Eur. J. Cancer 15: 173–181, 1979PubMedCrossRefGoogle Scholar
  874. 874.
    Whicher, J.T., Hawkins, L., Higginson, J.: Clinical applicaitions of immunofixation: A more sensitive technique for the detection of Bence Jones protein. J. Clin. Pathol. 33: 779–780, 1980PubMedCrossRefGoogle Scholar
  875. 875.
    Williams, R.C., Gibbons, R.J.: Inhibition of bacterial adherence by secretory immunoglobulin A: A mechanism of antigen disposal. Science 177: 697–699, 1972PubMedCrossRefGoogle Scholar
  876. 876.
    Wilson, W.L.: Chemotherapy of human solid tumors with 5-FU. Cancer 13: 1230–1239, 1960PubMedCrossRefGoogle Scholar
  877. 877.
    Wiltshaw, E.: Extramedullar plasmacytoma. Brit. Med. J. 2: 327, 1971PubMedCrossRefGoogle Scholar
  878. 878.
    Wiltshaw, E.: The natural history of extramedullar plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine 55: 217–238, 1976PubMedCrossRefGoogle Scholar
  879. 879.
    Wiltshaw, E.: Chemotherapy in the management of extramedullar plasmacytoma. Cancer Chemother. Pharmacol. 1: 167–175, 1978Google Scholar
  880. 880.
    Wintrobe, M.M.: Plasma cell dyscrasias. Multiple myeloma. In: Clinical Hematology. Hrsg.: Wintrobe, M.M., Lea & Febinger, Philadelphia, SS. 1599–1623, 1974Google Scholar
  881. 881.
    Wintrobe, M.M., Buell, M.V.: Hyperproteinemia associated with multiple myeloma: With report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud’s disease. Bull. John Hopkins Hosp. 52: 156–165, 1933Google Scholar
  882. 882.
    Wochner, R. D., Strober, W., Waldmann, T. A.: The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J. Exp. Med. 126: 207–221, 1967PubMedCrossRefGoogle Scholar
  883. 883.
    Wolf, N.S.: The haemopoietic microenvironment. In: Clinics in Haematology. Vol8/ 2, Hrsg.: Lajtha, L.G., Saunders Co Ltd, London-Philadelphia-Toronto, SS. 469–500, 1979Google Scholar
  884. 884.
    Wolfe, J. A.: Panhypopituitarism due to multiple myeloma. South. Med. J. 63: 32–33, 1970PubMedCrossRefGoogle Scholar
  885. 885.
    Woodroffe, A. J.: Multiple myeloma associated with long history of hyposensitization with allergen vaccines. Lancet 1: 99, 1972PubMedCrossRefGoogle Scholar
  886. 886.
    Woodruff, R.: Treatment of multiple myeloma. Cancer Treat. Rev. 8: 225–270, 1980CrossRefGoogle Scholar
  887. 887.
    Woodruff, R.K., Malpas, J.S., Paxton, A.M., Lister, T.A.: Plasma cell leukemia (PCL): A report on 15 patients. Blood 52: 839–845, 1978PubMedGoogle Scholar
  888. 888.
    Woodruff, R.K., Malpas, J.S., White, E.: Solitary plasmacytoma. Cancer 43: 2344–2347, 1979PubMedCrossRefGoogle Scholar
  889. 889.
    Woodruff, R.K., Sweet, B.J.: Multiple myeloma and massive Bence Jones proteinuria and preservation of renal function. Aust. N. Z. J. Med. 7: 60–62, 1977PubMedCrossRefGoogle Scholar
  890. 890.
    Woodruff, R. K., Wadsworth, J., Malpas, J. S., Tobias, J. S.: Clinical staging in multiple myeloma. Brit. J. Haematol. 42: 199–205, 1979CrossRefGoogle Scholar
  891. 891.
    Woodruff, R.K., Whittle, J.M., Malpas, J.S.: Solitary plasmacytoma I: Extramedullary soft tissue plasmacytoma. Cancer 43: 2340–2343, 1979PubMedCrossRefGoogle Scholar
  892. 892.
    Woolfenden, J.M., Pitt, M.S., Durie, B.G.M., Moon, T.E.: Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology 134: 723–728, 1980PubMedGoogle Scholar
  893. 893.
    Wright, C.J.E.: Long survival in solitar plasmacytoma of bone. J. Bone Joint Surg. 43: 767–771, 1961Google Scholar
  894. 894.
    Wright, J.H.: A case of multiple myeloma. John Hopkins Hosp. Rep. 9: 359–366, 1900Google Scholar
  895. 895.
    Wuhrmann, F., Märki, H.H.: Classification and clinical significance of dysproteine- mias and paraproteinemias. J. Soc. Cienc. Med. Lisboa 126: 1–18, 1962PubMedGoogle Scholar
  896. 896.
    Wurster Hill, D. H., Mclntyre, O. R., Cornwell, G. G. Ill: Chromosome studies in myelomatosis. Virchow’s Arch. Cell. Pathol. 29: 93–97, 1978Google Scholar
  897. 897.
    Wutke, K., Rüdiger, K. D., Kelenyi, G.: Prognose-relevante klinische und morphologi- sche Klassifikation des multiplen Myeloms. Arch. Geschwulstforsch. 49: 671–684, 1979PubMedGoogle Scholar
  898. 898.
    Yoneda, T., Mundy, G. R.: Prostaglandins are necessar for osteoclast activating factor production by activated peripheral blood leukocytes. J. Exp. Med. 149: 279–283, 1979PubMedCrossRefGoogle Scholar
  899. 899.
    Young, G.P., Bhatal, P.S., Wall, A. J., Sullivan, J.R., Hurley, T.H.: Jaundice in multiple myeloma: The role of oxymetholone. Aust. N. Z. J. Med. 8: 14–22, 1978CrossRefGoogle Scholar
  900. 900.
    Young, J. L., Asire, A. J., Pollack, E. S.: SEER program: Cancer incidence and mortality in the United States. 1973–1976. DHEW Publication No.(NIH)78–1837,1978Google Scholar
  901. 901.
    Zagury, D., Uhr, J.W., Jamieson, J.D., Palade, G.E.: Immunoglobulin synthesis and secretion. J. Cell. Biol. 46: 52–63, 1970PubMedCrossRefGoogle Scholar
  902. 902.
    Zavazal, V., Sach, J., Rozprimova, L., Brumelova, V.: An unusual case of IgE myeloma. Allergol. Immunopathol. 6: 423–426, 1978Google Scholar
  903. 903.
    Zawadzki, Z. A., Edwards, G. A.: Dysimmunoglobulinemia in the absence of clinical features of multiple myeloma and macroglobulinemia. Amer. J. Med. 42: 67–88, 1967PubMedCrossRefGoogle Scholar
  904. 904.
    Zawadzki, Z.A., Edwards, G.A.: Pseudoparaproteinemia due to hypertransferrine- mia. Amer. J. Clin. Pathol. 54: 802–809, 1970Google Scholar
  905. 905.
    Zawadzki, Z. A., Kapadia, S., Barnes, A.E.: Leukemic myelomatosis (plasma cell leukemia). Amer. J. Pathol. 70: 605–611, 1978Google Scholar
  906. 906.
    Zbigniew, A., Zawadzki, Z.A., Edwards, G.A., George, A.: Dysimmunglobulinemia associated with hepatobiliary disorders. Amer. J. Med. 48: 196–202, 1970CrossRefGoogle Scholar
  907. 907.
    Ziegler, J.B., Hansen, P. J., Penny, R.: Leukocyte function in paraproteinaemia. Aust. N. Z. J. Med. 5: 39–45, 1975PubMedCrossRefGoogle Scholar
  908. 908.
    Zielinski, C. C, Lanzer, G., Ludwig, H.: Defects of leukocyte locomotion in multiple myeloma. J. Clin. Lab. Immunol. 7: 111–114, 1982PubMedGoogle Scholar
  909. 909.
    Zimelman, A.P.: Thrombocytosis in multiple myeloma. (Letter), Ann. Intern. Med. 78: 970–971, 1973PubMedGoogle Scholar
  910. 910.
    Zinneman, H.H., Hall, W.H.: Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Ann. Intern. Med. 41: 1152–1163, 1954PubMedGoogle Scholar
  911. 911.
    Zucker-Franklin, D.: Multiple myeloma — II. Structural features of cells associated with paraproteinemias. Semin. Hematol. 1: 165–198, 1964PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • Heinz Ludwig
    • 1
  1. 1.Allgemeines KrankenhausStadt Wien II. Medizinische UniversitätsklinikWienAustria

Personalised recommendations